##### Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   (Mark One) ☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR  ☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period
from  to Commission File Number 001-38360   Solid
Biosciences Inc. (Exact name of Registrant as specified in its Charter)    Delaware

90-0943402(State or other jurisdiction of
incorporation or organization)

(I.R.S. EmployerIdentification No.)141 Portland Street, Fifth Floor
Cambridge, MA

02139(Address of principal executive offices)

(Zip Code) Registrants telephone number, including area code: (617) 337-4680   Securities registered pursuant to Section 12(b) of the Act:  Common Stock, $0.001 par
value per share

The Nasdaq Stock Market
LLC(Title of each class)

(Name of each exchange on which registered) Securities registered pursuant to Section 12(g) of the Act: None (Title of class)   Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.    YES  ☐    NO  ☒ Indicate by check mark if the Registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Act.    YES  ☐    NO  ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    YES  ☐    NO  ☒ Indicate by check mark whether the Registrant has
submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the Registrant was required to submit and post such files).    YES  ☐    NO  ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not
be contained, to the best of Registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.  Large accelerated filer

☐

Accelerated filer

☐Non-accelerated filer

☒  (Do not check if a smaller reporting company)

Smaller reporting company

☐Emerging growth company

☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the
Act).    YES  ☐    NO  ☒ As of June 30, 2017, the last business day of the
Registrants most recently completed second fiscal quarter, the Registrants common stock was not publicly traded. The Registrants common stock began trading on the Nasdaq Global Select Market on January 26, 2018. As of
March 15, 2018, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was approximately $157.4 million, based upon the closing price on the Nasdaq Global Select Market reported for
such date. Shares of common stock held by each of our officers and directors, together with their affiliated investment funds, and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons
may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of shares of Registrants common stock outstanding as of March 15, 2018 was 35,476,892.




---

##### Table of Contents

Table of Contents  PagePART I


1Item 1.

Business


1Item 1A.

Risk Factors


32Item 1B.

Unresolved Staff Comments


80Item 2.

Properties


80Item 3.

Legal Proceedings


80Item 4.

Mine Safety Disclosures


81PART II


82Item 5.

Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities


82Item 6.

Selected Financial Data


83Item 7.

Managements Discussion and Analysis of Financial Condition and Results of Operations


85Item 7A.

Quantitative and Qualitative Disclosures About Market Risk


102Item 8.

Financial Statements and Supplementary Data


102Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure


102Item 9A.

Controls and Procedures


103Item 9B.

Other Information


104PART III


105Item 10.

Directors, Executive Officers and Corporate Governance


105Item 11.

Executive Compensation


109Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters


117Item 13.

Certain Relationships and Related Transactions, and Director Independence


120Item 14.

Principal Accounting Fees and Services


125PART IV


126Item 15.

Exhibits, Financial Statement Schedules


126Item 16.

Form 10-K Summary


128SIGNATURES


129CONSOLIDATED FINANCIAL STATEMENTS


F-2  i




---

##### Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K includes forward-looking statements, which involve risks and uncertainties. These forward-looking statements
can be identified by the use of forward-looking terminology, including the terms believe, estimate, project, anticipate, expect, seek, predict, aim,
continue, possible, intend, may, might, will, could, would or should or, in each case, their negative, or other variations or comparable
terminology. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Annual Report on Form 10-K. We derive many of our forward-looking statements from our operating
budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to
anticipate all factors that could affect our actual results. All forward-looking statements are based upon information available to us on the date of this Annual Report on Form 10-K. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:  

the timing, progress and results of preclinical studies and clinical trials for SGT-001 and our other product candidates;  

our ability to resolve the full and partial clinical holds on SGT-001 and the requirements for and timing of any such resolutions;  

our ability to obtain and maintain U.S. regulatory approval of SGT-001, and the timing and scope thereof;  

our ability to obtain and maintain foreign regulatory approvals, and the timing and the scope thereof;  

the size of the patient populations and potential market opportunity for SGT-001 and our other product candidates, if approved for commercial use;  

our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes;  

our plans to develop and commercialize SGT-001 and our other product candidates, if approved;  

the pricing and reimbursement of SGT-001 and any other product candidates we may develop, if approved;  

the establishment of sales, marketing and distribution capabilities and entry into agreements with third parties to market and sell SGT-001 or our other product candidates, if approved;  

the rate and degree of market acceptance and clinical utility of SGT-001 and any other product candidates we may develop and for which we may receive approval;  

our expectations related to our use of capital resources;  

our estimates regarding expenses, ongoing losses, future revenue, capital requirements and need for and ability to obtain additional financing;  

our intellectual property position;  

our competitive and market position;  

developments relating to our competitors and our industry; and  

the impact of laws and regulations on our operations. By their nature, forward-looking
statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking  ii




---

##### Table of Contents

statements are not guarantees of future performance and that our actual results of operations, financial condition, business and prospects may differ materially from those made in or suggested by
the forward-looking statements contained in this Annual Report on Form 10-K. In addition, even if our results of operations, financial condition, business and prospects are consistent with the forward-looking statements contained in this Annual
Report on Form 10-K, those results may not be indicative of results in subsequent periods. You should read this Annual Report on Form
10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. As used in this Annual Report on Form 10-K, the terms Solid, the Company, we, us and
our refer to Solid Biosciences Inc. unless the context indicates otherwise.  iii




---

##### Table of Contents

PART I  Item 1.
Business. Overview Our mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that
usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases
in the United States alone. DMD is caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and
tear. Without functioning dystrophin and certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. There is no cure for
DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in
patients muscles. Based on our preclinical program that included multiple animal species of different phenotypes and genetic variations, we believe the mechanism of action of SGT-001, if our clinical trials prove to be successful, has the
potential to slow or even halt the progression of DMD, regardless of the type of genetic mutation or stage of the disease. SGT-001 has
been granted Rare Pediatric Disease Designation, or RPDD, in the United States and Orphan Drug Designations in both the United States and European Union. In November 2017, we initiated a Phase I/II clinical trial for SGT-001, called IGNITE DMD, and
in February 2018 we dosed the first patient, a non-ambulatory adolescent. On March 14, 2018, we announced that IGNITE DMD was placed on full clinical hold following a serious adverse event reported in the clinical trial. For patients suffering from DMD, symptoms usually begin to manifest between three and five years of age, when they fail to reach developmental
milestones or experience motor function challenges, such as difficulty walking or climbing stairs. As the disease progresses, patients with DMD experience frequent falls; can no longer run, play sports or perform most daily functions; and are
further weakened by physical activity. By their early teens, DMD patients typically lose their ability to walk and ultimately become dependent on a wheelchair for mobility. By their 20s, patients essentially become paralyzed from the neck down and
require a ventilator to breathe. Though disease severity and life expectancy vary, a DMD patients quality of life dramatically decreases over time, with death typically occurring by early adulthood from either cardiac or respiratory
complications. Our founders, who are personally touched by the disease, created a biotechnology company purpose-built to accelerate the
discovery and development of meaningful therapies for all patients affected by DMD. Through this disease-focused business model, our research team, led by experts in DMD biology and drug development, along with key opinion leaders in DMD,
continuously evaluate emerging science to identify high-potential product candidates. Our selection process includes extensive diligence and initial pharmacology research with highly specific, predefined criteria, which provide us with confidence in
our development program decisions. Through this data-driven selection process, we have evaluated a number of programs and identified gene therapy as a potentially beneficial approach for DMD, and thus initiated development of our lead product
candidate SGT-001. We will continue to apply this rigorous approach and reject the majority of the candidates we evaluate in our effort to develop only programs that we believe have the greatest likelihood of becoming therapies for DMD patients. Our product candidates SGT-001 is
our lead gene transfer candidate. Gene transfer, a type of gene therapy, is designed to address diseases caused by mutated genes through the delivery of functional versions of those genes, called transgenes. The transgenes are then utilized by the
body to produce proteins that are absent or not functional prior to  1




---

##### Table of Contents

treatment, potentially offering long-lasting beneficial clinical effects. SGT-001 is designed to address the underlying genetic cause of DMD by delivering a synthetic transgene that produces
dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Our SGT-001 vector is derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, or AAV, which was
selected for its ability to efficiently enter skeletal, diaphragm and cardiac muscle tissues. The vector is designed to carry a synthetic dystrophin transgene construct, called microdystrophin, that retains the most critical components of the
full-size dystrophin gene yet is small enough to fit within AAV packaging constraints. SGT-001 is designed to drive microdystrophin protein expression in affected muscles throughout the body. We have
studied the efficacy, safety and durability of SGT-001 in multiple preclinical models and its functional benefits in DMD animal studies. In contrast to other therapeutic approaches that are designed to target specific mutations in the dystrophin
gene, we believe SGT-001 is a mutation agnostic approach. In the fourth quarter of 2017, we initiated a randomized, controlled,
open-label, single-ascending dose Phase I/II clinical trial, called IGNITE DMD, to evaluate SGT-001 in ambulatory and non-ambulatory males with DMD aged four to 17 years. The primary objectives of IGNITE DMD are to assess the safety and tolerability
of SGT-001, as well as efficacy as defined by microdystrophin protein expression. The clinical trial is also designed to assess muscle function and mass, respiratory and cardiovascular function, serum and muscle biomarkers associated with
microdystrophin production, patient reported outcomes and quality of life measures, among other endpoints. IGNITE DMD is anticipated to enroll 16 to 32 patients with DMD, who will be randomly assigned to either an active treatment group or a delayed
treatment group. It is planned so that adolescents aged 12 to 17 years will receive treatment and, at a later stage of the clinical trial, children aged four to 11 years will be dosed. Efficacy will be assessed by comparing microdystrophin
protein expression in muscle biopsy before treatment and 12 months after treatment for each patient. Participants in the control group who continue to meet clinical trial criteria would receive active treatment after 12 months. In March 2018, the U.S. Food and Drug Administration, or the FDA, placed IGNITE DMD on full clinical hold following our report of a serious
adverse event in the clinical trial. On February 14, 2018, the first patient in IGNITE DMD, a non-ambulatory adolescent, received a dose of 5E13 vg/kg of SGT-001, the low dose in the clinical trial. Several days after administration the patient
was hospitalized due to laboratory findings that included a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation. The patient showed no signs or symptoms of coagulopathy (bleeding
disorder), had no relevant changes from baseline in liver function tests and responded well to medical treatment. We reported the serious
adverse event to the FDA and, because it was unexpected, classified it as a Suspected Unexpected Serious Adverse Reaction, or SUSAR. We have halted enrollment and dosing in IGNITE DMD and are awaiting the formal clinical hold letter from the FDA. Assuming successful resolution of the full clinical hold and based on data from the clinical trial, we will determine next steps for
SGT-001 clinical development, including additional clinical trials that may include other patient populations, as well as the need for larger confirmatory clinical trials. In addition, pursuant to a letter we received from the FDA in November 2017, we are not permitted to dose patients in the higher-dose group of
IGNITE DMD due to a partial clinical hold. The hold relates to the number of vials and manufacturing lots utilized per patient, as well as manufacturing processes to support the higher-dose group. We have submitted our response to the FDA and are
awaiting their feedback. If successfully developed and approved, we intend to commercialize SGT-001 in the United States and European
Union, and we may enter into licensing agreements or strategic collaborations to commercialize the product candidate in other markets.  2




---

##### Table of Contents

Taking into account the prevalence and incidence of DMD and the anticipated dosing
requirements for gene transfer, we anticipate that there will be a need for a substantial supply of SGT-001 for clinical trials and, if approved, for commercial markets. Through significant targeted investments to address this challenge, we
generated sufficient drug product supply to initiate our IGNITE DMD. We continue to develop our manufacturing process to meet future clinical and commercial production needs for SGT-001. While we believe gene transfer may be able to slow or halt DMD disease progression, many patients would still suffer from the manifestations
of the disease, such as tissue damage to their muscles, inflammation, cardiac dysfunction and fibrosis. As part of our disease-focused business model, we are also building a portfolio of complementary disease modifying therapies to address these
manifestations. Our portfolio currently includes an initial disease modifying candidate, SB-001, a monoclonal antibody designed to reduce fibrosis and inflammation, as well as a number of emerging and complementary programs. We intend to commence
preclinical activities for the SB-001 program in 2018. In addition to developing our pipeline of product candidates,we believe it
is critical to invest time and resources in tools and technologies designed to help us more effectively understand DMD, accurately monitor disease progression and assist patients in daily life. As part of this goal, we are developing biomarkers and
sensors that may allow us to identify treatment targets faster, measure the therapeutic impact of potential product candidates better and reach decision points earlier. In addition, through our Solid Suit program, we are developing a line of soft,
wearable assistive devices with the goal of providing functional and therapeutic benefits to DMD patients. Our pipeline  LOGO We seek to protect our proprietary and intellectual property position through a combination of patents,
trade secret laws, proprietary know-how, continuing technological innovation, and entering into non-disclosure, confidentiality and invention assignment agreements. We have exclusively licensed three issued U.S. patents, one pending U.S.
non-provisional patent application, and seven issued patents and eleven pending patent applications in foreign jurisdictions. We have filed three pending U.S. provisional patent applications. We intend to continue building out our intellectual
property protection to further strengthen our position in the DMD field. Who we are Solid Biosciences was founded in 2013 by our Chief Executive Officer, Ilan Ganot, our Chairman of the Board, Andrey Zarur, and our President,
Gilad Hayeem, with the goal of developing meaningful therapies for patients with DMD. Solid is the English translation of Eytani, the Hebrew name of Ilan and Annie Ganots son,  3




---

##### Table of Contents

who was diagnosed with the disease in 2012. Our founders, unsatisfied with the existing therapeutic landscape, proceeded to raise funds to execute on our disease-focused business model. We
assembled a passionate management team and scientific advisory board composed of individuals with extensive experience in DMD, gene therapy, product discovery, research and development, manufacturing, business strategy and finance. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the
University of Michigan, the University of Missouri and the University of Washington. Since then, we have continued to use our extensive network across the academic, business and patient communities to identify, vet and pursue high-potential
complementary product candidates to address the needs of DMD patients. Since our inception, we have raised private capital from a group
of top-tier corporate and private investors. In addition, three leading U.K.-based DMD charities provided initial seed funding for our gene transfer program in return for equity in our company, and we have accepted additional contributions from
several DMD charities to fund our early-stage research programs. In January 2018, we completed our initial public offering resulting in net proceeds of $129.3 million, after deducting underwriting discounts and commissions and offering expenses. We operated as a Delaware limited liability company under the name Solid Biosciences, LLC until immediately prior to the effectiveness of
our registration statement on Form S-1 on January 25, 2018, at which time we converted into a Delaware corporation pursuant to a statutory conversion and changed our name to Solid Biosciences Inc. Mission Our mission, which guides every
aspect of our operations, is to cure DMD. Underscoring this mission, our disease-focused business model is founded on the following fundamental values:  

identify and develop meaningful therapies for all patients with DMD;  

bring together the leading experts in DMD, science, technology, disease management and care; and  

be guided by the needs of DMD patients. About Duchenne muscular dystrophy DMD is an X-chromosome-linked, muscle-wasting disease, predominantly affecting boys. Progressive, irreversible and ultimately fatal, DMD occurs
in approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. In DMD, mutations in the dystrophin gene result in the bodys inability to produce functioning
dystrophin protein, which works to strengthen muscle fibers and protect them from daily wear and tear. Dystrophin protein also serves as the cornerstone of the dystrophin glycoprotein complex, or DGC, a group of proteins that links the inner and
outer components of muscle cells to ensure proper muscle function. Without dystrophin and the DGC, muscles suffer excessive damage from
normal daily activities and are unable to regenerate, leading to the build-up of scar and fat tissue. More than 1,000 dystrophin gene mutations, which can be inherited or can occur spontaneously, have been identified in people with DMD. For patients suffering from DMD, symptoms usually begin to manifest between three and five years of age, when they fail to reach developmental
milestones or experience motor function challenges, such as difficulty walking or climbing stairs. Muscle wasting initially presents in the legs and pelvic area, then in the muscles of the shoulders, neck and arms. As the disease progresses,
patients with DMD experience frequent falls, can no longer run, play sports or perform most daily functions, and are further weakened by physical activity. In addition to physical challenges, DMD also commonly involves cognitive difficulties and
behavioral challenges.  4




---

##### Table of Contents

By their early teens, DMD patients typically lose their ability to walk and become dependent
on a wheelchair for mobility. By their 20s, patients essentially become paralyzed from the neck down and require a ventilator to breathe. Though disease severity and life expectancy vary, a patients quality of life dramatically decreases over
time, with death typically occurring by early adulthood from either cardiac or respiratory complications. Need for effective therapies There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Glucocorticoid treatment, the current standard-of-care, has been shown to temporarily improve muscle strength, prolong the period of
ambulation and slow the progression of DMD. However, glucocorticoid use is associated with well-known adverse events, such as severe weight gain, stunted growth, weakening of bone structure and metabolic dysfunctions, among others. The most commonly
used glucocorticoids include prednisone and deflazacort (EMFLAZA). Deflazacort has been commercially available in several countries outside of the United States and was approved in the United States for the treatment of DMD in 2017. In recent years, certain regulators have conditionally approved two new therapies, eteplirsen (EXONDYS 51) and ataluren (Translarna),
which target specific mutations in the dystrophin gene. These therapies are indicated for only a small portion of the DMD patient population, and their respective efficacy profiles still need to be fully understood. Eteplirsen is an antisense oligonucleotide indicated for DMD patients who have a confirmed mutation of the dystrophin gene amenable to exon 51
skipping, which affects approximately 13% of DMD patients. Eteplirsen is administered as a weekly intravenous infusion. In 2016, eteplirsen was granted accelerated approval from the FDA based on an increase in dystrophin in skeletal muscle observed
in some patients who received the therapy. However, the FDA concluded that a clinical benefit, including improved motor function, has not been established. Eteplirsen is still under review by regulatory authorities outside of the United States. Ataluren is a small molecule indicated for the treatment of patients who have DMD resulting from nonsense mutations in the dystrophin gene,
which also affect approximately 13% of DMD patients. In 2014, ataluren received conditional marketing authorization from the European Commission, and has since been approved in several other countries outside of the United States. Atalurens
indication is currently limited to ambulatory patients five years of age and older. In February 2018, the FDA reiterated its denial of PTC Therapeutics, Inc.s appeal of the complete response letter for the new drug application for ataluren. Current best practices for treating DMD patients also dictate a multidisciplinary approach to disease management, which includes physical
and occupational therapy to preserve strength, function and flexibility, orthopedic management to reduce the risk of scoliosis and other bone and joint problems, pulmonary, cardiac and gastrointestinal management, and psychosocial management to
support behavior and learning. Burden of disease Despite recent therapeutic advances, DMD represents a significant societal and economic burden. The economic burden, estimated at
$1.2 billion annually in the United States (excluding costly mortality and end-of-life care expenses), includes costs associated with hospital admissions, medication, frequent doctor visits and investment in assistive devices, as well as
indirect costs related to productivity losses for the caregivers and costs due to pain, anxiety and social handicap. Of this amount, approximately 45% is represented by indirect costs. Only a small proportion of DMD patients are employed and many
caregivers reduce their hours or stop working altogether to care for their children, who progressively require more help with everyday tasks, such as eating, dressing and using the bathroom. In some cases, patients also experience serious mental
health issues that require additional support and treatment.  5




---

##### Table of Contents

Solids 360-degree solution We aim to address the full spectrum of DMD disease manifestation, from its underlying genetic cause to other disorders that result from disease
progression. We are advancing corrective therapies, disease-modifying therapies and assistive devices, as well as tools to accelerate drug development. Gene transferA corrective therapy Gene therapy is a therapeutic approach that aims to address diseases caused by gene mutations. A gene is a portion of deoxyribonucleic acid, or
DNA, that provides the instructions for the body to construct proteins that perform functions needed for life. Genes are prone to mutations, which can either be inherited or occur spontaneously. While many mutations are harmless, some lead to the
absence of crucial proteins, resulting in serious genetic diseases like DMD. Gene transfer, a type of gene therapy, is designed to
address diseases caused by mutated genes through the delivery of functional versions of those genes, called transgenes. The transgenes are then utilized by the body to produce proteins that are absent or not functional prior to treatment,
potentially offering long-lasting beneficial effects. We have focused our initial efforts on gene transfer because we believe it has the
greatest potential to address the root cause of DMD: the absence or near-absence of dystrophin protein. If successful, we believe gene transfer can slow or stop the progression of DMD in a majority of patients, irrespective of their genetic
mutation, by producing long-term, muscle-specific expression of a functional dystrophin-like protein. Our gene transfer candidate, or
vector, includes three components:  

a viral capsida protein shell utilized as a vehicle to deliver a transgene to cells in the body;  

a transgenea functional gene intended to produce a functional protein; and  

a promotera specialized DNA sequence that directs cells to produce the protein in specific tissues. SGT-001 SGT-001, our lead gene transfer
candidate, is designed to preserve muscle function in DMD patients after a single administration. The SGT-001 vector is comprised of a functional transgene and a muscle-specific promoter which are delivered via an AAV capsid. The vector is modified to no longer self-replicate, yet retains its ability to effectively introduce new genetic material directly into
patients cells. AAV vectors have been extensively studied in human clinical trials in multiple disease indications, including in clinical trials of high-dose, systemically delivered AAV gene therapies being conducted by third parties. Capsid: The capsid of the SGT-001 vector is derived from a naturally occurring, non-pathogenic virus called AAV. There are several
subtypes of AAV capsids that differ based on the proteins that make up their structure. These capsids have affinities for different sites in the body. We selected the AAV9 serotype capsid for clinical development based on our preclinical data, which
demonstrated the capsids ability to enter skeletal, diaphragm and cardiac muscle tissues. Transgene: Dystrophin, the largest
gene in the body, exceeds the carrying capacity of AAV vectors. To overcome this challenge, we advanced development of the SGT-001 transgene, a synthetic, dystrophin-like gene that fits into AAV and has the ability to drive functional protein
expression in skeletal, diaphragm and cardiac muscle tissue.  6




---

##### Table of Contents

The concept of a modified therapeutic dystrophin gene originated from research on Becker
muscular dystrophy, or BMD, where researchers discovered that certain BMD patients had mutations in the dystrophin gene that drove expression of a functional form of dystrophin protein, allowing patients to live relatively normal lives. This
discovery led scientists to engineer a number of synthetic, dystrophin transgene constructs, called microdystrophins, that retained only the most critical components of the full-size dystrophin gene yet were small enough to fit within AAV packaging
constraints. There are several types of microdystrophins that differ based on the configuration of their components. Microdystrophins were subsequently demonstrated to functionally protect muscle in mouse models of DMD. The SGT-001 microdystrophin construct, which is our lead clinical candidate for DMD, is based on three decades of development and optimization
work at the University of Missouri and the University of Washington as well as other academic institutions. In preclinical studies, Jeffrey Chamberlain, Ph.D., from the University of Washington, and Dongsheng Duan, Ph.D., from the University of
Missouri, identified a proprietary configuration of genetic components that, when administered systemically, produces functional microdystrophin protein expression that not only stabilizes muscle membranes and protects muscle against injury, but
also simultaneously restores the localization of DGC to the muscle membrane, notably increasing neuronal nitric oxide synthase, or nNOS, concentration. In subsequent published studies, Dr. Duan demonstrated in animal models that, in comparison
to earlier configurations, nNOS-restoring microdystrophins were more effective in improving muscle function and blood circulation. Promoter:The expression of the SGT-001 microdystrophin transgene is regulated by a modified, synthetic muscle-specific promoter
cassette called CK8, which is derived from the naturally occurring muscle creatine kinase promoter. Regulatory cassettes, such as CK8, are used to prompt gene expression specifically in muscle tissues. In comparison to other regulatory cassettes, we
chose CK8 due to its small size and its ability to drive microdystrophin transgene expression in skeletal, diaphragm and cardiac muscle tissues. In our preclinical studies in small and large animal models, CK8 restricted microdystrophin transgene
expression to these muscles. SGT-001 preclinical program Our comprehensive preclinical program for SGT-001 is comprised of studies that inform efficacy, durability and safety, as well as dose response
and the kinetics of transgene expression. Our program includes three different animal species: mice, dogs and non-human primates, or NHPs. Our preclinical studies were performed by third-party collaborators over the last three years. Well established mouse and dog disease models for DMD offered us the opportunity to better evaluate the potential translatability of SGT-001
to humans. While studies in dystrophic mice, such as the mdx mouse, provide important efficacy rationale, we chose to perform additional functional studies in dystrophic dogs because they exhibit a more severe dystrophic phenotype and progress
similarly to human patients at earlier stages of the disease. Dog models enabled us to assess various endpoints, including biodistribution, expression, durability and function in a large animal species. Because DMD is a disease defined by a lack of dystrophin protein, it is important to reliably detect microdystrophin expression in muscle
after SGT-001 treatment. As part of our core preclinical program, we developed well characterized and well recognized analytic approaches to confirm transgene expression and localization, using the following assays:  

Immunofluorescence: A qualitative method to determine if a transgene is expressed and localized to muscle membrane.  

Western blot: A recognized method to quantify dystrophin expression, which is a validated biomarker.  

Mass spectrometry: A highly sensitive analytical method to quantify transgene expression. We also employed
immunofluorescence to confirm if our microdystrophin construct restored the DGC, including key proteins such as sarcoglycan and nNOS.  7




---

##### Table of Contents

Efficacy in dystrophic mice Multiple studies in both dystrophic, or mdx, and healthy, or wild-type, mice have demonstrated that a single intravenous administration of
SGT-001 induces measurable levels of microdystrophin protein expression. In all studies, microdystrophin protein expression was measured using immunofluorescence, Western blot and mass spectrometry. In an mdx dose-response study, a clear dose-dependent pattern of transgene expression was observed at day 28 by all three assays. As an
example, at a dose of 1E14 vg/kg, transgene expression as quantified by positive immunoflouresence staining in the quadriceps and heart muscle tissues was 50% and 80%, respectively, of the full-length dystrophin levels quantified in
healthy wild-type control muscles. Similar levels of microdystrophin expression were found in all mdx studies completed to date. Efficacy studies performed in dystrophic mice treated with SGT-001 demonstrated significant, dose-responsive
improvements in both muscle morphology and multiple physiological parameters. In a blinded efficacy study performed in mdx mice dosed at approximately six weeks of age, SGT-001 treatment showed a statistically significant improvement in grip
strength, which assesses arm and leg strength, at multiple doses. In addition, using a treadmill exhaustion assay, the total distance run
by the SGT-001-treated mdx mice was approximately two- to fifteen-fold longer compared to the untreated mice at all time points five-weeks post-dose. At study termination, muscle force was measured ex vivo in the extensor digitorum longus muscle in all animals. SGT-001-treated mdx
mice, dosed at either 2E14 or 4.5E14 vg/kg, exhibited a 1.3-fold increase in specific muscle force over untreated controls when compared to the untreated mdx mice. In a second efficacy study employing a more severe dystrophic mouse model, or DBA/2J-mdx, a version of SGT-001 was administered at a dose of
1E15 vg/kg. Treated mice exhibited functional results that were similar to untreated wild-type animals. In the SGT-001-treated DBA/2J-mdx mice, the specific muscle force was similar to wild-type mice. Further, the treated animals were protected
against muscle damage associated with eccentric contractions, a type of contraction related to muscle lengthening under load that is known to be highly damaging to dystrophic muscles. In contrast, untreated DBA/2J-mdx mice showed significantly
reduced specific force and no protection against eccentric contraction induced muscle damage. Efficacy in dystrophic dogs Two independent studies in dystrophic dogs assessed durability of microdystrophin expression and efficacy, respectively. These studies were
performed in two distinct dystrophic dog models (mixed breed dystrophic dogs, or cDMD, and Golden Retriever Muscular Dystrophy, or GRMD), collectively encompassing a number of genetic mutations that lead to the absence of dystrophin protein. This
enabled us to assess SGT-001 across multiple mutations, which is more reflective of the composition of the DMD patient population. Both studies used a canine-optimized version of the microdystrophin gene. In a long-term dose-ranging study, five three-month-old, juvenile cDMD dogs received an intravenous dose of either 5E13 vg/kg (n=1), 1E14
vg/kg (n=2), 3E14 vg/kg (n=1) or 5E14 vg/kg (n=1). In this study, muscle biopsies were collected from the skeletal muscles at one, three, six, 12, 16, 20, 24 and 30 months after injection. Robust transgene expression was detected by
immunofluorescence at all time points and at all of the dose levels. In animals dosed with 1E14 vg/kg, approximately 70-90% of the muscle fibers were positive for microdystrophin. In treated muscle samples, transgene expression was associated with
stabilization of the DGC, including nNOS. To date, all doses have been well tolerated and there has been no observed immune response to the transgene. This study is currently ongoing. A blinded dose-ranging study in the GRMD model assessed the general safety and efficacy of the canine construct of SGT-001. The three dose
levels (1E13, 1E14 and 2E14 vg/kg) were administered at three months of age and animals were followed for three months following administration. All doses were well tolerated and there was no observed immune response to the transgene.  8




---

##### Table of Contents

Dose-dependent transgene expression was detected in interim biopsies of skeletal muscles at
day 28 and 45 and at the end of the study at day 91 in skeletal, diaphragm and cardiac muscles. A blinded histological evaluation of the muscle tissue revealed a reduction of dystrophic pathology at the higher dose levels. In the mid- and high-dose
groups, all muscles biopsied at the end of the study exhibited improved pathology compared to low dose and untreated controls. Biodistribution studies demonstrated dose dependent transgene expression that was only detectable in the muscle tissues. The observed dose response was detectable by both immunofluorescence and Western blot. Quantification by Western blot averaged less than
10% of wild-type in the low-dose (1E13 vg/kg) animals. In the mid-dose animals, the level of expression among the skeletal muscles ranged from an average of approximately 20% to approximately 50% of wild-type control muscles. At 2E14 vg/kg, the
level of expression ranged from 30% to 70% of wild-type dystrophin. This data also correlates to quantification of microdystrophin via mass spectrometry. Dose-dependent, sustained expression of microdystrophin not only correlated with histological improvements in muscle, but also provided
statistically significant improvements in measures of muscle function. At day 90, muscle force generation was improved in both the 1E14 vg/kg and 2E14 vg/kg cohorts, indicating that the microdystrophin produced by SGT-001 is highly protective in a
large animal dystrophic species. The efficacy data collectively described above in both dystrophic mouse and dog models was incorporated
into an overall nonclinical model to inform dose selection for our clinical program. Manufacturing comparability As part of our manufacturing process development, we have run comparability studies at each stage of our process scale-up. These comparability
studies were carried out using in vivo mouse models to ensure that our drug product produced at different scales is comparable to each other. Safety As part of our preclinical
program, we performed necessary good laboratory practices, or GLP, toxicology studies to establish the overall safety profile of SGT-001 in wild-type mice and NHPs. The data and our conclusions from these studies were included in our
Investigational New Drug application, or IND, submission to the FDA. Systemic administration of SGT-001 was generally well tolerated in both species. We observed no evidence of test-article-related toxicity for up to 13 weeks after
systemic administration of SGT-001 in either species that would prevent us from initiating clinical trials. In the NHP study, test-article-related effects were self-limited, mild chemistry and hematology changes with no microscopic
correlates at the end of the study. There was a transient and asymptomatic increase in liver function enzymes observed in NHPs starting on day 9, which returned to normal levels by day 21. We believe there were no other relevant
test-article-related adverse events associated with SGT-001 administration in either GLP study. In the NHP toxicology study, a single animal from the high dose cohort was euthanized after it did not recover from an anesthetic procedure. We believe
this event was attributed to procedural errors. However, AAV vector cannot be completely ruled out as a contributing factor to the toxicity that gave rise to the event. Clinical development of SGT-001 We are developing SGT-001 for the treatment of DMD through a single intravenous administration. In the fourth quarter of 2017, we announced the
initiation of IGNITE DMD, a randomized, controlled, open-label, single-ascending dose Phase I/II clinical trial designed to evaluate SGT-001 in ambulatory and non-ambulatory males with DMD aged four to 17 years. The primary objectives of IGNITE DMD
are to assess the safety and tolerability of SGT-001, as well as efficacy as defined by microdystrophin protein expression. The clinical  9




---

##### Table of Contents

trial is also designed to assess muscle function and mass, respiratory and cardiovascular function, serum and muscle biomarkers associated with microdystrophin production, patient reported
outcomes and quality of life measures, among other endpoints. IGNITE DMD is anticipated to enroll 16 to 32 patients with DMD. Key inclusion criteria include: established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of
DMD phenotype; anti-AAV9 antibodies below pre-specified thresholds; stable cardiac and pulmonary function; and a stable daily dose of oral corticosteroids for 24 weeks. There is no enrollment restriction in the clinical trial protocol based on a
patients underlying dystrophin gene mutation. IGNITE DMD participants will be randomly assigned to either an active treatment group
or a delayed treatment control group. The selection of our starting dose, 5E13 vg/kg, was based on safety and efficacy data observed in our preclinical studies. Dose escalation between cohorts and decisions regarding clinical trial progression will
occur after review by the Data Safety Monitoring Board, or DSMB. It is planned so that adolescents aged 12 to 17 years will be treated initially, followed by children aged four to 11 years. Efficacy will be assessed by comparing microdystrophin
protein expression in muscle biopsy before and 12 months after treatment for each patient. Other endpoints will be compared against the control group. We anticipate that the delayed treatment control group will be rolled into an active treatment
phase after 12 months, as long as participants continue to meet clinical trial criteria. Long-term follow up will continue per regulatory guidelines. In March 2018, the FDA placed IGNITE DMD on full clinical hold following our report of a serious adverse event in the clinical trial. On
February 14, 2018, the first patient in IGNITE DMD, a non-ambulatory adolescent, received a dose of 5E13 vg/kg of SGT-001, the low dose in the clinical trial. Several days after administration the patient was hospitalized due to laboratory
findings that included a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation. The patient showed no signs or symptoms of coagulopathy (bleeding disorder), had no relevant changes from
baseline in liver function tests and responded well to medical treatment. We reported the serious adverse event to the FDA and, because
it was unexpected, classified it as a Suspected Unexpected Serious Adverse Reaction, or SUSAR. We have halted enrollment and dosing in IGNITE DMD and are awaiting the formal clinical hold letter from the FDA. Assuming successful resolution of the full clinical hold and data from the clinical trial, we will determine next steps for SGT-001 clinical
development, including additional clinical trials that may include other patient populations, as well as the need for larger confirmatory clinical trials. In addition to the full clinical hold on IGNITE DMD, we also must resolve a partial clinical hold on the higher-dose group in the clinical
trial. Pursuant to a letter we received from the FDA in November 2017, we are not permitted to dose patients in the higher-dose group of the clinical trial until we decrease the number of vials and utilize no more than a single production lot per
patient, as well as demonstrate that we have the appropriate manufacturing processes in place to support the higher-dose group. We have submitted our response to the FDA and are awaiting their feedback. Manufacturing SGT-001 The
prevalence and incidence of DMD, combined with average patient weight and anticipated dosing requirements for SGT-001, result in a substantial supply need for clinical trials and, if approved, for commercial markets. To address this challenge, we
developed a manufacturing process that we believe will be scalable to meet clinical and commercial production needs for SGT-001. Our
suspension-based process is founded on seminal work by scientists at the University of Florida and has been optimized for manufacturability by our internal process development scientists with the support of our  10




---

##### Table of Contents

Contract Development Manufacturing Organizations, or CDMO, partners. The process consists of three steps. First, we produce two replication-incompetent Herpes Simplex Virus, or HSV, stocks, one
containing our microdystrophin construct and the other containing the critical elements of the AAV9. We then use these two HSV stocks to coinfect suspension-adapted human embryonic kidney cells (HEK-293), which are then purified and
concentrated in our downstream process to produce our gene transfer candidate. Our team has developed the analytical testing methods needed to support consistency and strict standards of quality and potency. We believe that this approach will
increase our speed of development, ensure consistent quality and regulatory compliance, and reduce the risk of delay or unexpected production costs. Current status and plans for clinical and commercial scale-up We believe that our investment in our scalable manufacturing process over the last several years will allow us to minimize the need for changes
throughout clinical development and upon commercialization, while ensuring supply at the high volume required at all stages. We intend to supply our clinical development program for SGT-001 with drug product produced at current good manufacturing
practices, or cGMP, - compliant facilities located at partner CDMOs. We are currently operating at 250-liter scale. Our in-house scientists are continuing to work to increase the productivity and efficiency of our manufacturing process. In addition,
we intend to establish the capability and capacity to supply SGT-001 at commercial scale from multiple sources, including potentially building our own GMP facility to ensure redundancy and reliability. Complementary disease-modifying therapies While we believe gene transfer may be able to slow or halt DMD disease progression, many patients would still suffer from the manifestations of
the disease, such as tissue damage to their muscles, impaired muscle strength, inflammation, cardiac dysfunction and fibrosis. We are building a portfolio of complementary disease-modifying therapies designed to address these manifestations. Our portfolio currently includes SB-001, our initial disease modifying candidate that is aimed at addressing fibrosis, as well as several
emerging and complementary programs. We have chosen to focus our efforts on these programs following rigorous preclinical testing and our assessment of clinical potential given natural human modifiers. If initial preclinical studies are successful,
we envision initiating additional studies for our disease-modifying programs in combination with SGT-001. We continue to assess additional emerging therapeutic approaches from academia and industry through our highly focused product candidate
selection process to further build our portfolio. SB-001 (LTBP4) SB-001 is a monoclonal antibody intended to reduce fibrosis and inflammation. It is designed to target and stabilize the LTBP4 protein. LTBP4
is highly expressed in muscle and, when stable, prevents fibrosis and inflammation by inhibiting the activation of the TGF-beta pathway. The rationale for targeting LTBP4 originated from observations in DMD natural history studies. Researchers found that subsets of patients with
genetic variants in the LTBP4 gene maintained their ability to walk longer compared to patients in the study who did not. Researchers discovered that these genetic variants lead to reduced TGF-beta signaling. Elizabeth McNally, M.D., Ph.D., Director
of the Center for Genetic Medicine at Northwestern University, hypothesized that stabilization of the LTBP4 protein in DMD patients could mimic the effect. In order to assess the efficacy of potential human antibody clinical candidates in preclinical models, mice expressing the human version of
LTBP4 were crossed with mdx mice to generate a DMD model that expressed human LTBP4 (hLTBP4:mdx). Preliminary studies showed that the hLTBP4:mdx animals treated with an anti-LTBP4 antibody showed significantly lower levels of fibrosis and
inflammation due to the stabilization of the LTBP4 protein.  11




---

##### Table of Contents

In partnership with Dr. McNally and Adimab LLC, SB-001 development efforts are underway
to optimize lead candidate human immunoglobulin G, or IgG, antibodies directed against LTBP4. Additional selection and characterization are being employed to obtain high affinity antibodies. We plan to conduct preclinical in vivo
efficacy, biodistribution and safety studies utilizing these human antibodies in hLTBP4:mdx mice beginning in 2018, following final in vitroantibody characterization and scale-up of manufacturing efforts. Tools to accelerate discovery and development We believe it is critical to invest time and research into tools designed to help us more effectively measure disease progression and the
therapeutic impact of our product candidates. We are focused on developing biomarkers and sensors that will allow us to identify treatment targets faster, better measure the therapeutic impact of potential product candidates and reach therapeutic
decision points earlier. Blood-based and imaging biomarkers We are working to identify non-invasive blood-based and imaging biomarkers that could potentially reduce or eliminate the need for muscle
biopsies in clinical trials, reducing stress on patients and allowing better evaluation of potential product candidates. We are developing a platform technology that may enable the non-invasive measurement of changes associated with increased
dystrophin and dystrophin-like protein expression in DMD patients by using established imaging techniques. We are also currently using leading, robust platforms to perform extensive analysis on blood-based samples to establish molecular signatures
based on various stages of DMD disease progression. Sensor-less mobility tracking We are working to develop naturalistic motor function measurement at home with an ambient measurement system, which is based on sensors such as
Microsoft Kinect. This system uses infrared technology to detect body movement and is designed to collect mobility data for DMD patients without requiring wearable sensors. If successful, this new non-invasive technology would enable us to
understand in greater detail the therapeutic impact of potential product candidates as they relate to everyday activities, and could provide information to establish and measure clinical endpoints in future clinical trials. Assistive devices Solid Suit We are currently developing a line of soft, wearable assistive devices that may have both functional and therapeutic benefits, with the goal of
helping patients perform day-to-day activities with greater ease and preserving their muscle function. We refer to these devices as the Solid Suit. This work is being done in collaboration with technology innovators and engineering and disease
experts, and is informed by input from the patient community. The Solid Suit utilizes cutting-edge technologies to power soft, light-weight comfortable exoskeletons with the potential to offset muscle fatigue and augment muscle strength. We are
developing the Solid Suit in three separate components, two of which are currently in prototype development. Intellectual property Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product
candidates, including SGT-001, and other know-how, to operate without infringing, misappropriating or otherwise violating the intellectual property rights of others, and to prevent others from infringing, misappropriating or otherwise violating our
intellectual property rights. We also rely on patents, trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.  12




---

##### Table of Contents

As of March 15, 2018, we have filed three pending U.S. provisional patent applications
and have exclusively licensed three issued U.S. patents, one pending U.S. non-provisional patent application, and seven granted patents and eleven pending patent applications in foreign jurisdictions. The issued U.S. patents are projected to expire
between 2021 and 2028, excluding any patent term adjustments and any patent term extensions, and any U.S. patents that may issue from the pending U.S. non-provisional patent application and U.S. provisional patent applications (assuming U.S.
non-provisional patent applications are timely filed with respect to such provisional patent applications and all other applicable requirements are satisfied) would be projected to expire between 2036 and 2039, excluding any patent term adjustments
and any patent term extensions. With respect to our gene transfer programs, we exclusively licensed patent families that relate to
microdystrophin genes. With respect to SGT-001, we exclusively licensed one issued U.S. patent and one pending U.S. non-provisional patent application, which generally claim the structural elements of SGT-001 and the promoter sequence used in
SGT-001. This issued U.S. patent is projected to expire in 2028, excluding any patent term adjustments and any patent term extensions. We also own one pending U.S. provisional patent application relating to SGT-001. Any U.S. patents that may issue
from the pending U.S. non-provisional patent application and our pending U.S. provisional patent application (assuming a U.S. non-provisional patent application is timely filed with respect to such provisional patent application and all other
applicable requirements are satisfied) would be projected to expire between 2036 and 2039, excluding any patent term adjustments and any patent term extensions. Substantive prosecution of our provisional patent application has not yet commenced at
the U.S. Patent and Trademark Office, or USPTO. Our provisional patent application is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of our
provisional patent application. If we do not timely file the non-provisional patent application, we may lose our priority date with respect to our provisional patent application and any patent protection on the inventions disclosed in our
provisional patent application. While we intend to file a non-provisional patent application, we cannot predict whether such future patent application will result in the issuance of a patent that effectively protects SGT-001, or if such issued
patent or any of our licensors issued patents will effectively prevent others from commercializing competitive products. In any event, patent prosecution is a lengthy process, during which the scope of the claims initially submitted for
examination by the USPTO offices are often significantly narrowed by the time they issue, if they issue at all. With respect to SB-001,
we do not currently own or in-license any issued patents or patent applications relating to such product candidate. We have an exclusive option to negotiate for licenses of certain patents and patent applications relating to SB-001 from Ikaika
Therapeutics, LLC. If we exercise such option, Ikaika Therapeutics, LLC is only required to negotiate the terms of a potential license agreement with us for certain specified periods of time and we may be unable to enter into such a definitive
license agreement within the required timeframe or under terms that are acceptable to us. If we are unable to enter into such a definitive license agreement, we will not have any license to such patents and patent applications. The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patents term may be lengthened by patent term adjustment, which compensates a patentee for
administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for
patent term extension when FDA approval is granted, subject to certain limitations and provided statutory and regulatory requirements are met (for more information, please see BusinessU.S. patent term restoration and marketing
exclusivity). In the future, if and when our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents we may obtain in the future covering those
products, depending upon the length of the clinical trials for each product and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable
adjustment to the term of any of our patents.  13




---

##### Table of Contents

As with other biotechnology and pharmaceutical companies, our ability to maintain and
solidify our proprietary and intellectual property position for our product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned and licensed pending patent
applications, and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued
patents that we may receive in the future may be challenged, invalidated or circumvented. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that,
before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting protection such patent would afford the respective product and any
competitive advantage such patent may provide. In addition to patents, we rely upon unpatented trade secrets and know-how and continuing
technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition,
non-solicitation, confidentiality, and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality
agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with
the respective counterparty. We cannot guarantee, however, that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. We also seek trademark protection in the United States and internationally where available and when appropriate. We currently own U.S. federal
registrations for the marks SOLID, SOLID GT and SOLID BIOSCIENCES and a European Union registration for the mark SOLID GT. Strategic partnerships and
collaborations/licenses We have certain obligations under licensing agreements with third parties that include annual maintenance fees
and payments that are contingent upon achieving various development, commercial and regulatory milestones. Pursuant to many of these license agreements, we are required to make milestone payments if certain development, regulatory and commercial
sales milestones are achieved, and may have certain additional research funding obligations. Also, pursuant to the terms of many of these license agreements, when and if commercial sales of a licensed product commence, we must pay royalties to our
licensors on net sales of the respective licensed products. University of Washington License Agreement In 2015, we entered into a license agreement with the University of Washington, acting through UW CoMotion, under which we obtained an
exclusive, royalty-bearing, sublicensable, worldwide license under certain patent applications owned by the University of Washington relating to novel micro-dystrophins to develop, manufacture, and commercialize products for use in the treatment of
DMD and related disease indications caused by a lack of functional dystrophin. We have the right to grant sublicenses to third parties contingent upon written approval by the University of Washington prior to executing such sublicense, which
approval may not be unreasonably withheld. In consideration for the rights granted by the agreement, we paid a one-time, non-refundable
license fee, which was recorded as a research and development expense in 2015. We are required to reimburse the University of Washington for costs incurred in applying for, prosecuting and maintaining patents and pay up to an aggregate of
approximately $1 million upon the achievement of certain milestones. There were no milestones achieved as of December 31, 2016 and 2015. In October 2017, the first milestone was achieved under this agreement. The  14




---

##### Table of Contents

milestone payment was recorded as a research and development expense in the fourth quarter of 2017. We must also pay royalties of a low single digit percentage of future sales by us and our
sublicensees of products developed under the licensed patent rights. In addition, we must pay an annual maintenance fee until certain milestones are achieved, at which time a minimum annual royalty requirement will replace such maintenance fee and
will apply to us and our sublicensees. We are obligated to use our commercially reasonable efforts, consistent with sound and reasonable
business practices and judgment, to commercialize the inventions covered by the licensed patent rights and to make and sell products based on that patent as soon as practicable and maximize sales thereof. The University of Washington controls the prosecution and maintenance of the licensed patents in consultation with us and at our expense. In
countries in which we have not requested prosecution or maintenance of licensed patents, the University of Washington may prosecute and maintain such licensed patents at its own cost. We have the first right to enforce such licensed patents at our
expense. However, we may not enter into any settlement in any manner relating to the licensed patents without the University of Washingtons prior written consent. The license agreement remains in effect until the expiration of the last-to-expire patent licensed under the agreement. We may terminate the
agreement at any time upon providing sixty days written notice to the University of Washington. The University of Washington may terminate the agreement upon our uncured, material breach of the agreement or if we enter into an
insolvency-related event. The University of Missouri License Agreement In 2015, we entered into a license agreement with the Curators of the University of Missouri, or the University of Missouri, a public
corporation of Missouri, under which we obtained an exclusive, royalty-bearing, sublicensable, worldwide license under certain patents and patent applications owned by the University of Missouri relating to a novel synthetic microdystrophin gene to
make, sell and distribute products for use in the treatment of DMD and related disease indications resulting from a lack of functional dystrophin. In consideration for the rights granted by the agreement, we paid a one-time, non-refundable license fee, which was recorded as a research and
development expense in 2015. We are required to reimburse the University of Missouri for costs incurred in applying for, prosecuting and maintaining the licensed patents and pay up to an aggregate of approximately $1 million upon the
achievement of certain milestones for each product developed based on the licensed patents. There were no milestones achieved as of December 31, 2016 and 2015. In October 2017, the first milestone was achieved under this agreement. The
milestone payment was recorded as a research and development expense in the fourth quarter of 2017. We must pay a royalty of a low single digit percentage of future sales by us or our sublicensees of products developed using the licensed patents. In
addition, we must pay an annual maintenance fee until certain milestones are achieved, after which time a minimum annual royalty will replace such maintenance fee. Under the agreement, we granted the University of Missouri a non-exclusive, royalty-free, irrevocable, paid-up license, with the right to
grant sublicenses to non-profit, academic, educational or governmental institutions, to practice and use improvements made by us using the licensed patent rights, solely for non-commercial research purposes. We are obligated to use our reasonable best efforts to introduce products based on the licensed patent rights into the commercial market as
soon as possible, consistent with sound and reasonable business practices and judgment, and thereafter to keep such products reasonably available to the public. The University of Missouri controls the prosecution and maintenance of the licensed patents in consultation with us and at our expense. In
countries in which we have not requested prosecution or maintenance of licensed  15




---

##### Table of Contents

patents, the University of Missouri may prosecute and maintain such licensed patents at its own cost. We have the first right to enforce such licensed patents at our expense. However, any
settlement, consent judgment or other voluntary disposition of litigation that materially limits the scope, validity or enforceability of the licensed patent or admits fault or wrongdoing on the part of the University of Missouri must be
pre-approved in writing by the University of Missouri. The license agreement remains in effect until the expiration of the last-to-expire
patent or the abandonment of the last to be abandoned patent application licensed under the agreement. The University of Missouri may terminate the agreement, or render the license granted thereunder non-exclusive, in individual countries if we and
our sublicensees fail to achieve certain milestones. We may terminate the license agreement at any time upon providing six months written notice to the University of Missouri and paying a termination fee. Each of the University of Missouri and
we may also terminate the agreement for an uncured default or breach of the agreement by the other party. Our ability to cure such breach only applies to the first two notices of such breach provided by the University of Missouri, and thereafter,
the University of Missouri may terminate the agreement for our default or breach of the agreement upon thirty days written notice without an opportunity to cure such default or breach. The University of Michigan License Agreement In 2016, we entered into a license agreement with the Regents of the University of Michigan, or the University of Michigan, a constitutional
corporation of Michigan, under which we obtained an exclusive, royalty-bearing, sublicensable, worldwide license to make, sell and distribute products under certain patents owned by the University of Michigan related to microdystrophin and utrophin
spectrin-like nucleic acid sequences for any use that, but for this agreement, would comprise an infringement of a valid claim included in the licensed patent rights. In consideration for the rights granted by the agreement, we paid a one-time license fee and a separate fee to cover past patent prosecution
costs. We recorded the upfront license fee as a research and development expense in 2016. We are required to reimburse the University of Michigan for costs incurred in applying for, prosecuting and maintaining patents, and pay up to an aggregate of
approximately $1 million upon the achievement of certain milestones. There were no milestones achieved as of December 31, 2017 and 2016. We must also pay royalties of a low single-digit percentage of future sales by us or our sublicensees
of products developed using the licensed rights, with a minimum annual royalty after certain milestones are achieved. In addition, we must pay an annual maintenance fee in any year in which the minimum annual royalty is not reached. Under the agreement, the University of Michigan reserves for itself and its affiliates the right to use the licensed rights for non-commercial
research, public service, internal and educational purposes and the right to grant the same limited non-commercial rights to other non-profit research institutions. We are obligated to use commercially reasonable efforts to bring one or more products based on the licensed patents to market through a
diligence program for utilizing the licensed patents, to continue diligent marketing efforts throughout the term of the agreement, and to make reasonable amounts of such products commercially available, in each case consistent with prudent business
practices and judgment. The University of Michigan controls the prosecution and maintenance of the licensed patents in consultation with
us and at our expense. In countries in which we have not requested prosecution or maintenance of licensed patents, the University of Michigan may prosecute and maintain such licensed patents at its own cost. We have the first right to enforce such
licensed patents at our expense. However, we may only enter into a settlement with the advice and consent of the University of Michigan. The license agreement remains in effect until the expiration of the last-to-expire patent licensed under the agreement. The University of
Michigan may terminate the agreement upon our uncured material breach of the  16




---

##### Table of Contents

agreement, including failure to make required payments under the agreement or to achieve certain milestones, or if we become insolvent or bankrupt. We may terminate the license agreement at any
time upon providing sixty days written notice to the University of Michigan. Harvard College License Agreements In 2016 and 2017, we entered into license agreements with the President and Fellows of Harvard College, or Harvard College, under which we
obtained non-exclusive, royalty-bearing, sublicensable, worldwide licenses to use certain intellectual property owned by Harvard College to develop, manufacture, and commercialize products for use in the treatment of DMD. In consideration for the rights granted by each agreement, we paid one-time, non-refundable license fees, which were recorded as a research
and development expense in 2016 and 2017. We are required to pay an annual license maintenance fee until certain milestones are achieved, after which time the annual maintenance fee will increase annually. Such annual maintenance fees will further
increase if we grant certain rights to a sublicensee or strategic partner with whom we collaborate on the development and commercialization of licensed products. The annual maintenance fees are creditable against royalty payments. We also must pay
milestone payments within thirty days after achieving certain milestones. There were no milestones achieved as of December 31, 2017 and 2016 under either agreement. We must pay a royalty on future sales by us or our sublicensees of products
developed using the licensed technology. The license agreements each remain in effect for an initial term of fifteen years, with
automatic three-year renewal periods thereafter unless one of the parties provides notice of non-renewal. We may terminate the license agreements at any time upon providing sixty days written notice to Harvard College. Harvard College may
terminate the agreements in the event we become bankrupt or insolvent. Both Harvard College and we may also terminate the agreements for an uncured material breach of the agreements by the other party. Other License Agreements In 2016,
we entered into a license agreement with Life Technologies Corporation, or Life Technologies. In consideration for obtaining a non-exclusive, royalty-free, worldwide license to use certain technologies and associated know-how to develop our product
candidates, we paid a one-time, non-refundable license fee. This fee was recorded as a research and development expense in 2016. The license agreement will remain effective in perpetuity unless earlier terminated. Life Technologies has the right to
terminate the agreement upon our material, uncured breach of the agreement or in the event that it determines that continued performance of the agreement may violate any laws. We are obligated to diligently pursue regulatory approval necessary for
the development, manufacture and sale of the licensed products. We have the right to terminate the agreement at any time upon providing thirty days written notice to Life Technologies. Competition The biotechnology and
pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is also true in treatments of DMD, as well as in gene therapy. While we believe that our
focus, strength of team, expertise in gene therapy, scientific knowledge and intellectual property provide us with competitive advantages, we face competition from several different sources, including large and small biopharmaceutical companies,
academic research institutions, government agencies and public and private research institutions. Not only must we compete with other companies that are focused on gene transfer technology, but any product candidates that we successfully develop and
commercialize will compete with existing therapies and new therapies that may become available in the future. Many of our competitors
have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals and product marketing than  17




---

##### Table of Contents

we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of
our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We are aware of several companies and research institutions focused on developing systemic gene transfers for DMD, including Pfizer Inc. and
Sarepta Therapeutics, Inc. Any advances in gene transfer technology made by a competitor may be used to develop therapies that could compete with our lead product candidate. For our gene transfer product candidate, we are aware of the following competitors:  

Pfizer Inc. is developing PF-06939926, an AAV-mediated microdystrophin gene transfer and we understand the clinical trial is currently recruiting patients.  

Sarepta Therapeutics, Inc. has entered into a research and option agreement with Nationwide Childrens Hospital for AAVrh74.MHCK7.micro-Dystrophin, its AAV-mediated microdystrophin gene transfer program. In January
2018, Sarepta announced that Nationwide Childrens Hospital had begun dosing patients in a Phase I/II clinical trial designed to assess the safety and tolerability of AAVrh74.MHCK7.micro-Dystrophin in individuals with DMD.  

Sarepta Therapeutics, Inc. and Genethon have entered into a research collaboration to develop an AAV-mediated microdystrophin gene transfer. In addition to the investigational gene transfer programs discussed above, there are two therapies, which are intended to be disease
modifying, that are currently approved for DMD by certain regulators. These products are eteplirsen (EXONDYS 51) and ataluren (Translarna), each of which is indicated for approximately 13% of DMD patients. Government regulation and product approval U.S.
government regulation and product approval In the United States, biologic products including gene therapy products, such as our
lead product candidate, are licensed for marketing by the FDA under the Public Health Service Act, or PHS Act, and regulated by the FDA under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, as well as by other federal, state and local
statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting,
advertising and other promotional practices involving biologic products. FDA approval must be obtained before conducting human clinical testing of biologic products. Additionally, each clinical trial protocol for a gene therapy product candidate is
reviewed by the FDA and, in limited instances, the U.S. National Institutes of Health, or the NIH, through its Office of Biotechnology Activities Recombinant DNA Advisory Committee, or RAC. FDA must license a biologic product before it may be
marketed within the United States. Within the FDA, the Center for Biologics Evaluation and Research, or the CBER, regulates gene therapy
products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies, or the OTAT, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise
CBER on its reviews. CBER works closely with the NIH and the RAC, which makes recommendations to the NIH on gene therapy issues and engages in a public discussion of scientific, safety, ethical and societal issues related to proposed and ongoing
gene therapy protocols. To date, the FDA has licensed one human gene therapy product for sale, and the agency has provided guidance for the development of other gene therapy products. This guidance includes a growing body of guidance documents on
chemistry, manufacturing and control, or CMC, clinical investigations and other areas of gene therapy development, all of which are intended to facilitate the industrys development of gene therapy products.  18




---

##### Table of Contents

U.S. biologic products development process The process required by the FDA before a biologic product may be marketed in the United States generally involves the following:  

completion of preclinical laboratory tests and in vivostudies according to the FDAs GLP requirements and applicable requirements for the humane use of laboratory animals or other applicable regulations;  

submission to the FDA of an application for an IND, which allows human clinical trials to begin unless the FDA objects within 30 days;  

approval by an institutional review board, or IRB, reviewing each clinical site before each clinical trial may be initiated;  

approval by an institutional biosafety committee, or IBC, assessing the safety of the clinical research and identifying any potential risk to public health or the environment;  

performance of adequate and well controlled human clinical trials according to the FDAs regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of
human research subjects and their health information, to establish the safety, potency and purity of the proposed biologic product for its intended use;  

preparation and submission to the FDA of a biologics license application, or BLA, for marketing approval that includes substantive evidence of safety, purity and potency from results of preclinical testing and clinical
trials, and detailed information about the CMC for the product, reports of the outcomes and full data sets of the clinical trials and proposed labeling and packaging for the product;  

review of the product candidate by an FDA advisory committee, if applicable;  

satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with cGMP requirements and to assure that the facilities,
methods and controls are adequate to preserve the biologic product candidates identity, safety, strength, quality and purity;  

potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA;  

payment of user fees;  

FDA review and licensure of the BLA; and  

compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement
to conduct post-approval studies. Before testing any biologic product candidate in
humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as
well as in vivostudies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of certain nonclinical studies must comply with federal regulations and requirements,
including GLPs. If a gene therapy trial is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA
research, prior to the submission of an IND to the FDA, a protocol and related documents must be submitted to, and the study registered with, the NIH Office of Biotechnology Activities, or OBA, pursuant to the NIH Guidelines for Research Involving
Recombinant DNA Molecules, or NIH Guidelines. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA. However, many companies and other institutions, not otherwise
subject to the NIH Guidelines, voluntarily follow them. NIH is responsible for convening the RAC that discusses protocols that raise  19




---

##### Table of Contents

novel or particularly important scientific, safety or ethical considerations at one of its quarterly public meetings. The OBA will notify the FDA of the RACs decision regarding the
necessity for full public review of a gene therapy protocol. RAC proceedings and reports are posted to the OBA website and may be accessed by the public. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any
available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is an exemption from the FD&C Act that allows an unapproved product to be shipped in interstate commerce for use in an investigational
clinical trial and a request for FDA authorization to administer an investigational product to humans. Some preclinical tests may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA,
unless the FDA places the clinical trial on a full clinical hold or partial clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. With gene therapy protocols, if the FDA
allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its IND review that the sponsor delay initiation of the protocol until after completion of the RAC review
process. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA
authorization and then only under terms authorized by the FDA. In addition, the FDA may impose a partial clinical hold at any time before
or during clinical trials. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND (e.g., a specific protocol or part of a protocol is not allowed to proceed; however, other protocols or parts of
the protocol are allowed to proceed under the IND). If the FDA requires that progress to the next study is contingent on (i) FDA review of additional data and (ii) subsequent specific permission for the study to proceed, this represents a
partial clinical hold. Human clinical trials under an IND Clinical trials involve the administration of the biologic product candidate to healthy volunteers or subjects under the supervision of
qualified investigators, generally physicians not employed by, or under the control of, the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing
procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any
amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDAs regulations comprising the GCP requirements, including the requirement that all research
subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution
at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are
reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative, reviews and approves the study protocol and
must monitor the clinical trial until completed. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group provides
authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Clinical trials involving recombinant DNA also must be reviewed by an IBC a local
institutional committee that reviews and oversees basic and clinical research and utilizes recombinant DNA at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.  20




---

##### Table of Contents

Human clinical trials are typically conducted in three sequential phases that may overlap or
be combined:  

Phase I. The investigational biologic product is initially introduced into a small group of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion
and, if possible, to gain an early understanding of its effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to
healthy volunteers, the initial human testing is often conducted in patients. Phase I clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.  

Phase II. The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.  

Phase III. Phase III clinical trials are commonly referred to as pivotal studies, which typically denotes a study that presents the data that the FDA or other relevant regulatory agency will use
to determine whether or not to approve a biologic product. In Phase III clinical trials, the investigational biologic product is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites
in adequate and well controlled clinical trials to generate sufficient data to statistically confirm the potency and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product
candidate and provide an adequate basis for product labeling. Post-approval clinical trials, sometimes referred to as
Phase IV clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities,
clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any
findings from other trials, in vivolaboratory tests or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in
the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or
life-threatening suspected adverse reaction within seven calendar days after the sponsors initial receipt of the information. The
FDA or the sponsor or its DSMB may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRBs requirements or if the biologic product candidate has been associated with unexpected serious harm to patients. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its
ClinicalTrials.gov website. Additional regulation for gene therapy clinical trials In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of
gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development,  21




---

##### Table of Contents

which relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure
product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends
that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by
questionnaire. The NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System,
which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. Compliance with cGMP requirements Manufacturers of biologics must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of
records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments
must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP
requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved BLA, and may extend to requiring withdrawal of the product from the market. The FDA will
not approve a BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification. Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about
the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of
adventitious agents or of causing other adverse events with the use of biologic products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be
capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life. U.S. review and approval processes After the completion of clinical trials of a biologic product, FDA licensure of a BLA must be obtained before commercial marketing of the
biologic product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under
the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biologic product for the claimed indications in all relevant pediatric subpopulations and to support dosing and
administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. According to the
FDAs fee schedule, effective from October 1, 2017 through September 30, 2018, the user fee for an application requiring clinical data, such as a new drug application, is $2,421,495. The sponsor of an approved application is also
subject to an annual program fee, which for fiscal year 2018 is  22




---

##### Table of Contents

$304,162. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user
fees are assessed on BLAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication. The FDA reviews a BLA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing. The
FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted
application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use,
and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the products identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel
biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the
application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biologic product approval process, the
FDA also will determine whether a REMS, is necessary to assure the safe use of the biologic product. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To
determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse
events and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the
product candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. cGMP, GLP and GCP compliance requires significant
expenditure of time, money and effort in the areas of training, recordkeeping, production and quality control. Notwithstanding the
submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret
data differently than how we would interpret the same data. On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response
letter. An approval letter authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require
substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDAs satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.
If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for
example, requiring labeling changes; or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for
approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.  23




---

##### Table of Contents

If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the
product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials,
sometimes referred to as Phase IV clinical trials, designed to further assess a biologic products safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in
ten months after the FDA accepts the BLA for filing, and priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject
to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the
submission within the last three months before the PDUFA goal date. Biosimilars and Exclusivity The Patient Protection and Affordable Care Act and the companion Health Care and Education Reconciliation Act, or the Health Care Reform Law,
which was signed into law on March 23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. That Act established a regulatory scheme authorizing the FDA to approve biosimilars and
interchangeable biosimilars. As of January 1, 2018, the FDA has approved nine biosimilar products for use in the United States. No interchangeable biosimilars, have been approved. The FDA has issued several guidance documents outlining an
approach to review and approval of biosimilars. Additional guidances are expected to be finalized by FDA in the near term. Under the Act,
a manufacturer may submit an application for licensure of a biologic product that is biosimilar to or interchangeable with a previously approved biological product or reference product. In order for the FDA to
approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as
interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the
reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of
the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company
could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsors own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and
potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed interchangeable by the FDA will, in fact, be
readily substituted by pharmacies, which are governed by state pharmacy law. Pediatric exclusivity Pediatric exclusivity is another type of non-patent exclusivity in the United States and, if granted, provides for the attachment of an
additional six months of marketing protection to the term of any existing regulatory exclusivity or patent protection, including the non-patent and orphan exclusivity. This
six-month exclusivity may  24




---

##### Table of Contents

be granted if an application sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the
pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDAs request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the
statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. Thus, pediatric exclusivity adds six months to existing exclusivity periods applicable to biological
products under the BPCIAnamely, the four-year period during which the FDA will not consider an application for a biosimilar product, and the 12-year period during which the FDA will not approve a biosimilar application. Orphan drug designation Under the
Orphan Drug Act, the FDA may designate a biologic product as an orphan drug if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases
in which there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment of the disease or condition will be recovered from sales of the product). Orphan product designation
must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any
advantage in, or shorten the duration of, the regulatory review and approval process. If a product with orphan status receives the first
FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic product for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the
drug to meet the needs of patients with the disease or condition for which the drug was designated. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity
regardless of a showing of clinical superiority. Competitors, however, may receive approval of different products for the same indication
for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan medicinal product status in the European Union has similar, but not identical,
benefits. Expedited development and review programs The FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a biologic product candidate
may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Biologic products are eligible for Fast Track designation if they are intended to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In
addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track BLA before the application is complete, a process known as rolling review. Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval.  

Breakthrough therapy designation.To qualify for the breakthrough therapy program, product candidates must
be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement  25




---

##### Table of Contents

on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an
efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.  

Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment,
diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.  

Accelerated approval.Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing
treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate
endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and
prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well
controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.  

Regenerative advanced therapy. With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative
advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates
that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review,
benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. None of these expedited programs change the standards for approval but they may help expedite the development or approval process of product
candidates. Post-approval requirements After regulatory approval of a product is obtained, there may be a number of post-approval requirements. For example, as a condition of
approval of a BLA, the FDA may require post-marketing testing and surveillance to monitor the products safety or efficacy. In addition, holders of an approved BLA are required to keep extensive records, to report certain adverse reactions and
production problems to the FDA, to provide updated safety and efficacy information and to comply with requirements concerning advertising and promotional labeling for their products. Also, quality control and manufacturing procedures must continue
to conform to cGMP regulations and practices, as well as the manufacturing conditions of approval set forth in the BLA. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP requirements, which impose certain
procedural, substantive and recordkeeping requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory
compliance. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products
may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to  26




---

##### Table of Contents

significant liability. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the
Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact,
including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. U.S. patent term restoration and marketing exclusivity Depending upon the timing, duration and specifics of FDA approval of product candidates, some of a sponsors U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for
patent terms lost during product development and FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the products approval date. The patent term
restoration period generally is one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an
approved biologic product is eligible for the extension, the application for the extension must be submitted prior to the expiration of the patent, and only those claims covering the approved drug, a method for using it or a method for manufacturing
it may be extended. Moreover, a given patent may only be extended once based on a single product. The USPTO in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Government regulation outside of the U.S. In addition to regulations in the United States, a manufacturer is subject to a variety of regulations in foreign jurisdictions to the extent
it chooses to sell any products in those foreign countries. Even if a manufacturer obtains FDA approval of a product, it must still obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical
trials or marketing of the product in those countries. Because biologically sourced materials are subject to unique contamination risks, their use may also be restricted in some countries. Clinical Trial Approval in the European Union Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on Good Clinical Practice, an applicant
must obtain approval from the competent national authority of the European Union Member State, or the EU Member State, in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent
authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a
favorable opinion. In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. The new Clinical Trials Regulation will be directly applicable
to and binding in all EU Member States without the need for any national implementing legislation. Clinical Trials Regulation (EU) No 536/2014 was published on June 16, 2014 but is not expected to apply until 2019. PRIME Designation In March 2016,
the European Medicines Agency, or the EMA, launched the PRIority MEdicines, or PRIME, initiative to foster research and development of medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without
treatment options. PRIME aims to strengthen clinical trial designs to facilitate the generation of high-quality data for the evaluation of an application for marketing authorization. To be accepted for PRIME, a medicine has to show its potential to
benefit patients with unmet medical needs  27




---

##### Table of Contents

based on preclinical and/or early clinical data. These medicines are considered priority medicines within the European Union. After an investigational candidate has been selected for PRIME, developers are assigned a rapporteur from the Committee for Medicinal Products
for Human Use, or CHMP, to provide continuous support and help to build knowledge ahead of a marketing authorization application, or MAA. A multidisciplinary group of experts will provide broader guidance on the overall development plan and
regulatory strategy of the product. Companies are also eligible for accelerated assessment at the time of their regulatory application. Marketing
Authorization In the European Union, marketing authorizations for medicinal products may be obtained through several different
procedures founded on the same basic regulatory process. The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid across the European Economic Area (i.e. the EU as well as Iceland, Liechtenstein and Norway). The centralized procedure is compulsory for medicinal products produced by certain biotechnological
processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of certain diseases. It is optional for those products that are highly innovative or for which a centralized process is
in the interest of patients. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the
applicant in response to questions asked by the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases. These are defined as circumstances in which a medicinal product is expected to be of a major public health
interest. Three cumulative criteria must be fulfilled in such circumstances: the seriousness of the disease, such as severely disabling or life-threatening diseases, to be treated; the absence or
insufficiency of an appropriate alternative therapeutic approach; and anticipation of high therapeutic benefit. In these circumstances, the EMA ensures that the opinion of the CHMP is given within 150 days. Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene
therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on
medicinal products. Regulation 1394/2007/EC lays down specific rules concerning the authorization, supervision, and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products.
Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety, and efficacy of their products to EMA which provides an opinion regarding the application for marketing authorization. The European Commission grants or
refuses marketing authorization in light of the opinion delivered by EMA. The decentralized procedure provides for approval by one or
more other concerned EU Member States of an assessment of an application for marketing authorization conducted by one EU Member State, known as the reference EU Member State. In accordance with this procedure, an applicant submits an application for
marketing authorization to the reference EU Member State and the concerned EU Member States. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU
Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States which, within 90 days of
receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the
assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European  28




---

##### Table of Contents

Commission, whose decision is binding on all EU Member States. In accordance with the mutual recognition procedure, the sponsor applies for national marketing authorization in one EU Member
State. Upon receipt of this authorization the sponsor can then seek the recognition of this authorization by other EU Member States. Authorization in accordance with either of these procedures will result in authorization of the medicinal product
only in the reference EU Member State and in the other concerned EU Member States. A marketing authorization may be granted only to an
applicant established in the European Union. Regulation No. 1901/2006 provides that, prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in a Pediatric
Investigation Plan, or PIP, approved by the Pediatric Committee of the EMA, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral
for one or more of the measures included in the PIP. In specific circumstances, E.U. legislation on Conditional Marketing Authorizations
for Medicinal Products for Human Use, or conditional marketing authorization, enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing
authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if the risk-benefit balance of the product candidate is positive, it is likely that the applicant will be
in a position to provide the required comprehensive clinical trial data, the product fulfills unmet medical needs and the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk
inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of
ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional Marketing Authorization Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and
after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional
marketing authorization. The requirements and processes governing the conduct of clinical trials, product licensing, pricing and
reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCPs and the applicable regulatory requirements of the country or countries in which the clinical trial is performed, as well as the
ethical principles that have their origin in the Declaration of Helsinki (whichever provides the greater protection to the clinical trial participants). Healthcare Law and Regulation Healthcare providers and third-party payors play a primary role in the recommendation and prescription
of products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse,
anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain business
and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:  

the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing
remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a
federal healthcare program such as Medicare and Medicaid;  29




---

##### Table of Contents



the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or
causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay
money to the federal government;  

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;  

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;  

the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment
for healthcare benefits, items or services;  

the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Health Care Reform Law, which requires certain manufacturers of drugs, devices, biologics and medical supplies to
report annually to the Centers for Medicare & Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and
teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and  

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industrys voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and foreign laws also
govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Pharmaceutical Insurance Coverage and Health Care Reform In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government
authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for
setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of
medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular
indication. Healthcare reforms may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage
criteria, new payment methodologies and additional downward pressure on the price for any  30




---

##### Table of Contents

approved product and/or the level of reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices or the frequency
with which products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Since enactment of the Health Care Reform Law, there
have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. In May 2017, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017. Thereafter, the Senate
Republicans introduced and then updated a bill to replace the Health Care Reform Law known as the Better Care Reconciliation Act of 2017. The Senate Republicans also introduced legislation to repeal the Health Care Reform Law without companion
legislation to replace it, and a skinny version of the Better Care Reconciliation Act of 2017. In addition, the Senate considered proposed healthcare reform legislation known as the Graham-Cassidy bill. None of these measures was passed
by the U.S. Senate. The Trump Administration has also taken executive actions to undermine or delay implementation of the Health Care
Reform Law. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Health Care Reform Law to waive, defer, grant exemptions from, or delay the implementation of any
provision of the Health Care Reform Law that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a
second Executive Order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the Health Care Reform Law exchanges. At the same time, the Administration
announced that it will discontinue the payment of cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums
on certain policies issued by qualified health plans under the Health Care Reform Law. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain. More recently, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress
repealed the individual mandate. The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will become effective in 2019. According to the Congressional Budget Office, the repeal of the
individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year
2018 that delayed the implementation of certain Health Care Reform Law-mandated fees, including the so-called Cadillac tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance
providers based on market share, and the medical device excise tax on non-exempt medical devices. The Congress will likely consider other legislation to replace elements of the Health Care Reform Law, during the next Congressional session. Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed
to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of products under Medicare and reform government program reimbursement methodologies for
products. At the federal level, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control costs. At the state level, individual states are increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding
procedures to determine what pharmaceutical products and which suppliers will be included in their prescription product and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure
on our product pricing.  31




---

##### Table of Contents

Environmental regulations We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control
Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations. These and other laws govern our use, handling and disposal of various biological and chemical substances used in, and waste
generated by, our operations. Our research and development involves the controlled use of hazardous materials, chemicals and viruses. Employees As of December 31, 2017, we had 60 full-time employees, 19 of whom hold Ph.D. or M.D. degrees, 22 of whom are engaged in research
and development activities, four of whom are engaged in clinical and regulatory activities and 34 of whom are engaged in business development, legal, finance, information systems, human resources or administrative support activities. Corporate Information We were originally
formed as SOLID Ventures Management, LLC in March 2013 as a Delaware limited liability company. In October 2013, we changed our name to Solid Ventures, LLC and in June 2015 we changed our name to Solid Biosciences, LLC. Immediately prior to the
effectiveness of our registration statement on Form S-1 on January 25, 2018, we converted into a Delaware corporation pursuant to a statutory conversion and changed our name to Solid Biosciences Inc. In addition, immediately following the
statutory conversion, entities formed solely for the purpose of holding membership interests in our limited liability company were merged with and into us. We refer to the corporate conversion and the mergers collectively as the Corporate
Conversion. Our principal executive offices are located at 141 Portland Street, Fifth Floor, Cambridge, Massachusetts 02139 and our telephone number is (617) 337-4680. Our website address is www.solidbio.com. The information contained in, or
accessible through, our website does not constitute a part of this Annual Report on Form 10-K.  Item 1A.
Risk Factors. You should carefully consider the following risk factors, in addition to the other
information contained in this Annual Report on Form 10-K, including the section of this report titled Managements Discussion and Analysis of Financial Condition and Results of Operations and our financial statements and related
notes. If any of the events described in the following risk factors and the risks described elsewhere in this Annual Report on Form 10-K occurs, our business, operating results and financial condition could be seriously harmed and the trading
price of our common stock could decline. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking
statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K. Risks related to our financial
position and need for capital requirements We have incurred significant net losses since inception and anticipate that we will continue to incur
net losses for the foreseeable future and may never achieve or maintain profitability. Since inception, we have incurred
significant net losses. Our net losses were $53.2 million, $23.8 million and $6.7 million for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017, we had an accumulated members deficit of
$124.3 million. To date, we have devoted substantially all of our efforts to research and development, including clinical development of our gene transfer product candidate, SGT-001, as well as to building out our management team and
infrastructure. We expect that it could be several years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses and  32




---

##### Table of Contents

increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as, we:  

seek to resolve the partial and full clinical holds on the Phase I/II clinical trial for SGT-001 and, if and when lifted, resume our clinical development of SGT-001;  

move other current or future product candidates into clinical trials;  

continue research and preclinical development of our other product candidate;  

seek to identify additional product candidates;  

seek marketing approvals for our product candidates that successfully complete clinical trials, if any;  

establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;  

arrange for manufacture of larger quantities of our product candidates for clinical development and potential commercialization;  

maintain, expand, protect and enforce our intellectual property portfolio;  

hire and retain additional clinical, quality control and scientific personnel;  

build out new facilities or expand existing facilities to support our ongoing development activity;  

acquire or in-license other drugs, technologies and intellectual property; and  

add operational, financial and management information systems and personnel. To become and
remain profitable, we must develop and eventually commercialize one or more product candidates with significant market potential. This will require us to be successful in a range of challenging activities, and our expenses will increase
substantially as we seek to resolve the clinical holds and complete clinical trials of SGT-001, obtain marketing approval for SGT-001, develop and validate commercial-scale manufacturing processes, manufacture, market and sell any future product
candidates for which we may obtain marketing approval and satisfy any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to
achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our
ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause stockholders to lose all or part of their investment. We will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may
force us to delay, limit or terminate our product development efforts or other operations. We expect our expenses to increase in
connection with our ongoing activities, particularly as we continue the research and development of, conduct clinical trials of, and seek marketing approval for, SGT-001 and our other product candidates. In addition, if we obtain marketing approval
for SGT-001 and our other product candidates, we expect to incur significant expenses related to product sales, marketing, manufacturing and distribution. We also incur additional costs associated with operating as a public company. While we believe
that our cash, cash equivalents and available-for-sale securities as of December 31, 2017, together with the net proceeds of $129.3 million from our recently completed initial public offering, after deducting underwriting discounts and
commissions and offering expenses, will enable us to fund our operating expenses and capital expenditure requirements until the end of 2019, we anticipate that we will need additional funding to complete the development of SGT-001 and our other
product candidates.  33




---

##### Table of Contents

Our future capital requirements will depend on many factors, including:  

our ability to favorably resolve the partial and full clinical holds on the Phase I/II clinical trial of SGT-001 and, if so resolved, the timing of such resolution;  

the progress and results of our Phase I/II clinical trial and future clinical trials of SGT-001 and our other product candidates;  

the costs, timing and outcome of regulatory review of SGT-001 and our other product candidates;  

the scope, progress, results and costs of discovery, laboratory testing, manufacturing, preclinical development and clinical trials for other product candidates that we may pursue in the future, if any;  

the costs associated with our manufacturing process development and evaluation of third-party manufacturers;  

the costs associated with constructing and validating our own manufacturing facility;  

revenue, if any, received from commercial sale of SGT-001 or our other product candidates, should any of our product candidates receive marketing approval;  

the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims;  

the outcome of any lawsuits filed against us;  

the terms of our current and any future license agreements and collaborations; and  

the extent to which we acquire or in-license other product candidates, technologies and intellectual property. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our
product revenue, if any, will be derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business
objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Raising additional capital may cause dilution
to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies, SGT-001 or our other product candidates. We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership of our common stock will be diluted and the terms may include liquidation or other preferences
that adversely affect the rights of our current stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, SGT-001 or our other product candidates, or grant licenses on terms unfavorable to us. We have never generated revenue from product sales and do not expect to do so for the next several years, if ever. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to
successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, SGT-001 and our other product candidate, SB-001, and any other product candidates  34




---

##### Table of Contents

that we may pursue in the future. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends
heavily on our success in:  

favorably resolving the full and partial clinical trial holds on the Phase I/II clinical trial for SGT-001;  

completing research and development of SGT-001 and our other product candidates in a timely and successful manner;  

seeking and obtaining regulatory and marketing approvals for any product candidates for which we complete clinical trials;  

launching and commercializing SGT-001 and any other product candidates for which we obtain regulatory and marketing approval by establishing a sales force and marketing and distribution infrastructure or, alternatively,
collaborating with a commercialization partner;  

maintaining and enhancing a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for SGT-001 and our other product candidates that is compliant with cGMPs;  

establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the commercial
demand for SGT-001 and our other product candidates, if approved;  

obtaining market acceptance, if and when approved, of SGT-001 and our other product candidate as a viable treatment option by patients, the medical community and third-party payors;  

qualifying for coverage and adequate reimbursement by government and third-party payors for SGT-001 and our other product candidates both in the U.S. and internationally;  

effectively addressing any competing technological and market developments;  

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements;  

maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trademarks, trade secrets and know-how;  

avoiding and defending against intellectual property infringement, misappropriation and other claims;  

implementing additional internal systems and infrastructure, as needed; and  

attracting, hiring and retaining qualified personnel. Our limited operating history may make it
difficult for our stockholders to evaluate the success of our business to date and to assess our future viability. We are a
development-stage company founded in 2013. Our operations to date, with respect to the development of SGT-001 and other potential product candidates, have been limited to organizing and staffing our company, business planning, raising capital,
acquiring rights to our technology, identifying SGT-001 as a potential gene transfer product candidate and undertaking preclinical studies and a clinical trial of that product candidate and establishing research and development and manufacturing
collaborations. We have not yet demonstrated the ability to complete clinical trials of SGT-001 or any other product candidate, obtain marketing approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary
for successful commercialization. Consequently, any predictions our stockholders make about our prospects may not be as accurate as they could be if we had a longer operating history.  35




---

##### Table of Contents

Risks related to the development of our product candidates SGT-001 is a gene transfer candidate based on a novel technology, which makes it difficult to predict the time and cost of development and of
subsequently obtaining regulatory approval. To our knowledge, only one gene transfer product has been approved in the United States for commercialization and only two such products have been approved in the European Union. We have concentrated our research and development efforts on SGT-001 for the treatment of DMD and our future success depends on our successful
development of that product candidate. Our risk of failure is high. We have experienced, and may experience additional, problems or delays in developing SGT-001. Any such problems or delays would cause unanticipated costs, and any development
problems may not be solved. For example, we or another party may uncover a previously unknown risk associated with SGT-001, the AAV vector, toxicity or other issues that may be more problematic than we currently believe and this may prolong the
period of observation required for obtaining, or result in the failure to obtain, regulatory approval or may necessitate additional clinical testing. In addition, the product specifications and the clinical trial requirements of the FDA, the European Commission, the EMA, and other regulatory
authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidate. The regulatory
approval process for novel product candidates such as ours is unclear and can be more expensive and take longer than for other, better known or more extensively studied product candidates. To our knowledge, only one in vivo gene transfer
product, Spark Therapeutics, Inc.s Luxturna, has received FDA approval and only one in vivo gene transfer product, uniQure N.V.s Glybera, has received marketing authorization from the European Commission. As a result, it is
difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for SGT-001 in either the United States or the European Union. Approvals by the European Commission may not be indicative of what the FDA may
require for approval and vice versa. The FDA has placed the Phase I/II clinical trial of SGT-001 on full clinical hold after we reported a serious
adverse event in the first patient dosed in the clinical trial. We may not conduct any clinical trials of SGT-001 until such full clinical hold is lifted by the FDA. In addition, the FDA placed the SGT-001 Phase I/II clinical trial on partial
clinical hold requiring us to submit additional CMC information that demonstrates that manufacturing capacity and product attributes can support the high-dose group. Our business may be adversely affected if the full and partial clinical holds are
not timely and favorably resolved or if such regulatory concerns lead to more burdensome preclinical studies or clinical trials that cause significant delays in or end development of SGT-001. In March 2018, the FDA placed a full clinical hold on SGT-001 following a serious adverse event in our Phase I/II clinical trial, called IGNITE
DMD, which is designed to evaluate SGT-001 in ambulatory and non-ambulatory males with DMD aged four to 17 years. On February 14, 2018, the first patient in the IGNITE DMD clinical trial, a non-ambulatory adolescent, was dosed with 5E13 vg/kg
of SGT-001. Several days after administration the patient was hospitalized due to laboratory findings that included a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation. We reported the
serious adverse event to the FDA and, because it was unexpected, classified it as SUSAR. We have halted enrollment and dosing in IGNITE DMD and are awaiting the formal clinical hold letter from the FDA. We cannot assure our stockholders that the FDA
will timely lift the full clinical hold, or at all, and, if it fails to do so, our development timeline and our business would be adversely affected and our stock price would likely decline. In addition, pursuant to a letter we received from the FDA in November 2017, we are not permitted to dose patients in the higher-dose group of
IGNITE DMD, until we resolve the partial clinical hold on SGT-001. In order to do so, we will need to decrease the number of vials and utilize no more than a single production lot per patient and demonstrate that we have the appropriate
manufacturing processes in place to support the higher-dose group. In addition, the FDA had additional comments and requests for information that were characterized as not  36




---

##### Table of Contents

clinical hold comments. We have submitted our response to the FDA, in which we aim to address the specific deficiencies identified by the FDA with information that we believe demonstrates
manufacturing capacity and product attributes that will support the high-dose group. However, unless and until the full and partial clinical holds are lifted, we will not be able to fully evaluate the safety, tolerability and efficacy of SGT-001. We cannot assure our stockholders that the FDA will lift the full and/or partial clinical hold and allow us to pursue further development
of SGT-001 as planned, or at all. Further, even if the FDA lifts the full and partial clinical hold, or if the FDA or other regulatory agencies continue to express safety concerns even after the hold is lifted, additional preclinical studies or
clinical trials involving SGT-001 or changes to our manufacturing process may be needed and difficult to complete. In such instance, our progress in the development of SGT-001 may be significantly slowed or stopped and the associated costs may be
significantly increased, adversely affecting our business. In addition, we may not be able to obtain IRB approvals for our Phase I/II
clinical trial as a result of the full or partial clinical hold or any related risks, which could delay our ability to open new trial sites and enroll patients into the clinical trial. Any inability to continue or complete our clinical trial of
SGT-001, as a result of the full or partial clinical hold or otherwise, will delay or terminate our clinical development plans for SGT-001, may require us to incur additional clinical development costs and could impair our ability to ultimately
obtain FDA approval for SGT-001. Delays in the completion of any clinical trial of SGT-001, our lead product candidate, or any other product candidate will increase our costs, slow down our product candidate development and approval process and
delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial
of regulatory approval of SGT-001 or our product candidates. Our product candidates may cause undesirable side effects or have other properties
that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval. During the conduct of clinical trials, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal
outcome. Often, it is not possible to determine whether the product candidate being studied caused these conditions. For instance, recently we reported a serious adverse event in the SGT-001 Phase I/II IGNITE DMD clinical trial, which resulted in a
full clinical hold. In addition, it is possible that as we test SGT-001 or our other product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory
approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times,
side effects are only detectable after investigational products are tested in large-scale, Phase III clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical
experience indicates that SGT-001 or any other product candidate has side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received
regulatory approval, such approval may be revoked. There have been several significant adverse side effects in gene therapy treatments in
the past, including reported cases of leukemia and death seen in other clinical trials using other vectors. While new recombinant vectors have been developed with the intent to reduce these side effects, gene therapy is still a relatively new
approach to disease treatment and additional adverse side effects could develop. Patients will create antibodies to the AAV vector and a second administration of gene transfer might not be successful. There also is the potential risk of delayed
adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that may occur with treatment
with gene therapy products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment or represent safety risks for patients. Additionally, in previous clinical trials involving AAV
vectors for gene therapy, some subjects  37




---

##### Table of Contents

experienced the development of a positive ELISPOT test associated with T-cell responses, which is of unclear clinical translatability. If T-cells are activated, the cellular immune response
system may trigger the removal of transduced cells. If our gene transfer candidate demonstrates a similar effect, we may decide or be required to halt or delay further clinical development of SGT-001. As part of our preclinical program, we performed necessary GLP toxicology studies to establish the overall safety profile of SGT-001 in
wild-type mice and NHPs. The data and our conclusions from these studies were included in our IND submission to the FDA. Systemic administration of SGT-001 was generally well tolerated in both species. We observed no evidence of test-article-related
toxicity for up to 13 weeks after systemic administration of SGT-001 in either species that would prevent us from initiating clinical trials. In the NHP study, test-article-related effects were self-limited, mild chemistry and hematology changes
with no microscopic correlates at the end of the study. There was a transient and asymptomatic increase in liver function enzymes observed in NHPs starting on day 9, which returned to normal levels by day 21. We believe there were no other relevant
test-article-related adverse events associated with SGT-001 administration in either GLP study. In the NHP toxicology study, a single animal from the high dose cohort was euthanized after it did not recover from an anesthetic procedure. We believe
this event was attributed to procedural errors. However, AAV vector cannot be completely ruled out as a contributing factor to the toxicity that gave rise to the event. In addition to side effects caused by SGT-001 and our other product candidates, the administration process or related procedures also can
cause adverse side effects. For example, integration of AAV DNA into the host cells genome has been reported to occur. Further, our AAV delivery system has not been validated in human clinical trials previously, and if such delivery system
does not meet the safety criteria or cannot provide the desired efficacy results, then we may be forced to suspend or terminate our development of SGT-001. In addition, the relatively high dosing requirements for SGT-001 may amplify the risk of
adverse side effects relating to the AAV vector. Recently, James M. Wilson, M.D., Ph.D., resigned from our Scientific Advisory Board citing emerging concerns about the possible risks of high systemic dosing of AAV. If any such adverse side effects
were to occur in the future and we are unable to demonstrate that they were not caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further
development of, or deny approval of, SGT-001 or our other product candidate for any or all targeted indications. Even if we are able to demonstrate that any serious adverse events are not product-related, such occurrences could affect patient
recruitment or the ability of enrolled patients to complete the clinical trial. Additionally, if SGT-001 or our other product candidates
receive marketing approval, the FDA could require us to adopt an REMS to ensure that the benefits outweigh the risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a
communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by SGT-001 or our other product candidates, several potentially significant negative
consequences could result, including:  

regulatory authorities may suspend or withdraw approvals of such a product candidate;  

regulatory authorities may require additional warnings on the label;  

we may be required to change the way a product candidate is administered or conduct additional clinical trials;  

we could be sued and held liable for harm caused to patients; and  

our reputation may suffer.  38




---

##### Table of Contents

We only recently initiated our first clinical trial for SGT-001 and have not commenced preclinical
studies for our other product candidates. We have never completed a clinical trial, and may be unable to do so for any product candidates we may develop, including SGT-001. We will need to successfully complete clinical trials in order to obtain FDA approval to market SGT-001 or our other product candidates. We
only recently initiated our first clinical trial for SGT-001, have limited experience in preparing, submitting and prosecuting regulatory filings, and have not previously submitted a BLA for any product candidate. The FDA placed SGT-001 on a full
clinical hold and a partial clinical hold. If the clinical holds are not lifted on our Phase I/II clinical trial, we will not be able to evaluate or fully evaluate the safety, tolerability and efficacy of SGT-001. We cannot be sure that submission
of an IND will result in the FDA allowing clinical trials to begin or that, once begun, issues will not arise that suspend or terminate such clinical trials. Carrying out later-stage clinical trials and the submission of a successful BLA is a
complicated process. This may be particularly true for design of a pivotal trial for the treatment of DMD as the FDA has not given clear guidance as to the necessary endpoints for approval of a treatment for DMD. In addition, we have had limited
interactions with the FDA and cannot be certain how many clinical trials of SGT-001 or our other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and
complete necessary clinical trials in a way that leads to BLA submission and approval of SGT-001 or our other product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory
approvals of product candidates that we develop. Failure to commence or complete, or delays in, clinical trials, could prevent us from or delay us in commercializing SGT-001 and our other product candidates. Success in preclinical studies or early clinical trials, including our recently initiated Phase I/II trial, may not be indicative of results obtained in
later trials. Results from preclinical studies or early clinical trials, including our recently initiated Phase I/II trial, are
not necessarily predictive of future clinical trial results and are not necessarily indicative of final results. There is a high failure rate for gene therapy and biologic products proceeding through clinical trials. Many companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical
activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. We also may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the
period of our product candidate development. Our preclinical studies for SGT-001 in animals have been limited and we have only recently dosed a human patient with SGT-001. SGT-001 or our other product candidates may fail to show the desired safety
and efficacy in clinical development despite positive results in preclinical studies. This failure would cause us to abandon SGT-001 or our other product candidates. We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable
regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of SGT-001 or our other
product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot
guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical
development include:  

delays in reaching a consensus with regulatory authorities on trial design;  

delays in or the inability to successfully resolve the full or partial clinical hold placed on our Phase I/II clinical trial for SGT-001;  

delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;  39




---

##### Table of Contents



delays in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;  

delays in recruiting suitable subjects to participate in our clinical trials, including because such trials may be placebo-controlled trials and patients are not guaranteed to receive treatment with our product
candidates;  

failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;  

failure to perform in accordance with FDA GCPs or applicable regulatory guidelines in the European Union and other countries;  

delays in the testing, validation, manufacturing and delivery of SGT-001 or our other product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those
functions;  

delays in subjects completing participation in a trial or returning for post-treatment follow-up;  

clinical trial sites or subjects dropping out of a trial;  

selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;  

imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations, trial sites or manufacturing facilities;  

occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; or  

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with
SGT-001 or our other product candidates, we may:  

be delayed or fail in obtaining marketing approval for SGT-001 or our other product candidates;  

obtain approval for indications or patient populations that are not as broad as we intended or desired;  

obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;  

be subject to changes in the way the products are administered;  

be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;  

have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS;  

be sued and held liable for harm caused to patients; or  

experience damage to our reputation. Our product development costs will increase if we
experience delays in testing or marketing approvals. In addition, if we make manufacturing or other changes to SGT-001 or our other product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier
versions. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could
shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates.  40




---

##### Table of Contents

If our third-party clinical trial vendors fail to comply with strict regulations, the clinical trials
for SGT-001 or our other product candidates may be delayed or unsuccessful. We do not have the personnel capacity to conduct or
manage the clinical trials that will be necessary for the development of SGT-001 or our other product candidates. For our Phase I/II trial of SGT-001 we are relying, and for any future clinical trials we will rely, on third parties to assist us in
managing, monitoring and conducting our clinical trials. If these third parties fail to comply with applicable regulations or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into
alternative arrangements without undue delay or additional expenditures and, therefore, the clinical trials for SGT-001 or our other product candidates may be delayed or unsuccessful. Furthermore, the FDA can be expected to inspect some or all of the clinical sites participating in our clinical trials to determine if our
clinical trials are being conducted according to GCPs. If the FDA determines that these clinical sites are not in compliance with applicable regulations, we may be required to delay, repeat or terminate the clinical trials. We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of SGT-001 or
our other product candidates. Identifying and qualifying patients to participate in any clinical trials of SGT-001 and our other
product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients to participate as well as complete required follow-up periods. If patients are unwilling to participate in our gene therapy
clinical trials because of negative publicity from adverse events related to our product candidates, including the serious adverse event we recently reported, other approved gene therapies, the biotechnology or gene therapy fields, competitive
clinical trials for similar patient populations, clinical trials in products employing our vector or our platform or for other reasons, the timeline for recruiting patients, conducting clinical trials and obtaining regulatory approval of SGT-001 may
be delayed. We may also experience delays if patients withdraw from the clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing SGT-001 or our other product candidates,
delays in testing the effectiveness of SGT-001 and our other product candidates or termination of clinical trials altogether. We may not
be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete any clinical trials in a timely manner. Patient enrollment and trial completion is affected by many factors,
including:  

size of the patient population and the process for identifying subjects;  

design of the trial protocol;  

eligibility and exclusion criteria, including that some patients may have pre-existing antibodies to AAV vectors precluding them from being able to receive AAV-mediated gene transfer;  

restrictions on our ability to conduct clinical trials, including full and partial clinical holds on ongoing or planned clinical trials;  

perceived risks and benefits of the product candidate under study;  

perceived risks and benefits of gene therapy-based approaches to the treatment of diseases;  

availability of competing therapies and clinical trials;  

severity of the disease;  

proximity and availability of clinical trial sites for prospective subjects;  

ability to obtain and maintain subject consent;  

risk that enrolled subjects will drop out before completion of the trial;  41




---

##### Table of Contents



patient referral practices of physicians;  

ability to monitor subjects adequately during and after treatment; and  

in the case of pivotal trials, the risk that patients may opt not to enroll because they are not assured treatment with our product candidate. In March 2018, the FDA placed our Phase I/II clinical trial of SGT-001 on full clinical hold following our report of a serious adverse event
in the clinical trial. As a result, we have halted enrollment and dosing in the clinical trial and are awaiting the formal clinical hold letter from the FDA. If we are unable to satisfy any requests of the FDA in a timely manner, or at all, or if
the FDA does not lift the full or partial clinical hold in a timely manner, or at all, we would be further delayed or prevented from enrolling patients in our Phase I/II clinical trial of SGT-001. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to
conducting business in foreign countries, including:  

different standards for the conduct of clinical trials;  

absence in some countries of established groups with sufficient regulatory expertise for review of gene therapy protocols;  

difficulty in identifying and partnering with qualified local consultants, physicians and partners; and  

the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology research and products. Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize SGT-001 or our
other product candidates and the approval may be for a more narrow indication than we seek. We cannot commercialize SGT-001 or our
other product candidates until the appropriate regulatory authorities have reviewed and approved the product candidate. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes
and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the
regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee or other regulatory authority recommends non-approval
or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy during the period of product
development, clinical trials and the regulatory review process. Even if we receive regulatory approval, regulatory authorities may
approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. Regulatory authorities may require precautions or contra-indications with
respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful
commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight. Even if we obtain any regulatory approval for SGT-001 or our other product candidates, we will be subject to ongoing regulatory requirements
for manufacturing, labeling, packaging, storage, advertising, promotion,  42




---

##### Table of Contents

sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates may also be subject to a REMS, limitations
on the approved indicated uses for which the product may be marketed or conditions of approval, or requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the quality, safety
and efficacy of the product. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. If we fail to comply with applicable regulatory requirements following approval of SGT-001 or our other product candidates, a regulatory
authority may, among other things, suspend or withdraw regulatory approval, narrow the product label, restrict the marketing or manufacturing of the product, suspend any ongoing clinical trials or seize or detain the product or otherwise require the
withdrawal of the product from the market. Even if we obtain and maintain approval for SGT-001 or our other product candidates from the FDA, we may
never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and adversely affect our business. Even if we receive FDA approval of SGT-001 or our other product candidates in the United States, approval of a product candidate in the United
States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign
countries or by the FDA. Future sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials, manufacturing and marketing approval. Approval procedures vary among
jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States,
a product candidate must be approved for reimbursement before it can be approved for sale in that country. We intend to submit an MAA to the EMA for approval of SGT-001 in the European Union, but obtaining such approval from the European Commission
following the opinion of the EMA is a lengthy and expensive process. Regulatory authorities in countries outside of the United States and the European Union also have requirements for approval of product candidates with which we must comply prior to
marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of SGT-001 or our
other product candidates in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory
authorities in other countries. Also, regulatory approval for SGT-001 or our other product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced, and our ability to realize the full
market potential of our product candidates will be harmed. Regulatory requirements governing gene therapy products have changed frequently and may
continue to change in the future. The FDA has established the OTAT within its CBER to consolidate the review of gene therapy and
related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH also
are potentially subject to review by the RAC; however, the NIH announced that the RAC will soon only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides
whether individual gene therapy protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the
FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, that institutions IBC as well as
its IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse  43




---

##### Table of Contents

developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.
Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. In addition, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional
regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our
product candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is
impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. As we advance SGT-001 and our other product candidates, we will be required to consult with these regulatory and advisory groups, and comply
with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to
changes in regulatory positions and interpretations, delay or prevent approval and commercialization of SGT-001 or our other product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or
unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue. We may not be able to benefit from orphan drug designation for SGT-001 or any of our product candidates. The FDA and EMA granted SGT-001 orphan drug designation for the treatment of DMD in August 2016 and September 2016, respectively. The
designation of SGT-001 as an orphan drug does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug
designation to product candidates of other companies that treat the same indications as our product candidate prior to our product candidate receiving exclusive marketing approval. We may lose orphan drug exclusivity if the FDA or EMA determines that the request for designation was materially defective or if we
cannot assure sufficient quantity of the applicable drug to meet the needs of patients with DMD. Even if we maintain orphan drug
exclusivity for SGT-001 or obtain orphan drug exclusivity for our other product candidate, the exclusivity may not effectively protect the product candidate from competition because regulatory authorities still may authorize different drugs for the
same condition or the same drug for the same condition if it is determined by the FDA to be clinically superior to the product with orphan drug exclusivity. We may seek a breakthrough therapy designation for SGT-001 or our other product candidates, but we might not receive such designation, and even if we
do, such designation may not lead to a faster development or regulatory review or approval process. We may seek a breakthrough
therapy designation for SGT-001 or our other product candidates; however, we cannot assure our stockholders that SGT-001 or our other product candidates will meet the criteria for that designation. A breakthrough therapy is defined as a therapy that
is intended, alone or in combination with one or more other therapies, to treat a serious condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the
sponsor of  44




---

##### Table of Contents

the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as
breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the new drug application is submitted to the FDA. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates
meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a product candidate may
not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product
candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. The FDA has granted RPDD to SGT-001; however, a BLA for SGT-001 may not meet the eligibility criteria for a priority review voucher upon approval. The FDA has granted RPDD to SGT-001. RPDD does not guarantee that a BLA for such drug will meet the eligibility criteria for a
rare pediatric disease priority review voucher at the time the application is approved. We will need to request a rare pediatric disease priority review voucher in our BLA for SGT-001. The use of a priority review voucher allows for a drug to be
reviewed by the FDA within six months. However, the FDA may determine that a BLA for SGT-001 does not meet the eligibility criteria for a priority review voucher upon approval. Moreover, even if SGT-001 does satisfy those criteria, the product will
need to be licensed before September 30, 2022 in order to be granted a rare disease priority review voucher. We may seek fast track
designation for SGT-001 or our other product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process. If a therapy is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet
medical need for this condition, a drug sponsor may apply for FDA fast track designation. If we seek fast track designation for a product candidate, we may not receive it from the FDA. Even if we receive fast track designation, fast track
designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with fast track designation
compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not
guarantee qualification for the FDAs priority review procedures. We may seek priority review designation for SGT-001 or our other product
candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process. If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a
significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard
review period of ten months. We may request priority review for our product candidates, however, we cannot assume that SGT-001 or our other product candidates will meet the criteria for that designation. The FDA has broad discretion with respect to
whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does
not  45




---

##### Table of Contents

necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving
priority review from the FDA does not guarantee approval within the six-month review cycle or at all. We face significant competition and our
competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize SGT-001 or our other product candidates. We operate in a highly competitive segment of the biopharmaceutical market. We face competition from many different sources,
including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully
developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of product candidates, including gene therapies, in development for DMD. Many of our
competitors have significantly greater financial, product candidate development, manufacturing and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining
regulatory approval for their products, and mergers and acquisitions within these industries may result in even more resources being concentrated among a smaller number of larger competitors. Our commercial opportunity could be reduced or eliminated
if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than any product candidate that we may develop. We are aware of several companies focused on developing gene therapies in various indications, as well as several companies addressing other
methods for modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against SGT-001 or any future gene therapy product candidates we develop. We may fail to capitalize on other potential product candidates that may represent a greater commercial opportunity or for which there is a greater
likelihood of success. The success of our business depends upon our ability to develop and commercialize SGT-001 and our other
product candidates. Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential than SGT-001 or our other
product candidates. Our spending on current and future research and development programs may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential for a particular product candidate, we may
relinquish valuable rights to that product candidate through strategic collaborations, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such
product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. If any of these events occur, we may be forced to
abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate. Risks
related to the manufacturing and commercialization of SGT-001 and our other product candidates We may not be successful in finding strategic
collaborators for continuing development of SGT-001 or our other product candidates or successfully commercializing or competing in the market for certain indications. We may seek to establish strategic partnerships for developing SGT-001 or our other product candidates due to capital costs required to
develop, manufacture and commercialize our product candidates. We may not be successful in our efforts to establish such strategic partnerships or other alternative arrangements because our research and development pipeline may be insufficient,
SGT-001 may be deemed to be at too early of a stage of  46




---

##### Table of Contents

development for collaborative effort or third parties may not view SGT-001 as having the requisite potential to demonstrate safety and efficacy. We cannot be certain that, following a strategic
transaction, we will achieve an economic or business benefit that justifies such transaction. If we seek to but are unable to reach
agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail, reduce or delay the development of a product candidate, delay its potential commercialization, reduce the scope of any sales or
marketing activities or increase our expenditures and undertake development, manufacturing or commercialization activities independently. If we elect to fund our own independent development or commercialization activities, we will need to obtain
additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development, manufacturing
and commercialization activities, we may not be able to further develop SGT-001 or our other product candidates. We have limited gene transfer
manufacturing experience and could experience production problems and delays in obtaining regulatory approval of our manufacturing processes, which could result in delays in the development or commercialization of SGT-001 or our other product
candidates. The manufacturing process we use to produce SGT-001 is complex and has not been validated for commercial use. We have
no experience manufacturing SGT-001 and our other product candidates. Building our own manufacturing facility would require substantial additional investment, would be time-consuming and may be subject to delays, including those resulting from
compliance with regulatory requirements. In addition, building a manufacturing facility may cost more than we currently anticipate. Although we may establish our own manufacturing facility to support a commercial launch, if we are unable to do so or
otherwise decide not to do so, we may be unable to produce commercial materials or meet demand, if any should develop, for SGT-001 and our other product candidates. Any such failure could delay or prevent our commercialization of SGT-001 or our
other product candidates. The production of SGT-001 requires processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a gene
transfer such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our
manufacturing process to assure that the process works and that SGT-001 is made strictly and consistently in compliance with the process. As a result of the limited number of FDA approvals for gene transfer products to date, the timeframe required
for us to obtain approval for a cGMP gene therapy manufacturing facility in the United States is uncertain. We must supply all necessary documentation in support of a BLA or other MAA on a timely basis and must adhere to the FDAs and the
European Unions cGMP requirements before SGT-001 and our other product candidates can obtain marketing approval. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP
requirements, and perform extensive audits of contract laboratories, manufacturers and suppliers. We currently rely on third-party
manufacturers for our SGT-001 supply. In order to produce sufficient quantities of SGT-001 for clinical trials and initial U.S. commercial demand, we will need to increase the scale of our manufacturing process at our third-party manufacturers, and
potentially through our own commercial-scale manufacturing facility. We may need to change our current manufacturing process. We may not be able to produce sufficient quantities of SGT-001 due to several factors, including equipment malfunctions,
facility contamination, material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. For example, through our contract manufacturer we have performed and
released within specifications manufacturing runs of SGT-001 for clinical supply and have experienced variability with respect to the success and yield of these runs. We continue to engage in process development activities to improve the
reproducibility, reliability and consistency of yields of our manufacturing process. Additional manufacturing runs will be required to produce necessary or adequate supply for our Phase I/II clinical trial of SGT-001 and there is no guarantee
that all of those runs will be within specifications or  47




---

##### Table of Contents

produce adequate supply. If we are not able to produce sufficient supply on the timeline expected, our overall development schedule for SGT-001 could be delayed, and we could incur additional
expense. If supply from a manufacturing facility is interrupted, there could be a significant disruption in supply of SGT-001 or our
other product candidates. Further, we may not be able to enter into arrangements with additional third-party manufacturers on favorable terms or at all. Use of new third-party manufacturers could increase the risk of delays in production or
insufficient supplies of our product candidates as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our product candidates. In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by
the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such
as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring
recall or withdrawal of the product from the market or suspension of manufacturing. In addition, the FDA, the EMA and other foreign
regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory
authorities may require that we not distribute a lot until the agency authorizes its release. Lot failures or product recalls could cause us to delay or abandon clinical trials or product launches. We also may encounter problems hiring and retaining the experienced specialist scientific, quality control and manufacturing personnel needed
to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger
pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process or facilities also could restrict our ability to meet market demand for
SGT-001, our other product candidates or future product candidates. Although we may establish our own SGT-001 manufacturing facility, we expect to
utilize third parties to conduct our product manufacturing for the foreseeable future. Therefore, we are subject to the risk that these third parties may not perform satisfactorily or meet regulatory requirements. Until such time, if ever, as we establish a manufacturing facility that has been properly validated to comply with FDA cGMP requirements, we
will not be able to independently manufacture material for our current and future clinical programs. For clinical trials of SGT-001, we intend to utilize materials manufactured by cGMP-compliant third-party suppliers. Even following our potential
establishment of a validated cGMP manufacturing facility, we intend to maintain our current and additional third-party manufacturing capabilities in order to provide multiple sources of supply. In the event that the establishment of our own
manufacturing facility is delayed or not otherwise pursued and if these third-party manufacturers do not successfully carry out their contractual duties, meet expected deadlines or manufacture SGT-001 in accordance with regulatory requirements or if
there are disagreements between us and these third-party manufacturers, we may not be able to complete, or may be delayed in completing the clinical trials required for approval of SGT-001. In such instances, we may need to locate an appropriate
replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense prior to the approval of our product candidates. Additionally, we rely on our third-party manufacturers for their compliance with the cGMP and their maintenance of adequate quality control,
quality assurance and qualified personnel. Furthermore, all of our third-party suppliers and manufacturers are engaged with other companies to supply and/or manufacture materials or  48




---

##### Table of Contents

products for such companies, which exposes them to regulatory risks for the production of such materials and products. FDA inspections may identify compliance issues at third-party manufacturer
facilities or at the facilities of third-party suppliers that may disrupt production or distribution, or require substantial resources to correct and prevent recurrence of any deficiencies, and could result in fines or penalties by regulatory
authorities. In addition, discovery of problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product
from the market or other voluntary, FDA-initiated or judicial action, including fines, injunctions, civil penalties, license revocations, seizure, total or partial suspension of production or criminal penalties, any of which could significantly and
adversely affect supplies of our product candidates. In addition, we do not currently have long-term supply or manufacturing arrangements
in place for the production of SGT-001 at commercial scale. Although we intend to establish additional sources for long-term supply, potentially including our own commercial-scale cGMP-compliant manufacturing facility and one or more third-party
manufacturers, if the gene therapy industry were to grow, we may encounter increasing competition for the materials necessary for the production of SGT-001. We may experience difficulties in scaling up production beyond clinical batches.
Furthermore, demand for third-party cGMP manufacturing facilities may grow at a faster rate than existing manufacturing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities
of SGT-001 for future clinical trials or to meet initial commercial demand in the United States. We currently rely, and expect to continue to rely, on additional third parties to manufacture materials for our product candidates and to perform
quality testing. Even following the potential establishment of our own cGMP-compliant manufacturing capabilities, we intend to maintain third-party manufacturers for these materials, as well as to serve as additional sources of SGT-001, which will
expose us to risks including:  

reduced control of manufacturing activities;  

the inability of certain contract manufacturing organizations, or CMOs, to produce our product candidates in the necessary quantities, or in compliance with current cGMP or in compliance with pertinent regulatory
requirements and within our planned time frame and cost parameters;  

termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and  

disruptions to the operations of our third-party manufacturers and suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier. Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize SGT-001
or our other product candidates. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of product manufacture. If we are unable to establish sales, distribution and marketing capabilities or enter into agreements with third parties to market and sell SGT-001 and
our other product candidates, we will be unable to generate any product revenue. We currently have no sales, distribution or
marketing organization. To successfully commercialize any product candidate that may result from our development programs, we will need to develop these capabilities, either on our own or with others. The establishment and development of our own
commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to
successfully develop this capability. We may enter into collaborations regarding SGT-001 and our other product candidates with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into
such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable to develop the necessary  49




---

##### Table of Contents

capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and
well-funded sales, distribution and marketing operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of SGT-001 and our
other product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. If we are unable to establish medical affairs capabilities, we will be unable to establish an educated market of physicians to administer SGT-001 or our
other product candidates. We currently have no medical affairs team. If we are unable to successfully build a medical affairs team
to address scientific and medical questions and provide expert guidance and education in the application, administration and utilization of SGT-001 and our other product candidates to physicians, we may not be able to establish an educated market
for our products. The establishment and development of our own medical affairs team will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. If the market opportunities for SGT-001 are smaller than we believe they are, our revenue prospects may be adversely affected and our business may
suffer. We currently focus our research and product development on treatments for DMD. Our understanding of the patient population
with this disease is based on estimates in published literature and by DMD foundations. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of this disease. The number of patients in the United
States, the European Union and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidate or patients may become increasingly difficult to identify and access. Further, there are several factors that could contribute to making the actual number of patients who receive SGT-001 less than the potentially
addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. Further, the severity of the progression of a degenerative disease such as DMD up to the time of
treatment will likely diminish the therapeutic benefit conferred by a gene therapy due to irreversible cell damage. Certain patients immune
systems might prohibit the successful delivery of certain gene therapy products, thereby potentially limiting treatment outcomes for these patients. As with many AAV-mediated gene therapy approaches, certain patients immune systems might prohibit the successful delivery of certain gene
therapy products, thereby potentially limiting treatment outcomes of these patients. While we are working to better understand the prevalence of neutralizing antibodies to AAV, or seroprevalence, as it relates to gene therapies for DMD, the exact
DMD-wide seroprevalence is currently unknown and it varies by AAV serotype and age. We may not be able to address this potentially limiting factor for gene therapy as a treatment for certain patients. The commercial success of any of our product candidates, including SGT-001, if approved, will depend upon market acceptance by physicians, patients,
third-party payors and others in the medical community. Even with the requisite approvals from the FDA in the United States, the
European Commission in the European Union and other regulatory authorities internationally, the commercial success of SGT-001 will depend, in part, on the acceptance of physicians, patients and health care payors of gene therapy products in general,
and SGT-001 in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community due to ethical, social, medical and
legal concerns. If these products do not achieve an adequate level  50




---

##### Table of Contents

of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and, in particular, SGT-001, if approved for
commercial sale, will depend on multiple factors, including:  

the efficacy and safety of SGT-001 as demonstrated in clinical trials;  

the efficacy and potential and perceived advantages of SGT-001 over alternative treatments;  

the cost of treatment relative to alternative treatments;  

the clinical indications for which SGT-001 is approved by the FDA or the European Commission;  

the willingness of physicians to prescribe new therapies;  

the willingness of the target patient population to try new therapies;  

the prevalence and severity of any side effects;  

product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a products approved labeling;  

relative convenience and ease of administration;  

the strength of marketing and distribution support;  

the timing of market introduction of competitive products;  

the availability of products to meet market demand;  

publicity concerning our product candidates or competing products and treatments;  

any restrictions on the use of our products together with other medications; and  

favorable third-party payor coverage and adequate reimbursement. Even if a potential product displays a
favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of SGT-001 and our other product candidates may require
significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our potential product candidates. If SGT-001 or our other product candidates are approved
but fail to achieve market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenue from any such product. Our gene transfer approach utilizes a vector derived from a virus, which may be perceived as unsafe or may result in unforeseen adverse events. Negative
public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our SGT-001 gene transfer product candidate and adversely affect our ability to conduct our business or obtain regulatory approvals for
SGT-001. Gene transfer remains a novel technology and public perception may be influenced by claims that gene transfer is unsafe,
and gene transfer may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of DMD prescribing treatments that involve the use of SGT-001 in lieu of, or
in addition to, other treatments with which they are more familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion may delay or impair the development and commercialization of
SGT-001 or demand for any product candidate we may develop. A public backlash developed against gene therapy following the death of a patient in 1999 during a gene therapy clinical trial of research subjects with ornithine transcarbamylase, or OTC,
deficiency, a rare disorder in which the liver lacks a functional copy of the OTC gene. The death of the clinical  51




---

##### Table of Contents

trial subject was due to complications of adenovirus vector administration. Dr. James M. Wilson, former chair of our Scientific Advisory Board, was a co-investigator of the 1999 trial
while he was Director of the Institute for Human Gene Therapy of the University of Pennsylvania. Serious adverse events in our clinical trials, including the event that led to our Phase I/II clinical trial of SGT-001 being placed on full clinical
hold, or other clinical trials involving gene transfer products or our competitors products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation,
unfavorable public perception, potential regulatory delays in the testing or approval of SGT-001, stricter labeling requirements for SGT-001 if approved and a decrease in demand for SGT-001. Failure to comply with ongoing regulatory requirements could cause us to suspend production or put in place costly or time-consuming remedial measures. The regulatory authorities may, at any time following approval of a product for sale, audit the manufacturing facilities for such
product. If any such inspection or audit identifies a failure to comply with applicable regulations, or if a violation of product specifications or applicable regulations occurs independent of such an inspection or audit, the relevant regulatory
authority may require remedial measures that may be costly or time-consuming to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a manufacturing
facility. Any contamination in our manufacturing process, shortages of materials or failure of any of our key suppliers to deliver necessary
components could result in interruption in the supply of our product candidates and delays in our clinical development or commercialization schedules. Given the nature of biologics manufacturing, there is a risk of contamination in our manufacturing processes. Any contamination could
materially adversely affect our ability to produce SGT-001 on schedule and could cause reputational damage. Some of the materials
required in our manufacturing process are derived from biologic sources. Such materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically
derived substances in the manufacture of SGT-001 could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development timelines. The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue. There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. We expect the cost of a single
administration of gene transfer products, such as those we are developing, to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most
patients to be able to afford these treatments. Accordingly, sales of SGT-001, if approved, will depend substantially, both domestically and abroad, on the extent to which the costs of SGT-001 will be paid by health maintenance, managed care,
pharmacy benefit and similar health care management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon
several factors, including the third-party payors determination that use of a product is:  

a covered benefit under its health plan;  

safe, effective and medically necessary;  

appropriate for the specific patient;  

cost-effective;  52




---

##### Table of Contents



durable and a one-time treatment; and  

neither experimental nor investigational. Obtaining coverage and reimbursement for a product
from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data. If coverage and reimbursement are not available, or are available only at
limited levels, we may not be able to successfully commercialize SGT-001 and our other product candidates. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment. To our knowledge, no gene transfer product has been approved for coverage and reimbursement by the Centers for Medicare & Medicaid
Services, or the CMS, the agency responsible for administering the Medicaid program. It is difficult to predict what the CMS will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of
established practices and precedents for these types of products either in the United States or the European Union. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for
reimbursement in certain European Union member states and vice versa. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for SGT-001 and our other product candidates. Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any. Outside the United States, international operations generally are subject to extensive government price controls and other market regulations,
and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In general, the prices of therapeutics outside the United States are substantially lower than in the United
States. Other countries may allow companies to fix their own prices for therapeutics, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulations could restrict the amount that we are able to
charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable product
revenue. Additionally, in countries where the pricing of gene therapy products is subject to governmental control, pricing negotiations
with governmental authorities can take considerable time after the receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after
reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain reimbursement or pricing
approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Reimbursement of our products may be unavailable or limited in scope or amount,
which would adversely affect our revenue, if any. If we obtain approval to commercialize SGT-001 and our other product candidates outside of the
United States, in particular in the European Union, a variety of risks associated with international operations could materially adversely affect our business. We expect that we will be subject to additional risks in commercializing SGT-001 and our other product candidates outside the United States,
including:  

different regulatory requirements for approval of therapeutics in foreign countries;  

reduced protection for intellectual property rights;  

the existence of additional third-party patent rights of potential relevance to our business;  53




---

##### Table of Contents



unexpected changes in tariffs, trade barriers and regulatory requirements;  

economic weakness, including inflation, or political instability in particular foreign economies and markets;  

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;  

foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;  

foreign reimbursement, pricing and insurance regimes;  

production shortages resulting from any events affecting material supply or manufacturing capabilities abroad; and  

business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires. The failure to comply with applicable foreign regulatory requirements may result in, among other things, fines, suspension, variation or withdrawal of
regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Additionally, on June 23, 2016, the
electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On March 29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon
Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of our
product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the
United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United
Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business. If we engage in future
acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including:  

increased operating expenses and cash requirements;  

the assumption of additional indebtedness or contingent liabilities;  

assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;  

the diversion of our managements attention from our existing product candidates and initiatives in pursuing such acquisition or strategic collaboration;  

retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;  

risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and  54




---

##### Table of Contents



our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or collaboration or even to offset transaction costs. In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses
and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain
access to technology or products that may be important to the development of our business. Risks related to our business operations Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. We are highly dependent on members of our executive team, the loss of whose services may adversely impact the achievement of our
objectives. While we have entered into employment agreements with certain of our executive officers, any of them could leave our employment at any time. We currently do not have key person insurance on any of our employees. The loss of
the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel,
also will be critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and
vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for
individuals with similar skill sets. In addition, the clinical trial holds on SGT-001, or the failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified
personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives. If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer. If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and
resources to manage our operations, continue our research and development activities and, in the longer term, build a commercial infrastructure to support commercialization of SGT-001 and any other product candidate that is approved for sale. Future
growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need
to effectively manage our operations, growth and any future product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain sufficient
numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals. Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including
non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other
misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other
jurisdictions, provide  55




---

##### Table of Contents

accurate information to the FDA, the EMA and other regulatory authorities, comply with health care fraud and abuse laws and regulations in the United States and abroad, report financial
information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such
misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, including insider trading, which could result in regulatory sanctions and cause
serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting
our rights, those actions could result in the imposition of significant fines or other sanctions. Enacted and future legislation may increase the
difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. Our business and financial prospects could be affected by changes in health care spending and policy in the United States and abroad. We
operate in a highly regulated industry and new laws or judicial decisions, or new interpretations of existing laws or decisions, related to health care availability, the method of delivery or payment for health care products and services could
negatively impact our business, operations and financial condition. For example, in the United States there is significant interest in
promoting health care reform, as evidenced by the enactment of the Health Care Reform Law. The Health Care Reform Law increased federal oversight of private health insurance plans and included a number of provisions designed to reduce Medicare
expenditures and the cost of health care generally, to reduce fraud and abuse, and to provide access to increased health coverage. The
Health Care Reform Law also imposed substantial changes to the U.S. system for paying for health care, including programs to extend medical benefits to millions of individuals who have lacked insurance coverage. Generally, implementation of the
Health Care Reform Law has thus far included significant cost-saving, revenue and payment reduction measures with respect to, for example, several government health care programs that might cover our products in the United States, should they be
commercialized, including Medicaid and Medicare. Additional downward pricing pressure associated with the Health Care Reform Law includes that the Health Care Reform Law established and provided significant funding for a Patient-Centered Outcomes
Research Institute to coordinate and fund Comparative Effectiveness Research, as those terms are defined in the Health Care Reform Law. While the stated intent of Comparative Effectiveness Research is to develop information to guide providers to the
most efficacious therapies, outcomes of Comparative Effectiveness Research could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be approved for sale, but
then determined to be less cost-effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be adversely impacted. Another provision of the Health Care Reform Law, generally referred to as the Physician Payment Sunshine Act or Open Payments Program, has
imposed new reporting and disclosure requirements for pharmaceutical and medical device manufacturers and distributors with certain FDA-approved products, such as approved vaccines, with regard to payments or other transfers of value made to certain
U.S. health care practitioners, such as physicians and academic medical centers, and with regard to certain ownership interests held by physicians in reporting entities. The CMS publishes information from these reports on a publicly available
website, including amounts transferred and the physician and teaching hospital identities.  56




---

##### Table of Contents

Under the Physician Payment Sunshine Act, we are required to collect and report detailed
information regarding certain financial relationships we have with physicians and teaching hospitals. Our compliance with these rules may also impose additional costs. With enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress repealed the
individual mandate. The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will become effective in 2019. According to the Congressional Budget Office, the repeal of the individual
mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Further, each chamber of the Congress has put forth multiple bills designed to repeal or repeal and replace portions of the Health
Care Reform Law. Although none of these measures has been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the Health Care Reform Law. The Congress will likely consider other legislation to
replace elements of the Health Care Reform Law, during the next Congressional session. The Trump Administration has also taken executive
actions to undermine or delay implementation of the Health Care Reform Law. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Health Care Reform Law to waive, defer,
grant exemptions from, or delay the implementation of any provision of the Health Care Reform Law that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or
medical devices. In October 2017, the President signed a second Executive Order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the Health Care
Reform Law exchanges. At the same time, the Administration announced that it will discontinue the payment of CSR payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments
is expected to increase premiums on certain policies issued by qualified health plans under the Health Care Reform Law. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain. The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States,
and members of Congress and the Administration have stated that they will address such costs through new legislative and administrative measures. To date, there have been several recent U.S. congressional inquiries and proposed state and federal
legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement
methodologies for drug products. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after
the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available
therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired. The uncertain status of the Health
Care Reform Law ability to may have a negative impact on our business. The Drug Supply Chain Security Act imposes new obligations on
manufacturers of pharmaceutical products related to product tracking and tracing. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We
are not sure whether additional legislative changes will be enacted, or whether the current regulations, guidance or interpretations will be changed, or what the impact of such changes on our business, if any, may be. There have been a number of federal and state legislative changes made over the last few years regarding the pricing of pharmaceutical and
biologic products. Concerns about drug pricing have been expressed by members of Congress and the President.  57




---

##### Table of Contents

It is likely that federal and state legislatures within the United States and foreign
governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing
efforts of the government, insurance companies, managed care organizations and other health care payors of to contain or reduce costs of health care may adversely affect:  

the demand for any product candidates for which we may obtain regulatory approval;  

our ability to set a price that we believe is fair for our products;  

our ability to obtain coverage and reimbursement approval for a product;  

our ability to generate revenue and achieve or maintain profitability; and  

the level of taxes that we are required to pay. Our relationships with customers, physicians and
third-party payors will be subject, directly or indirectly, to federal and state health care fraud and abuse laws, false claims laws, health information privacy and security laws, and other health care laws and regulations. If we are unable to
comply, or have not fully complied, with such laws, we could face substantial penalties. If we obtain FDA approval for SGT-001 or
our other product candidates and begin commercializing those products in the United States, our operations will be directly or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws
and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal laws and Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed
sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited
to:  

the federal Health Care Program Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any
kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal health care program, such as the
Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The Health Care Reform Law amended the
intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;  

federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or
approval from Medicare, Medicaid or other government payors that are false or fraudulent. The Health Care Reform Law provides and recent government cases against pharmaceutical and medical device manufacturers support the view that Federal
Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;  

HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud any health care benefit program,
regardless of the payor (e.g., public or private);  

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA
Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy,
security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;  58




---

##### Table of Contents



federal transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
Medicaid or the Childrens Health Insurance Program, with specific exceptions, to report annually to the CMS information related to: (i) payments or other transfers of value made to physicians and teaching hospitals and
(ii) ownership and investment interests held by physicians and their immediate family members;  

state and foreign law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care
providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
compliance efforts in certain circumstances, such as specific disease states; and  

state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is
possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we
may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the
regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and
divert our managements attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or
reporting requirements increases the possibility that we may run afoul of one or more of the requirements. Product liability lawsuits against us
could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop. We
face an inherent risk of product liability exposure related to the testing of SGT-001, our other product candidates and any future product candidate in preclinical studies and clinical trials and may face an even greater risk if we commercialize any
product candidate that we may develop. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may
result in:  

decreased demand for any product candidate that we may develop;  

loss of revenue;  

substantial monetary awards to trial participants or patients;  

significant time and costs to defend the related litigation;  

withdrawal of clinical trial participants;  

the inability to commercialize any of our product candidates; and  

injury to our reputation and significant negative media attention. Although we maintain
product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we  59




---

##### Table of Contents

commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a
reasonable cost or in an amount adequate to satisfy any liability that may arise. If we fail to comply with environmental, health and safety laws
and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. Our operations involve the use
of hazardous and flammable materials, including chemicals and viruses and other biologic materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We
cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages. We also could incur significant
costs associated with civil or criminal fines and penalties. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and
fines arising from biological or hazardous waste exposure or contamination. Although we maintain workers compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an
amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. In addition, we may incur substantial
costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or
production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities. Our internal computer systems, or those of our collaborators, contractors or consultants, may fail or suffer security breaches, which could result in a
material disruption of our product development. Despite the implementation of security measures, our internal computer systems and
those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are
not aware of any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our or our collaborators, contractors or consultants operations, it could result in a
material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from preclinical
studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage
to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of SGT-001 and our other
product candidates could be delayed. Risks related to our intellectual property We heavily rely on certain in-licensed patents and other intellectual property rights in connection with our development of SGT-001 and may be required
to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize SGT-001. Our ability to develop and commercialize SGT-001 and other product candidates is heavily dependent on licenses to patent rights and other
intellectual property granted to us by third parties. In particular, we have  60




---

##### Table of Contents

licensed certain patents and patent applications from the University of Michigan, the University of Missouri and the University of Washington that are important or necessary to the development of
SGT-001 and other elements of our gene transfer program. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, development and commercialization obligations, milestone payments,
royalties and other obligations on us. If we fail to comply with our obligations under these agreements, we may be subject to damages, which may be significant, and the licensor may have the right to terminate the license, in which event we may not
be able to develop or market product candidates or technologies covered by the license, including SGT-001. In addition, certain of these license agreements are not assignable by us without the consent of the respective licensor, which may have an
adverse effect on our ability to engage in certain transactions. Under our existing license agreements, we do not have, and under future
license agreements we may not have, the right to control the preparation, filing and prosecution of patent applications, or the maintenance, enforcement and defense of the patents and patent applications that we license from third parties. For
example, under our inbound license agreements with the University of Michigan, the University of Missouri and the University of Washington, each of the applicable licensors controls the prosecution of patent applications and the maintenance of
patents and patent applications. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to
maintain, enforce or defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject
of such licensed rights, including SGT-001, could be adversely affected. For more information, see BusinessStrategic partnerships and collaborations/licenses. Moreover, licenses to additional third-party intellectual property, technology and materials are required for our development programs but may
not be available in the future or may not be available on commercially reasonable terms. For example, we are aware of certain third-party patents related to certain microdystrophin constructs, which, if in force at the time of SGT-001s
commercialization, may be claimed by third parties to cover SGT-001. In addition, third parties may claim that the AAV vector we are developing for use in SGT-001 are covered by patents held by them. We believe that we would have valid defenses to
any such claims; however, if any such claims were ultimately successful, we might require a license to continue to use and sell SGT-001 and such AAV vector. Such licenses may not be available on commercially reasonable terms, or at all. Moreover,
even if we are able to obtain such licenses, they may only be non-exclusive, which could permit competitors and other third parties to use the same intellectual property in competition with us. If we are unable to successfully obtain rights to any
third-party intellectual property rights that are required for the development and commercialization of SGT-001 or any of our other product candidates, and such third-party intellectual property rights are successfully asserted against us, we may be
liable for damages, which may be significant, and we may be required to cease the development and commercialization of SGT-001 or our other product candidates. If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not
sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected. Our success depends, in large part, on our and our licensors ability to seek, obtain, maintain, enforce and defend patent rights in the
United States and other countries with respect to SGT-001, our other product candidates and our future innovation related to our manufacturing technology. Our licensors and we have sought, and we intend to continue to seek, to protect our
proprietary position by filing patent applications in the United States and, in at least some cases, one or more countries outside the United States related to SGT-001 and certain other product candidates that are important to our business. However,
we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents or whether the claims of any issued patents will provide us with a competitive advantage.  61




---

##### Table of Contents

Moreover, we currently do not own any issued patents or pending non-provisional patent
applications and we only own two provisional patent applications in the United States. Each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application
within 12 months of the filing date of each provisional patent application. If we do not timely file a non-provisional patent application in respect of a provisional patent application, we may lose our priority date with respect to such provisional
patent application and any patent protection on the inventions disclosed in such provisional patent application. While we intend to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict
whether such future patent applications will result in the issuance of patents that effectively protect any of our product candidates or will effectively prevent others from commercializing competitive products. We also currently do not own or license any issued patents or pending patent applications with respect to our product candidate SB-001. While
we have an option to negotiate a license for issued patents and pending patent applications relating to such product candidate, we may not exercise our option in a timely manner or at all, or satisfy any conditions upon which our option to such
patents and patent applications is contingent. In addition, the third party granting us such option may breach our option agreement and license such patents and patent applications to other third parties, including our competitors, before we
exercise our option. In any event, even if we exercise such option, we are still required to negotiate and enter into a definitive agreement pursuant to which we could license rights to the optioned patents and we may be unable to enter into such a
definitive agreement within the required timeframe or under terms that are acceptable to us. If we are unable to do so, the party who has granted us our option may offer the patent rights to other parties. If we are unable to secure a license to any
issued patents and pending patent applications relating to SB-001, we may need to cease our development of such product candidate. We may not be
able to file, prosecute, maintain, enforce, defend or license all patents that are necessary to our business. The patent
prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patents and patent applications at a reasonable cost or in a
timely manner. It is also currently unknown what claims may, if ever, issue from pending applications included in our patent rights.
Additionally, certain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore we will be unable to obtain patent protection for our product candidates in certain jurisdictions. We or our
licensors may not be able to obtain or maintain patent protection with respect to SGT-001 or our other product candidates. Changes in
either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights, and more generally, could affect the value of
our intellectual property rights or narrow the scope of our licensed patents or future owned patents. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or
patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach
the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Patent  62




---

##### Table of Contents

applications included in our current and future patent rights may not result in patents being issued that protect our product candidates, effectively prevent others from commercializing
competitive products or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. Even assuming patents issue from patent applications in which we have rights, changes in either the patent laws or
interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patents or narrow the scope of our patent protection. Other parties have developed products that may be related or competitive to our own and such parties may have filed or may file patent
applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our patent applications or issued patents. We may not be aware of all third-party intellectual property rights
potentially relating to SGT-001, SB-001 or our other current or future product candidates. In addition, we cannot provide any assurances that any of the inventions disclosed in our patent applications will be found to be patentable, including over
third-party or our own prior art patents, publications or other disclosures, or will issue as patents. Even if our patent applications issue as patents, we cannot provide any assurances that such patents will not be challenged or ultimately held to
be invalid or unenforceable. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18 months
after filing, or, in some cases, at all. Therefore, we cannot know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that
they were the first to file for patent protection of such inventions. Similarly, should we own any issued patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions
claimed in such patents or patent applications. Furthermore, given the differences in patent laws in the United States, Europe and other foreign jurisdictions, for example, the availability of grace periods for filing patent applications and what
can be considered as prior art, we cannot make any assurances that any claims in our pending and future patent applications in the United States or other jurisdictions will issue, or if they do issue, whether they will issue in a form that provides
us with any meaningful competitive advantage. Similarly, we cannot make any assurances that if the patentability, validity, enforceability or scope of our pending or future patents and patent applications in the United States or foreign
jurisdictions are challenged by any third party, that the claims of such pending or future patents and patent applications will survive any such challenge in a form that provides us with any meaningful competitive advantage. For example, we are
aware of certain third-party patents and publications related to certain microdystrophin constructs. While we believe that our owned or in-licensed patents and patent applications claim novel and non-obvious features of microdystrophin constructs
that are not described in such third-party patents or publications, such third-party patents and publications may have earlier priority or publication dates and may be asserted as prior art against our owned or in-licensed patents and applications.
Any such challenge, if successful, could limit or eliminate patent protection for our products and product candidates or otherwise materially harm our business. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights cannot be predicted with any certainty. Moreover, the coverage claimed in a patent application can be significantly reduced
before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or may own in the future do issue as patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents that we license or may own in the future may be challenged, narrowed, circumvented, or invalidated by third
parties. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar
or alternative products in a non-infringing manner. The degree of patent protection we require to successfully compete in the marketplace
may be unavailable. We cannot provide any assurances that any of the patents or patent applications included in our patent rights include or will include claims with a scope sufficient to protect SGT-001 and our other product candidates or otherwise
provide any competitive advantage. In addition, the laws of foreign countries may not protect our  63




---

##### Table of Contents

proprietary rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty
years after it is filed. Certain extensions may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent rights may not provide us with adequate and continuing patent protection sufficient to exclude others from
commercializing products similar or identical to our product candidates, including biosimilar versions of such products. Our licensed patents, and
any patents we may own in the future, may be challenged, narrowed, invalidated or held unenforceable. Even if we acquire patent
protection that we expect should enable us to maintain some competitive advantage, third parties, including competitors, may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or
held unenforceable. In litigation, a competitor could claim that our in-licensed patents or any patents we may own in the future are not valid or enforceable for a number of reasons. If a court agrees, we would lose our rights to those challenged
patents. Even if issued, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our
current and future patent rights may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the validity of one or more claims
of patents included in our patent rights. Such submissions may also be made prior to a patents issuance, precluding the granting of a patent based on one of the pending patent applications included in our patent rights. We may become involved
in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or interference proceedings challenging one or more patents included in our patent rights. For example, competitors may claim that they invented the
inventions claimed in patents or patent applications included in our patent rights, such as the microdystrophin we use in SGT-001, prior to the inventors of such patents or patent applications, or may have filed one or more patent applications
before the filing of the patents or patent applications included in our patent rights. A competitor who can establish an earlier filing or invention date may also assert that we are infringing their patents and that we therefore cannot practice our
technology related to our product candidates as claimed in the patents or patent applications included in our patent rights. Competitors may also contest patents or patent applications included in our patent rights by showing that the claimed
subject matter was not patent-eligible, was not novel or was obvious or that the patent claims failed any other requirement for patentability or enforceability. In addition, we may in the future be subject to claims by our or our licensors
current or former employees or consultants asserting an ownership right in the patents or patent applications included in our patent rights as an inventor or co-inventor, as a result of the work they performed. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar therapeutics, without payment to us, or could limit the duration of the patent protection
covering our product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third-party patent rights, and we may be required to obtain a license from third parties,
which may not be available on commercially reasonable terms or at all, or we may need to cease the development, manufacture and commercialization of one or more of our product candidates. In addition, if the breadth or strength of protection
provided by the patents and patent applications included in our patent rights is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such proceedings also may
result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Even if they are unchallenged, the patents and pending patent applications included in our patent rights may not provide us with any
meaningful protection or prevent competitors from designing around our patent claims to  64




---

##### Table of Contents

circumvent our patent rights by developing similar or alternative therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapeutic that provides benefits
similar to one or more of our product candidates but that uses a vector or an expression construct that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we license or pursue
with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected. Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our
rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. We
currently depend, and will continue to depend, on our license, collaboration and other similar agreements. Further development and commercialization of SGT-001 and our other current and future product candidates may require us to enter into
additional license, collaboration or other similar agreements. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to
multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected product candidates. If any of our licenses or material relationships are
terminated or breached, we may:  

lose our rights to develop and market SGT-001 or our other product candidates;  

lose patent protection for SGT-001 or our other product candidates;  

experience significant delays in the development or commercialization of SGT-001 or our other product candidates;  

not be able to obtain any other licenses on acceptable terms, if at all; or  

incur liability for damages. These risks apply to any agreements that we may enter into in the future for
SGT-001 and our other current and future product candidates. If we fail to comply with our obligations in the agreements under which we license
intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. We have certain obligations under licensing agreements with third parties that include annual maintenance fees and payments that are contingent
upon achieving various development, commercial and regulatory milestones. Pursuant to many of these license agreements, we are required to make milestone payments if certain development, regulatory and commercial sales milestones are achieved, and
may have certain additional research funding obligations. Also, pursuant to the terms of many of these license agreements, when and if commercial sales of a licensed product commence, we must pay royalties to our licensors on net sales of the
respective licensed products. We have entered into license agreements with third parties and may need to obtain additional licenses from
one or more of these same third parties or from others to advance our research or allow our commercialization of SGT-001 or other product candidates. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on
reasonable terms, if at all. In that event, we may be required to expend significant time and  65




---

##### Table of Contents

resources to redesign SGT-001, our other product candidates or the methods for manufacturing them or to develop or license replacement products, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize SGT-001 or our other product candidates. We cannot provide any assurances that third-party patents or other intellectual property rights do not exist that
might be enforced against our manufacturing methods, product candidates or any technologies we may develop, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay
royalties and/or other forms of compensation to third parties. In each of our existing license agreements, and we expect in our future
agreements, patent prosecution of our licensed technology is controlled solely by the licensor, and we may be required to reimburse the licensor for their costs of patent prosecution. If our licensors fail to obtain and maintain patent or other
protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the
intellectual property. Further, in each of our license agreements our licensors have the first right to bring any actions against any third party for infringing on the patents we have licensed. Our license agreements also require us to meet
development thresholds to maintain the license, including establishing a set timeline for developing and commercializing product candidates. Disputes may arise regarding intellectual property subject to our licensing agreements, including:  

the scope of rights granted under the license agreement and other interpretation-related issues;  

the extent to which our products or processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;  

the sublicensing of patent and other rights under our collaborative development relationships;  

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;  

the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and  

the priority of invention of licensed patented inventions. If disputes over intellectual
property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize SGT-001 or our other product candidates. In spite of our best
efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby resulting in disputes or litigation, which could cause us to incur substantial costs and
distract managements time, and if we are unsuccessful, we could lose our ability to develop and commercialize products covered by these license agreements. If these licenses are ultimately terminated by the licensor, or if the underlying
patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our
commercial success depends upon our ability and the ability of our future collaborators to develop, manufacture, market and sell SGT-001 and our other current and future product candidates without infringing, misappropriating or otherwise violating
the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We or our licensors
may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to SGT-001 or our other product candidates, including
interference proceedings, post grant review and inter partes  66




---

##### Table of Contents

review before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that, among other things, our therapeutics, manufacturing methods, formulations
or administration methods are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain
or guarantee that a court would hold that SGT-001 or any of our other product candidates does not infringe an existing patent or a patent that may be granted in the future. Many companies and institutions have filed, and continue to file, patent
applications related to gene therapy and related manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical
and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent
applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending that may later result in issued patents that may be infringed by the
manufacture, use, sale or importation of our product candidates and we may or may not be aware of such patents. If a patent holder believes the manufacture, use, sale or importation of one of our product candidates infringes its patent, the patent
holder may sue us even if we have licensed other patent protection for our product candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our licensed patent
portfolio may therefore have no deterrent effect. It is also possible that we have failed to identify relevant third-party patents or
applications for which we may need a license to develop and commercialize SGT-001 and our other product candidates. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed
outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates because patent searching
is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent
applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our product candidates. In addition, we may be unaware of one or more issued patents that would be
infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that
have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates. Third
parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to
otherwise assert their patent or other intellectual property rights against us. For example, as discussed above, third parties may claim that the microdystrophin or the AAV vector we are developing for use in SGT-001 is covered by patents held by
them. Even if we believe such claim, or other intellectual property claims alleged by third parties are without merit, there is no assurance that we would be successful in defending such claims. A court of competent jurisdiction could hold that
these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize SGT-001 or our other product candidates covered by the asserted third-party patents. In order to successfully
challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent
claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Similarly, there is no assurance that a court of competent jurisdiction would find that SGT-001 or our other product candidates
did not infringe a third-party patent. Patent and other types of intellectual property litigation can involve complex factual and legal
questions, and their outcome is uncertain. If we are found, or believe there is a risk that we may be found, to infringe, misappropriate or otherwise violate a third partys intellectual property rights, and we are unsuccessful in  67




---

##### Table of Contents

demonstrating that such intellectual property rights are invalid or unenforceable, we could be required or may choose to obtain a license from such third party to continue developing,
manufacturing and marketing our product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our
competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and
commercializing the infringing product candidate, including SGT-001. In addition, we could be found liable for monetary damages, including treble damages and attorneys fees, if we are found to have willfully infringed a patent or other
intellectual property right. A finding of infringement, misappropriation or other violation of intellectual property rights, or claims that we have done so, could prevent us from manufacturing and commercializing our product candidates or force us
to cease some or all of our business operations. Intellectual property litigation could cause us to spend substantial resources and distract our
personnel from their normal responsibilities. Litigation or other legal proceedings relating to intellectual property claims, with
or without merit, is unpredictable and generally expensive and time-consuming. Competitors may infringe patents that we may own in the future or the patents of our licensing partners or we may be required to defend against claims of infringement.
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect
on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be
able to prevent third parties from infringing or misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a
material adverse effect on our ability to compete in the marketplace. We may not be successful in obtaining necessary rights to SGT-001 or our
other product candidates through acquisitions and in-licenses. We currently have certain rights to intellectual property, through
licenses from third parties, to develop SGT-001. Because development and commercialization of our current and future product candidates may require the use of additional proprietary rights held by these or other third parties, the growth of our
business may depend, in part, on our ability to acquire, in-license or use these additional proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third
parties that we identify as necessary for SGT-001 or our other product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to
license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and
commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would
allow us to make an appropriate return on our investment.  68




---

##### Table of Contents

We may collaborate with non-profit and academic institutions to accelerate our preclinical
research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institutions rights in technology resulting from the collaboration. Regardless of
such option, we may be unable to negotiate a license within the required timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking
our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property rights or
maintain the existing intellectual property rights we have, we may have to abandon development of SGT-001 or our other product candidates. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid
to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and applications and any patents and patent applications we may own in the future. The USPTO and various non-U.S.
government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable intellectual property law firms and other professionals to help
us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by
other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business. Some intellectual property that we have in-licensed may have been discovered through government-funded programs and thus may be subject to federal
regulations such as march-in rights, certain reporting requirements, and a preference for U.S. manufacturing. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. Some of the intellectual property rights we have licensed, including such rights licensed from the University of Michigan, the
University of Missouri and the University of Washington, are stated to have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. As a result, the U.S. government may have certain
rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a
non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of
these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is
necessary to meet requirements for public use under federal regulations (also referred to as march-in rights). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose
the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements,
compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be
manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar
terms to potential  69




---

##### Table of Contents

licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S.
manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government
funding, the provisions of the Bayh-Dole Act may similarly apply. We may not be able to protect our intellectual property and proprietary rights
throughout the world. Filing, prosecuting, maintaining, enforcing and defending patents on product candidates in all countries
throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Although our license agreements grant us worldwide
rights, certain of our in-licensed U.S. patents lack corresponding foreign patents or patent applications. For example, the issued U.S. patents we license from the University of Michigan do not have any corresponding foreign patents or patent
applications. Thus, we will not have the opportunity to obtain patent protection for the subject matter of such patents outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the
same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all
countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use
our inventions in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where
enforcement is not as strong as it is in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to biotechnology products, which could make it
difficult for us to stop the infringement of our patents, if pursued and obtained, or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property
and proprietary rights in foreign jurisdictions could (i) result in substantial costs and divert our efforts and attention from other aspects of our business, (ii) put our patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing and (iii) provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Issued patents relating to SGT-001 or our other product candidates could be found invalid or unenforceable if challenged. If one of our licensing partners or we initiate legal proceedings against a third party to enforce a patent relating to SGT-001 or our other
product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are
commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent eligible subject matter.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties
also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review, interference  70




---

##### Table of Contents

proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation or cancellation of or
amendment to our licensed patents and any patents we may own in the future in such a way that they no longer cover SGT-001 or our other product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner, we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal
assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on SGT-001 or our other product candidates or technologies. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of the discovery and development processes of SGT-001 and our other product candidates that involve
proprietary know-how, information or technology that is not covered by patents. Our manufacturing process is protected by trade secrets. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less
willing or unwilling to protect trade secrets. We seek to protect our proprietary know-how, trade secrets and processes, in part, by
entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our employees, consultants, scientific advisors, CROs, manufacturers and contractors. These agreements
typically limit the rights of third parties to use or disclose our confidential information. However, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these
agreements, despite the existence generally of confidentiality agreements and other contractual restrictions. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or
proprietary processes. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary know-how and trade secrets will be effective. If any of our employees, collaborators,
CROs, manufacturers, consultants, advisors and other third parties who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. As a result, we could lose our trade secrets. We also seek to preserve the integrity and
confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these security measures, they may still be
breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be
independently discovered by competitors. Competitors could purchase our product candidates, if approved, and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or
otherwise violate our intellectual property rights, design around our protected know-how and trade secrets, or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be
lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not
adequately protected so as to protect our market against competitors products and technologies, our competitive position could be adversely affected.  71




---

##### Table of Contents

We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used
or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in
their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individuals current or former employer. Litigation
may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or
features would have a material adverse effect on our business and may prevent us from successfully commercializing our product candidates. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire
employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management. In addition, while it is our policy to require our employees and
contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives
or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be
breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Moreover, individuals executing agreements with us may
have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. Changes in either the patent laws or the interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes several
significant changes to U.S. patent law. Prior to March 2013 in the United States, assuming that other requirements for patentability are met, the first to make the claimed invention was entitled to the patent, while outside the United States, the
first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the
first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the invention. The Leahy-Smith Act also includes a number of significant changes that affect the
way patent applications will be prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through
various post-grant proceedings administered by the USPTO. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and
in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business as, among other reasons, the USPTO must still
implement various regulations. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.  72




---

##### Table of Contents

The patent positions of companies engaged in the development and commercialization of
biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and gene patents have been decided by the Supreme Court of the United States, or the Supreme Court. On March 20, 2012, the
Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, a case involving patent claims directed to a process of measuring a metabolic product in a patient to optimize a drug dosage for the
patient. According to the Supreme Court, the addition of well understood, routine or conventional activity such as administering or determining steps was not enough to transform an otherwise patent-ineligible natural
phenomenon into patent-eligible subject matter. On July 3, 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or
correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the patent claim amounts to significantly more than the natural
principle itself should be rejected as directed to patent-ineligible subject matter. On June 13, 2013, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving
patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not
patent-eligible subject matter, but that complementary DNA may be patent-eligible. The USPTO issued a guidance memorandum to patent
examiners entitled 2014 Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products. These guidelines instruct USPTO examiners on the ramifications
of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. Certain claims of our licensed patents and patent applications contain, and any future patents we
may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties. In addition, the 2014 USPTO guidance
could impact our ability to pursue similar patent claims in patent applications we may prosecute in the future. We cannot assure our
stockholders that our efforts to seek patent protection for our product candidates will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully
predict what impact the Supreme Courts decisions in Prometheus and Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the
USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future. Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject
matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity
positions, or paying to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be
forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. If we do not obtain patent
term extension for patents relating to SGT-001 or our other product candidates, our business may be materially harmed. Depending
upon the timing, duration and specifics of any FDA marketing approval of SGT-001 and our other product candidates, one or more U.S. patents that we license or may own in the future may be eligible for limited patent term extension under the
Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or
biologic. A patent term extension  73




---

##### Table of Contents

cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a
method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply
within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of
any such extension is less than we request, our competitors may be able to enter the market sooner. If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition and our business may be adversely affected. We have
registered trademarks with the USPTO for the marks SOLID BIOSCIENCES, SOLID GT and SOLID. Once registered, our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times,
competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or
tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on
our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or
other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Intellectual property rights and
regulatory exclusivity rights do not necessarily address all potential threats. The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:  

others may be able to make gene therapy products that are similar to our product candidates but that are not covered by the claims of the patents that we license or may own in the future;  

we, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;  

we, or our current and future license partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;  

others may independently develop similar or alternative products or duplicate any of our processes without infringing our owned or licensed intellectual property rights;  

others may circumvent our regulatory exclusivities, such as by pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical data, rather than relying on the
abbreviated pathway provided for biosimilar applicants;  

it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;  

issued patents that we hold rights to now or in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors;  74




---

##### Table of Contents



others may have access to the same intellectual property rights licensed to us;  

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our
major commercial markets;  

we may not develop additional proprietary technologies that are patentable;  

the patents or other intellectual property rights of others may have an adverse effect on our business; and  

we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. Risks related to ownership of our common stock Our
executive officers, directors and principal stockholders maintain the ability to control all matters submitted to our stockholders for approval. Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own
shares representing approximately 65.9% of our common stock outstanding as of March 15, 2018. As a result, if these stockholders were to act together, they would be able to control all matters submitted to our stockholders for approval, as well
as our management and affairs. For example, these persons, if they act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power
could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in management of our company with which our public stockholders disagree. A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which
could cause the market price of our common stock to drop significantly, even if our business is performing well. Sales of a
substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell
shares, could reduce the market price of our common stock. As of March 15, 2018, we had outstanding 35,476,892 shares of common stock. This includes the shares that we sold in our initial public offering, which was completed on January 30,
2018, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. The remaining 26,492,517 shares of common stock that were issued prior to our initial public offering pursuant to our Corporate
Conversion are currently restricted as a result of securities laws or lock-up agreements entered into in connection with our initial public offering but will be able to be sold into the public market in the near future. Moreover, as of
March 15, 2018, holders of an aggregate of approximately 24.2 million shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in
registration statements that we may file for ourselves or other stockholders. In addition, on January 29, 2018, we filed a Registration Statement on Form S-8 to register approximately 5.0 million shares reserved for future issuance under
our 2018 Omnibus Incentive Plan will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. These shares can be freely sold in the public market upon issuance, subject to volume limitations
applicable to affiliates and the lock-up agreements entered into in connection with our initial public offering. In addition, J.P. Morgan
Securities LLC, Goldman Sachs & Co. LLC and Leerink Partners LLC, the representatives of the underwriters in our initial public offering, may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements
at any time and for any reason. Sales of a substantial number of such shares upon expiration of the lock-up agreements, the perception that such sales may occur, or early release of these agreements, could cause our market price to fall or make it
more difficult for an investor to sell our common stock at a time and price that the investor deems appropriate.  75




---

##### Table of Contents

The price of our common stock has been and may in the future be volatile and fluctuate substantially,
which could result in substantial losses for holders of our common stock. Our stock price has been and may in the future be
volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result
of this volatility, our stockholders may not be able to sell their shares of common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:  

results of clinical trials of SGT-001 or our other product candidates or those of our competitors;  

the success of competitive products or technologies;  

regulatory or legal developments in the United States, the European Union and other countries;  

the recruitment or departure of key personnel;  

the level of expenses related to any of our product candidates, or our clinical development programs and our commercialization efforts;  

the results of our efforts to discover, develop, acquire or in-license additional product candidates;  

actual or anticipated changes in our development timelines;  

our ability to raise additional capital;  

our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;  

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates;  

significant lawsuits, including patent or stockholder litigation;  

variations in our financial results or those of companies that are perceived to be similar to us;  

changes in the structure of health care payment systems;  

market conditions in the pharmaceutical and biotechnology sectors;  

general economic, industry and market conditions; and  

the other factors described in this Risk factors section. If our quarterly
operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock
to fluctuate substantially. In the past, following periods of volatility in the market price of a companys securities, securities
class-action litigation often has been instituted against that company. On March 27, 2018, James Watkins, a purported stockholder of ours (the Plaintiff), filed a putative class action complaint alleging violations of the federal
securities laws, in the United States District Court for the District of Massachusetts (Case No. 18-10587), against us, Ilan Ganot, our Chief Executive Officer, Jennifer Ziolkowski, our Chief Financial Officer, and the underwriters in our initial
public offering, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Leerink Partners, LLC, Nomura Securities Co., LLC and Chardan Capital Markets LLC. The Plaintiff claims to represent purchasers of our common stock during the period from
January 25, 2018 to March 14, 2018 and seeks unspecified damages arising out of the alleged failure to disclose risks associated with toxicity and potential for adverse events related to our lead product candidate. This litigation, and any
additional litigation instituted against us, could cause us to incur substantial costs to defend such claims and divert managements attention and resources.  76




---

##### Table of Contents

If securities analysts do not publish research or reports about our business or if they publish
negative evaluations of our stock, the price of our stock could decline. The trading market for our common stock relies, in part,
on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of
these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. An active trading market for our common stock may not be sustained Prior to our initial public offering, which occurred on January 26, 2018, there was no public market for our common stock. Although our
common stock is listed on the Nasdaq Global Select Market, given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not continue to develop or be sustained. If an active market for our
common stock does not continue to develop or is not sustained, it may be difficult our stockholders to sell shares without depressing the market price for the shares, or at all. We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. We are an emerging growth company, or EGC, as defined in the Jumpstart our Business
Startups Act of 2012, or the JOBS Act. We will remain an EGC until the earliest of: (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) December 31, 2023; (iii) the
date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; and (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission,
or the SEC. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:  

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404;  

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors report providing
additional information about the audit and the financial statements;  

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced Managements discussion and analysis
of financial condition and results of operations disclosure;  

reduced disclosure obligations regarding executive compensation; and  

an exemption from the requirement to seek nonbinding advisory votes on executive compensation or golden parachute arrangements. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in
this Annual Report on Form 10-K. In particular, we have not included all of the executive compensation information that would be required if we were not an EGC. We cannot predict whether investors will find our common stock less attractive if we
rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We incur increased costs as a result of operating as a public company, and our management is now required to devote substantial time to new compliance
initiatives. As a public company, and particularly after we are no longer an EGC, we incur significant legal, accounting and other
expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules  77




---

##### Table of Contents

subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some
activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting,
including, once we are no longer an EGC, an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we
will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt
a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that
our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if
we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely
affect our business and stock price. We have identified material weaknesses in our internal control over financial reporting. A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be
prevented or detected on a timely basis. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be
able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, our stock price. In connection with the audits of our consolidated financial statements as of and for the years ended December 31, 2015 and
December 31, 2016, we identified material weaknesses in our internal control over financial reporting. The material weaknesses we identified were as follows:  

We did not design or maintain an effective control environment commensurate with our financial reporting requirements. We lacked a sufficient number of professionals with an appropriate level of accounting knowledge,
training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, the limited personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in
pursuit of our financial reporting objectives, as demonstrated by, among other things, our insufficient segregation of duties in our finance and accounting functions. This material weakness contributed to the additional material weaknesses detailed
below.  

We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and
review of account reconciliations and journal entries. Additionally, we did not design and maintain controls over the appropriate cut-off, classification and presentation of accounts and disclosures in the financial statements.  

We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. Specifically, we did not design and maintain controls to analyze, account for and disclose complex transactions, including variable interest entities, preferred units, the preferred unit tranche right and equity-based compensation.  78




---

##### Table of Contents

Each of the control deficiencies could result in a misstatement of our accounts or disclosures that would
result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected, and accordingly, we determined that these control deficiencies constitute material weaknesses. These material weaknesses also resulted in a restatement of our previously issued 2015 annual consolidated financial statements and
adjustments to our 2016 annual consolidated financial statements, which were recorded prior to their issuance. We are in the process of
implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses, including hiring additional finance and accounting personnel and initiating design
and implementation of our financial control environment, including the establishment of formal accounting policies and procedures, financial reporting controls and controls to account for and disclose complex transactions. We cannot assure our stockholders that the measures we have taken to date, and actions we may take in the future, will be sufficient to
remediate the control deficiencies that led to our material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. In addition, neither our management nor an independent
registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our independent
registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are unable to
successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we
may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our share
price may decline as a result. Provisions in our certificate of incorporation and our bylaws and under Delaware law could make an acquisition of
us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control
of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions also could limit the price that investors might be willing to pay in the future for
shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts
by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:  

establish a classified board of directors such that not all members of our board are elected at one time;  

allow the authorized number of our directors to be changed only by resolution of our board of directors;  

limit the manner in which stockholders can remove directors from the board;  

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;  

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;  

limit who may call stockholder meetings;  

authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a stockholder rights plan, or so-called poison pill, that would work to dilute the stock  79




---

##### Table of Contents

ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and  

require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation or bylaws. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware
General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in
excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Because we do not anticipate
paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, is the only sole source of gain for an investment in our common stock. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for an
investor for the foreseeable future. Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive
forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees. Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any
derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim
arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. The choice of forum provision may limit a stockholders ability
to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court
were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.  Item 1B.
Unresolved Staff Comments. None.  Item 2.
Properties. We lease our corporate headquarters, which consists of approximately 16,000
square feet in Cambridge, Massachusetts. The lease for our corporate headquarters has an initial term of approximately 4 years that expires in February 2022. In addition, we lease our primary laboratory space, which consists of 9,500 square feet in
Cambridge, Massachusetts, under a lease with an initial term of five years and includes an option to extend for one additional two-year term. In addition, we lease smaller office space.  Item 3.
Legal Proceedings. On March 27, 2018, James Watkins, a purported stockholder of ours
(the Plaintiff), filed a putative class action complaint alleging violations of the federal securities laws, in the United States District Court for the District of Massachusetts (Case No. 18-10587), against us, Ilan Ganot, our Chief
Executive Officer, Jennifer Ziolkowski, our Chief Financial Officer, and the underwriters in our initial public offering, J.P. Morgan  80




---

##### Table of Contents

Securities LLC, Goldman Sachs & Co. LLC, Leerink Partners, LLC, Nomura Securities Co., LLC and Chardan Capital Markets LLC. The Plaintiff claims to represent purchasers of our common stock
during the period from January 25, 2018 to March 14, 2018 and seeks unspecified damages arising out of the alleged failure to disclose risks associated with toxicity and potential for adverse events related to our lead product candidate. While we
believe that we have meritorious defenses to the allegations made in the complaint, it is not currently possible to assess whether or not the outcome of this suit may have a material adverse effect on our business, financial condition, results of
operations or prospects. In addition, we may be involved in various other legal proceedings arising out of our operations. We are not
currently a party to any such other legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business, financial condition, results of operations or prospects. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.  Item 4.
Mine Safety Disclosures. Not applicable.  81




---

##### Table of Contents

PART II  Item 5.
Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Price Range of Common Stock Our common stock commenced
trading on the Nasdaq Global Select Market under the symbol SLDB on January 26, 2018 in connection with our initial public offering. Prior to that date, there was no established public trading market for our common stock. The following table sets forth for the period indicated the high and low sale prices per share for our common stock as reported on the Nasdaq Global Select
Market for the period indicated:  2018

High


LowFirst Quarter (January 26, 2018 through March 15, 2018)

$
33.74


$
8.95 Holders As
of March 15, 2018, we had approximately 116 holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater
than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares
may be held in trust by other entities. Dividend Policy We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation
and expansion of our business. We do not currently anticipate declaring any cash dividends for the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various
factors, including our results of operations, financial condition, future prospects, then applicable contractual restrictions, and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the
expectation of receiving cash dividends. Purchase of Equity Securities We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. Recent Sales of Unregistered Securities During the
period covered by this Annual Report on Form 10-K, we have issued securities in the transactions described below without registration under the Securities Act of 1933, as amended, or the Securities Act. Solid Biosciences, LLC During the year ended
December 31, 2017, Solid Biosciences, LLC issued the following securities that were not registered under the Securities Act:  

Throughout 2017, we granted 895,325 Series D Common Units to employees and consultants in consideration of services, of which 13,500 units were forfeited.  

On March 29, 2017, we issued and sold to investors an aggregate of 2,500,000 Series 1 Senior Preferred Units, for aggregate consideration of $25 million.  82




---

##### Table of Contents



On October 26, 2017, we issued and sold to investors an aggregate of 4,886,000 Series 2 Senior Preferred Units, for aggregate consideration of $55 million. Pursuant to the Agreement and Plan of Merger by and between Solid Biosciences, LLC and Solid GT, LLC, dated as of March 29, 2017, units of Solid
Biosciences, LLC and units of Solid GT, LLC were exchanged for new series of units of Solid Biosciences, LLC. Solid GT, LLC During the year ended December 31, 2017, Solid GT, LLC, a subsidiary of Solid Biosciences, LLC, did not issue any securities that were not registered
under the Securities Act. None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering,
and we believe each transaction was exempt from the registration requirements of the Securities Act in reliance upon Section 4(2) of the Securities Act or Regulation D promulgated under the Securities Act. Furthermore, we affixed appropriate
legends to any unit certificates and instruments issued in each foregoing transactions setting forth that the securities had not been registered and the applicable restrictions on transfer. Use of Proceeds from Initial Public Offering On
January 30, 2018, we closed our initial public offering, in which we issued and sold 8,984,375 shares of common stock, including 1,171,875 shares of our common stock pursuant to the underwriters over-allotment, at a public offering price
of $16.00 per share. The aggregate gross proceeds to us from our initial public offering were approximately $143.8 million. All of the shares of common stock issued and sold in our initial public offering were registered under the Securities Act
pursuant to a registration statement on Form S-1 (Registration No. 333-222357), which was declared effective by the SEC on January 25, 2018 and a registration statement on Form S-1 MEF (Registration No. 333-222705) filed pursuant to
Rule 462(b) of the Securities Act. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Leerink Partners LLC were joint book-running managers for the initial public offering. The offering commenced on January 25, 2018 and did not
terminate until the sale of all of the shares offered. The aggregate net proceeds to us were approximately $129.3 million, after deducting underwriting discounts and commissions and offering expenses payable by us of approximately $14.5 million. Except as set forth below, no offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons
owning ten percent or more of any class of our equity securities or to any other affiliates, JPMC Strategic Investments II Corporation, or JPMC, owned in excess of 10% of our issued and outstanding common stock immediately prior to our initial
public offering, and JPMC is an affiliate of J.P. Morgan Securities LLC, which was a book running manager in our initial public offering. In addition, Mr. Robert Huffines, one of our directors, is an employee of J.P. Morgan Securities LLC. Because the closing of our initial public offering occurred on January 30, 2018, as of December 31, 2017, we had not yet received the net proceeds
from the sale of shares of common stock in our initial public offering and, therefore, had used none of the proceeds as of December 31, 2017. There has been no material change in our planned use of the net proceeds from the offering as
described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.  Item 6.
Selected Financial Data. The statement of operations data for the years ended December 31, 2017,
2016 and 2015 and the balance sheet data as of December 31, 2017 and 2016 are derived from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The selected balance sheet data as of
December 31, 2015 is derived from our audited consolidated financial statements that are not included in this Annual Report on Form 10-K.  83




---

##### Table of Contents

Our historical results are not necessarily indicative of results that should be expected in any future
period. The following selected financial data should be read in conjunction with the section of this report entitled Managements Discussion and Analysis of Financial Condition and Results of Operations and our financial statements
and the related notes included elsewhere in this Annual Report on Form 10-K.  Year ended December 31,2017


2016


2015(in thousands, except units and per unit data)Consolidated statements of operations data:Revenue

$



$



$
Operating expenses:Research and development


39,905



20,116



4,192General and administrative


14,952



5,460



2,372Total operating expenses


54,857



25,576



6,564Loss from operations


(54,857
)


(25,576
)


(6,564
)Other income (expense):Revaluation of preferred unit tranche rights


459



1,163



(103
)Interest and other income


1,220



640



3Total other income (expense), net


1,679



1,803



(100
)Net loss

$
(53,178
)

$
(23,773
)

$
(6,664
)Net loss attributable to Solid Biosciences, LLC

$
(52,118
)

$
(21,539
)

$
(6,377
)Net loss attributable to common unitholders

$
(39,317
)

$
(17,230
)

$
(6,445
)Net loss per unit attributable to common unitholders, basic and diluted (1)

$
(2.88
)

$
(10.14
)

$
(7.61
)Weighted average common units outstanding, basic and diluted (1)


13,649,485



1,698,904



846,569  As of December 31,2017


2016


2015(in thousands)Consolidated balance sheet data:Cash, cash equivalents and available-for-sale securities

$
69,094


$
37,658


$
55,387Working capital (2)


59,387



33,099



41,772Total assets


76,193



40,636



55,696Redeemable preferred units


124,179



71,649



61,697Accumulated members deficit


(124,258
)


(84,941
)


(67,711
)Total deficit


(59,257
)


(37,886
)


(19,925
)  (1)
See Note 15 to our consolidated financial statements in this Annual Report on Form 10-K for details on the calculation of basic and diluted net loss per unit attributable to common unitholders. (2)
We define working capital as current assets less current liabilities.  84




---

##### Table of Contents

Item 7.
Managements Discussion and Analysis of Financial Condition and Results of Operations. The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information
contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and
uncertainties. As a result of many factors, including those factors set forth in the Risk Factors section of this Annual Report on Form 10-K, our actual results could differ materially from the results described, in or implied, by these
forward-looking statements. Overview Our mission is to cure Duchenne muscular dystrophy, or DMD, a genetic muscle-wasting disease predominantly affecting boys, with symptoms that
usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000
cases in the United States alone. DMD is caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and
tear. Without functioning dystrophin and certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. There is no cure for
DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in
patients muscles. Based on our preclinical program that included multiple animal species of different phenotypes and genetic variations, we believe the mechanism of action of SGT-001, if our clinical trials prove to be successful, has the
potential to slow or even halt the progression of DMD, regardless of the type of genetic mutation or stage of the disease. Since our
inception, we have devoted substantial resources to identifying and developing SGT-001 and our other product candidates, developing our manufacturing processes, organizing and staffing our company and providing general and administrative support for
these operations. We have incurred significant losses every year since our inception. We do not have any products approved for sale. To date, we have not generated any revenue. Our ability to eventually generate any product revenue sufficient to
achieve profitability will depend on the successful development, approval and eventual commercialization of SGT-001 and our other product candidates. If successfully developed and approved, we intend to commercialize SGT-001 in the United States and
European Union and may enter into licensing agreements or strategic collaborations in other markets. If we generate product sales or enter into licensing agreements or strategic collaborations, we expect that any revenue we generate will fluctuate
from quarter to quarter and year to year as a result of the timing and amount of any product sales, license fees, milestone payments and other payments. If we fail to complete the development of SGT-001 and our other product candidates in a timely
manner or obtain regulatory approval of them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected. In November 2017, we initiated a Phase I/II clinical trial for SGT-001, called IGNITE DMD, and in February 2018 we dosed the first patient, a
nonambulatory adolescent. On March 14, 2018, we announced that IGNITE DMD was placed on full clinical hold following a serious adverse event reported in the clinical trial. We have halted enrollment and dosing in IGNITE DMD and are awaiting the
formal clinical hold letter from the FDA. Due to our significant research and development expenditure, licensing and patent investment,
and general administrative costs associated with our operations, we have generated substantial operating losses in each period since our inception. Our net losses were $53.2 million, $23.8 million and $6.7 million, for the years ended
December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017, we had an accumulated members  85




---

##### Table of Contents

deficit of $124.3 million. We expect to incur significant expenses and increasing operating losses for the foreseeable future. As we seek to develop and commercialize SGT-001 and our other product candidates, we anticipate that our expenses will increase significantly
and that we will need substantial additional funding to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or
private equity financings, debt financings or other sources, which may include licensing agreements or strategic collaborations. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms,
if at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of SGT-001 or our other product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of
increased expenses or determine when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain
profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. On January 30, 2018, we completed our initial public offering in which we sold 8,984,375 shares of our common stock, including shares of
our common stock pursuant to underwriters over-allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $129.3 million, after deducting underwriting discounts and commissions and offering expenses. On October 26, 2017, we completed the sale of 4,886,000 Series 2 Senior Preferred Units at a price of $11.26 per unit resulting in net
proceeds of $55.0 million. As of December 31, 2017, we had cash, cash equivalents and available-for-sale securities of
$69.1 million. We believe that our cash, cash equivalents and available-for-sale securities as of December 31, 2017, together with the net proceeds of $129.3 million from our recently completed initial public offering, will enable us to
fund our operating expenses and capital expenditure requirements until the end of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently anticipate. Corporate conversion We operated as a
Delaware limited liability company under the name Solid Biosciences, LLC until immediately prior to the effectiveness of our registration statement on Form S-1 on January 25, 2018, at which time we converted into a Delaware corporation pursuant
to a statutory conversion and changed our name to Solid Biosciences Inc. In addition, immediately following the statutory conversion, entities formed solely for the purpose of holding membership interests in our limited liability company were merged
with and into us. We refer to the corporate conversion and the mergers, collectively as the Corporate Conversion. As a result of the Corporate Conversion, the holders of the Series 1 and 2 Senior Preferred and Junior Preferred Units and Series A, B,
C and D Common Units of Solid Biosciences, LLC became holders of common stock of Solid Biosciences Inc. The consolidated financial
statements included elsewhere in this Annual Report on Form 10-K are those of Solid Biosciences, LLC and its subsidiaries. We do not expect that the Corporate Conversion will have a material effect on the results of our core operations. Merger and recapitalization We
historically owned 100% of the voting units of our wholly owned subsidiary, Solid GT, LLC, or Solid GT, and the results of Solid GT are included in our consolidated financial statements. Solid GT was organized in  86




---

##### Table of Contents

Delaware in August 2014 and was engaged in the business of developing disease-modifying interventions for DMD through gene therapy. In November 2015, Solid GT issued voting units to new
investors, which decreased our voting ownership in Solid GT to 77%. We consolidated the results of Solid GT as we owned a majority voting interest in Solid GT and we directed the activities of Solid GT. Net loss attributable to non-controlling interests in our consolidated statement of operations and comprehensive loss consists of the portion
of the net income or loss of Solid GT that is not allocated to us. Changes in the amount of net loss attributable to non-controlling interests are directly impacted by changes in the net income or loss of Solid GT. On March 29, 2017, we merged
the operations of Solid GT into the company and Solid GT ceased to exist as a separate legal entity. As a result, for periods subsequent to March 29, 2017, we no longer report any non-controlling interests related to Solid GT. Financial operations overview Revenue We have not generated any revenue to date and do not expect to generate any revenue from the sale of our products for the next few years, if
ever. If our development efforts for SGT-001 or our other product candidates are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a
combination of product sales or payments from those collaboration or license agreements. Operating expenses We classify our operating expenses into two categories: research and development, and general and administrative expenses. Personnel costs,
including salaries, benefits, bonuses and equity-based compensation expense, comprise a significant component of each of these expense categories. We allocate expenses associated with personnel costs based on the nature of work associated with these
resources. Research and development expenses Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the
development of SGT-001 and our other product candidates and include:  

expenses incurred under agreements with third parties, including CROs, that conduct research and preclinical activities on our behalf, as well as CMOs, that manufacture SGT-001 and our other product candidates for use
in our preclinical studies and clinical trials;  

salaries, benefits and other related costs, including equity-based compensation expense, for personnel engaged in research and development functions;  

costs of outside consultants, engaged to assist in our research and development activities, including their fees, equity-based compensation and related travel expenses;  

costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;  

costs incurred in seeking regulatory approval of SGT-001 and our other product candidates;  

expenses incurred under our intellectual property licenses; and  

facility-related research and development expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical research
and development, based on an evaluation of the progress to completion of  87




---

##### Table of Contents

specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Payments for these activities are based on the terms of the individual
agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. We typically use our employee and infrastructure resources across our product candidates. We track outsourced development costs and milestone
payments made under our licensing arrangements by product candidates, but we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to product candidates on a program-specific basis. These
costs are included in unallocated research and development expenses in the table below. The following table summarizes our research and
development expenses by product candidates for the respective periods:  Year ended December 31,2017


2016


2015SGT-001

$
24,674


$
13,891


$
1,940Other product candidates


1,619



1,021



233Unallocated research and development expenses


13,612



5,204



2,019Total research and development expenses

$
39,905


$
20,116


$
4,192 We cannot determine with certainty the duration, costs and timing of clinical trials of SGT-001 and our other
product candidates or if, when or to what extent we will generate revenue from the commercialization and sale of any our product candidates for which we obtain marketing approval or our other research and development expenses. We may never succeed
in obtaining marketing approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:  

the scope, rate of progress, expense and results of any clinical trials of SGT-001 or other product candidates and other research and development activities that we may conduct;  

the imposition of regulatory restrictions on clinical trials, including full and partial clinical holds and the time and activities required to lift any such holds;  

uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates;  

significant and changing government regulation and regulatory guidance;  

potential additional studies or clinical trials requested by regulatory agencies;  

the timing and receipt of any marketing approvals; and  

the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. Research and development activities are central to our business model. Product candidates in later stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for
the foreseeable future as we proceed with clinical trials for SGT-001, initiate clinical trials for product candidates other than SGT-001 and continue to identify and develop additional product candidates. General and administrative expenses General and administrative expenses consist primarily of salaries and other related costs, including equity-based compensation, for personnel
in our executive, finance, business development and administrative functions.  88




---

##### Table of Contents

General and administrative expenses also include legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs,
travel expenses, and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of office facilities and other operating costs. We expect that our general and administrative expenses will increase in the future as we increase our general and administrative personnel
headcount to support our research and development activities and activities related to the potential commercialization of SGT-001 and our other product candidate. We also expect to incur increased expenses associated with being a public company,
including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs and investor and public relations costs. Other income (expense) Revaluation of
preferred unit tranche rights Included in the terms of the Redeemable Preferred Unit Purchase Agreement was a right, which we refer to
as the Redeemable Preferred Tranche Right, granted to the holders of the Redeemable Preferred Units issued in December 2013. The Redeemable Preferred Tranche Right obligated the holders to purchase, and provided the holders with the right to
purchase, additional redeemable preferred units under certain circumstances. The Redeemable Preferred Tranche Right was transferrable by the investors. The terms of the Series 1 Senior Preferred Unit Purchase Agreement, as amended on September 1, 2017, also contained a right, which we
refer to as the Series 1 Tranche Right. The Series 1 Tranche Right obligated the holders of the Series 1 Senior Preferred Units to purchase 1,973,430 Series 2 Senior Preferred Units at a purchase price of $12.67 per unit in the event we
achieved certain preclinical milestones. In addition, the holders of a majority of the Series 1 Senior Preferred Units had the right to require the holders of the Series 1 Senior Preferred Units to purchase the Series 2 Senior Preferred Units
at any time prior to December 1, 2017. The Series 1 Tranche Right was subject to certain transfer rights. We concluded that the
Redeemable Preferred Tranche Right and the Series 1 Tranche Right, together the Tranche Rights, met the definition of a freestanding financial instrument as the Tranche Rights were legally detachable and separately exercisable from the Redeemable
Preferred Units and the Series 1 Senior Preferred Units. Therefore, we allocated the net proceeds between the Tranche Rights and the Redeemable Preferred Units or the Series 1 Senior Preferred Units. The Tranche Rights were initially recorded at
fair value and are re-measured at fair value each reporting period. Changes in the fair market value are recognized as a component of other income (expense), net, in the consolidated statements of operations. In October 2016, the Redeemable Preferred Tranche Right was settled with the closing of the Redeemable Preferred Unit financing. In October
2017, the Series 1 Tranche Right was settled in connection with the closing of the Series 2 Senior Preferred Financing. Interest income Interest income consists of interest income earned on our cash, cash equivalents and available-for-sale securities. Other income We have received funding
from charitable organizations, which are not considered to be an ongoing major or central part of our business. The amounts received are recorded as other income as services are performed and research expenses are incurred in the consolidated
statements of operations.  89




---

##### Table of Contents

Income taxes Since our inception in 2013 through the date of the Corporate Conversion, we were organized as a Delaware limited liability company for federal
and state income tax purposes and treated as a partnership for U.S. income tax purposes. As such, we were not viewed as a taxpaying entity in any jurisdiction and do not require a provision for income taxes. Each member of our company was
responsible for the tax liability, if any, related to its proportionate share of our taxable income. As a result of the Corporate
Conversion, we will be treated as a corporation from the date of the Corporate Conversion for U.S. income tax purposes and thus will become subject to U.S. federal, state and local income taxes and will be taxed at the prevailing corporate tax
rates. Among other things, we may begin to generate net operating losses at the corporate level. We will account for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated
realizable value. We will account for uncertainty in income taxes recognized in the financial statements by applying a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed
more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50%
likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and
penalties. Critical accounting policies and use of estimates Our managements discussion and analysis of financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions
that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events
and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We
evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. While our significant
accounting policies are described in more detail in the notes to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the
judgments and estimates used in the preparation of our consolidated financial statements. Accrued research and development expenses As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contract and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred
for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met;
however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our  90




---

##### Table of Contents

consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to:  

CROs in connection with performing research activities on our behalf and conducting clinical trials and preclinical studies on our behalf;  

vendors in connection with preclinical development activities;  

vendors related to product manufacturing and development and distribution of clinical and preclinical supplies; and  

third parties under our intellectual property licenses. We base our expenses related to
preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these
agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the
expense. In accruing fees, we estimate the time period over which services will be performed, and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate,
we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the
actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and
development expenses. Tranche Rights We measured the fair value of the Tranche Rights based on the fair value of the Tranche Rights at inception and remeasured their fair value at
each reporting date until settled. Changes in the fair market value were recognized as a component of other income (expense), net in the consolidated statement of operations. As there has been no public market for our preferred units, the
estimated fair value of our preferred units was determined from our most recently available third-party valuations of preferred units. These third-party valuations were performed in accordance with the guidance outlined in the American
Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, also known as the Practice Aid. Our preferred unit valuations were prepared using a
market approach based on the most recent round of equity financing and an option-pricing method, or OPM, with the exception of the December 6, 2016 valuation, which was performed using the hybrid method and the expected probability of closing a
financing round. The hybrid method was used in anticipation of an equity financing transaction, which had not closed as of the valuation date. The OPM treats preferred units and common units as call options on the total equity value of a company,
with exercise prices based on the value thresholds at which the allocation among the various holders of a companys securities changes. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity value in one
or more scenarios is calculated using OPM. The PWERM is a scenario-based methodology that estimates the fair value of preferred units based upon an analysis of future values for the company, assuming various outcomes. The preferred unit value is
based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of units. The values of the preferred units under each outcome is
probability weighted to arrive at an indication of value for the common units. The OPM and hybrid methods were selected to properly account for the limited liability company structure. Equity-based compensation Certain
of our employees and consultants have received grants of common units in our company. These awards are accounted for in accordance with guidance prescribed for accounting for equity-based compensation.  91




---

##### Table of Contents

Based on this guidance and the terms of the awards, the awards are equity classified. Prior to the Corporate Conversion, the common units were to receive distributions only if a threshold that
was equivalent to the overall value of our company on the grant date was exceeded. The threshold impacted the fair value of our common units because proceeds were distributed in an order of priority in accordance with our limited liability company
agreement. As the overall value of our company increased, common units with a lower threshold had a higher per unit fair value than common units subject to higher thresholds. Under the terms of our limited liability company agreement, upon conversion to a corporation, holders of our preferred units were
contractually entitled to receive the number of shares of common stock in the converted corporation that equals the value of the units that such holders held in our company immediately prior to the conversion. Therefore, if the equity value of our
company had not reached a specific threshold that would allow the holders of preferred units to receive their full value, such holders, pursuant to the terms of our limited liability company agreement, would have been entitled to receive more shares
of common stock upon the corporate conversion in order to make them whole. This contractual protection for the benefit of holders of our preferred units could have resulted in the holders of our Series D Common Units receiving less value
for their Series D Common Units in an initial public offering. For example, until such time as the equity value of our company increased to reach the specified threshold that resulted in the Series D Common Unit holders having caught up to the value
of the holders of our preferred units, Series D Common Unit holders would receive fewer shares of common stock in the converted corporation than originally issued, and certain Series D Common Unit holders with a higher specified threshold (due to
receiving their units at a later grant date) may not have received any shares in an initial public offering. Until January 26, 2018,
we were a private company with no active public market for our common units. Therefore, we have periodically determined the overall value of our company and the estimated per share fair value of our common units at their various dates using
contemporaneous valuations performed in accordance with the guidance outlined in the Practice Aid. As a result of the completion of our initial public offering in January 2018, it is no longer necessary for us to estimate the fair value of our
common stock in connection with our accounting for equity awards we may grant, as the fair value of our common stock is the public market trading price. For financial reporting purposes, we performed common unit valuations with the assistance of a third-party specialist, for the years ended
December 31, 2017, 2016, 2015, and 2014 and for each quarter in the period from January 1, 2016 through December 31, 2017. Our common unit valuations were prepared using a market approach based on the most recent round of equity financing and an OPM, with the
exception of the December 6, 2016 and the December 31, 2017 valuations, which were performed using the hybrid method and the expected probability of closing a financing round. The hybrid method was used in anticipation of an
anticipated equity financing transaction, which had not closed as of the valuation date. The OPM treats common units and preferred units as call options on the total equity value of a company, with exercise prices based on the value thresholds at
which the allocation among the various holders of a companys securities changes. Under this method, the common unit has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation
preference at the time of the liquidity event, such as a strategic sale, merger or public offering. The hybrid method is a PWERM where the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology
that estimates the fair value of common units based upon an analysis of future values for the company, assuming various outcomes. The common unit value is based on the probability-weighted present value of expected future investment returns
considering each of the possible outcomes available as well as the rights of each class of units. The values of the common unit under each outcome is probability weighted to arrive at an indication of value for the common unit. The OPM and hybrid
methods were selected to properly account for the limited liability company structure.  92




---

##### Table of Contents

In connection with the preparation of valuations of our common units, our management and
valuation specialists collectively used various objective and subjective factors to determine the fair value of our common unit as of each grant date, including:  

the prices at which we sold preferred units and the superior rights and preferences of the preferred units relative to our common units at the time of each grant;  

the progress of our research and development programs, including the status and results of clinical trials and preclinical studies for our product candidates;  

our stage of development and commercialization and our business strategy;  

external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry;  

our financial position, including cash on hand, and our historical and forecasted performance and operating results;  

the lack of an active public market for our common units and preferred units;  

the likelihood of achieving a liquidity event, such as an initial public offering or sale of our company in light of prevailing market conditions; and  

the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry. The assumptions underlying these valuations represented managements best estimate, which involved inherent uncertainties and the
application of managements judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common units and our equity-based compensation expense could have been materially different. Our December 31, 2017 common unit valuation (the December 2017 Valuation) was prepared using a PWERM and considered two
future-event scenarios: (i) a near-term initial public offering, or IPO, scenario, on a fully-diluted basis, in which we complete an IPO by February 1, 2018 and (ii) a longer-term exit scenario in which we would complete an IPO by
April 1, 2018 using an OPM allocation. The two exit scenarios assumed that all preferred units would convert into common units and no longer have the preferences and preferential rights attributable to the preferred units as compared to the
common units prior to the IPO, unless the value of the company were to substantially decline prior to an April 1, 2018 IPO. The two IPO scenarios also were prepared based on the expected price range of the IPO which was determined based on
input received from our lead underwriters in December 2017. The December 2017 Valuation probability weighted the near-term IPO scenario at 90% and the longer-term IPO scenario at 10% based on our assessment of market conditions. We also applied a
discount for lack of marketability and lack of voting rights in the near-term and longer-term IPO scenarios. The December 2017 Valuation resulted in a valuation of our Series D Common Units of $12.69 per unit. Based on that result, as well as
consideration of other qualitative factors, our board of directors determined that the fair value of our Series D Common Units was $12.69 on December 31, 2017. We used the fair value of $12.69 to account for all common unit grants made in the
fourth quarter of 2017.  93




---

##### Table of Contents

Results of operations Comparison of the years ended December 31, 2017 and 2016 The following table summarizes our results of operations for the years ended December 31, 2017 and 2016:  Years ended December 31,


Increase(decrease)2017


2016(in thousands)Revenue

$



$



$
Operating expenses:Research and development


39,905



20,116



19,789General and administrative


14,952



5,460



9,492Total operating expenses


54,857



25,576



29,281Loss from operations


(54,857
)


(25,576
)


(29,281
)Other income (expense):Revaluation of preferred unit tranche rights


459



1,163



(704
)Interest income


219



369



(150
)Other income


1,001



271



730Total other income (expense)


1,679



1,803



(124
)Net loss

$
(53,178
)

$
(23,773
)

$
(29,405
) Research and development expenses  Years ended December 31,


Increase(decrease)2017


2016(in thousands)SGT-001

$
24,674


$
13,891


$
10,783Other product candidates


1,619



1,021



598Unallocated research and development expenses


13,612



5,204



8,408Total research and development expenses

$
39,905


$
20,116


$
19,789 Research and development expenses for the year ended December 31, 2017 were $39.9 million, compared to
$20.1 million for the year ended December 31, 2016. The increase of $19.8 million in research and development costs was due to a $10.8 million increase in clinical and preclinical research and manufacturing costs related to our
lead product candidate SGT-001, $0.6 million increase in costs related to our other product candidates and $8.4 million increase in unallocated research and development costs due primarily to increased compensation and headcount. General and administrative expenses General and administrative expenses were $15.0 million for the year ended December 31, 2017, compared to $5.5 million for the
year ended December 31, 2016. The increase of $9.5 million was primarily due to in an increase in equity-based compensation of $3.9 million, an increase of $2.9 million in professional fees related to our initial public offering,
an increase of $2.1 million in personnel-related expenses and an increase of $0.6 million in other corporate expenses. The increase in equity-based compensation of $3.9 million during the year ended December 31, 2017 was primarily due
to a charge associated with the exchange of certain of our vested common units in connection with the recapitalization of our company and our merger with Solid GT on March 29, 2017.  94




---

##### Table of Contents

Revaluation of preferred unit tranche rights The revaluation of the Redeemable Preferred Tranche Right resulted in a gain of $1.2 million for the year ended December 31, 2016 due
to a decrease in the fair value of the preferred units. We issued the Series 1 Tranche Right on March 29, 2017 and it was settled in October 2017 in connection with the Series 2 senior preferred unit financing. The revaluation of the Series 1
Tranche Right resulted in a gain of $0.5 million in the year ended December 31, 2017 due to the settlement of the tranche right. Interest income Interest income remained consistent at $0.2 million and $0.4 million for the years ended December 31, 2017 and 2016,
respectively. Other income Other
income for the year ended December 31, 2017 was $1.0 million compared to $0.3 million for the year ended December 31, 2016. The increase of $0.7 million was due to income from charitable organizations. We do not expect these
contributions to significantly increase in future periods. Comparison of the years ended December 31, 2016 and 2015 The following table summarizes our results of operations for the years ended December 31, 2015 and 2016:  Year ended December 31,


Increase(decrease)2016


2015(in thousands)Revenue

$



$



$
Operating expenses:Research and development


20,116



4,192



15,924General and administrative


5,460



2,372



3,088Total operating expenses


25,576



6,564



19,012Loss from operations


(25,576
)


(6,564
)


(19,012
)Other income (expense):Revaluation of preferred unit tranche rights


1,163



(103
)


1,266Interest income


369



3



366Other income


271







271Total other income (expense)


1,803



(100
)


1,903Net loss

$
(23,773
)

$
(6,664
)

$
(17,109
) Research and development expenses  Year ended December 31,


Increase(decrease)2016


2015(in thousands)SGT-001

$
13,891


$
1,940


$
11,951Other product candidates


1,021



233



788Unallocated research and development expenses


5,204



2,019



3,185Total research and development expenses

$
20,116


$
4,192


$
15,924 Research and development expenses for the year ended December 31, 2016 were $20.1 million, compared
to $4.2 million for the year ended December 31, 2015. The increase of $15.9 million in research and  95




---

##### Table of Contents

development costs was due to a $12.0 million increase in preclinical research and manufacturing costs related to our lead product candidate, SGT-001, $0.8 million increase in costs
related to our other product candidates due to increased discovery costs, and $3.2 million increase in unallocated research and development costs due primarily to increased compensation and headcount, the full year impact of employees hired in
2015 and an increase of $0.6 million in equity-based compensation. General and administrative expenses General and administrative expenses were $5.5 million for the year ended December 31, 2016, compared to $2.4 million for the
year ended December 31, 2015. The increase of $3.1 million was due to an increase of $1.8 million in compensation and related costs due to increased headcount and new hires, $0.7 million in legal and accounting fees,
$0.4 million of other corporate-related costs, and $0.2 million in facilities costs due to new corporate and research space. The increase in professional fees was due to increases in the use of accounting consultants and in legal fees. Revaluation of preferred unit tranche rights The revaluation of the Redeemable Preferred Tranche Right resulted in a gain of $1.2 million for the year ended December 31, 2016
compared to a loss of $0.1 million for the year ended December 31, 2015. The increase of $1.3 million was due to a decrease in the underlying preferred units during the year ended December 31, 2016. The Redeemable Preferred
Tranche Right expired in October 2016. Interest income Interest income was $0.4 million for the year ended December 31, 2016, compared to $0.1 million for the year ended
December 31, 2015. The increase of $0.3 million was due to increased cash, cash equivalents and available-for-sale securities for the year ended December 31, 2016 compared to the year ended December 31, 2015. Other income Other income was $0.3
million for the year ended December 31, 2016 compared to no other income for the year ended December 31, 2015. The increase of $0.3 million was due to income from charitable organizations. Liquidity and capital resources Sources of
liquidity Through December 31, 2017, we have financed our operations primarily through private placements of preferred units.
Through December 31, 2017, we raised an aggregate of $144.6 million of gross proceeds from our sales of preferred units, which includes $25.0 million from our sale of our Series 1 Senior Preferred Units on March 29, 2017 and
$55.0 million from our sale of our Series 2 Senior Preferred Units in the Series 2 Senior Preferred Financing on October 26, 2017. On January 30, 2018, we completed our initial public offering in which we sold 8,984,375 shares of common stock, including shares of
common stock issued upon the exercise in full of the underwriters over-allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $129.3 million, after deducting underwriting discounts and commissions and
offering expenses. As of December 31, 2017, we had cash, cash equivalents and available-for-sale securities of $69.1 million
and had no debt outstanding.  96




---

##### Table of Contents

Cash flows The following table summarizes our sources and uses of cash for each of the periods presented:  Year ended December 31,2017


2016


2015(in thousands)Cash used in operating activities

$
(43,224
)

$
(20,120
)

$
(4,204
)Cash provided by (used in) investing activities


10,548



(4,217
)


(26,806
)Cash provided by financing activities


77,078



3,420



51,592Net increase (decrease) in cash and cash equivalents

$
44,402


$
(20,917
)

$
20,582 Operating activities. During the year ended December 31, 2017, operating activities used
$43.2 million of cash, primarily resulting from our net loss of $53.2 million offset by net non-cash charges of $5.5 million due primarily to equity-based compensation of $5.3 million, which included $3.7 million associated
with the exchange of Series A common units into Series B and D common units, and cash provided by changes in our operating assets and liabilities of $4.4 million. Net cash provided by changes in our operating assets and liabilities during the
year ended December 31, 2017 consisted of a decrease in prepaid expenses and other currents assets of $0.8 million due to the timing of prepaid research and development expense payments and net increase in accounts payable and accrued
expenses of $3.6 million due to the timing of payments and the increase in the overall activity of the company. During the year
ended December 31, 2016, operating activities used $20.1 million of cash, primarily resulting from our net loss of $23.8 million offset by non-cash charges of $0.9 million and cash provided by changes in our operating assets and
liabilities of $2.8 million. Non-cash charges of $0.9 million represented equity-based compensation expense of $1.5 million and amortization of premiums on available-for-sale securities of $0.5 million, offset by
$1.1 million of gains on the revaluation of our Redeemable Preferred Tranche Right due to a decrease in the fair value of the underlying preferred units for the year ended December 31, 2016. Net cash provided by changes in our operating
assets and liabilities during the year ended December 31, 2016 consisted of an increase of $4.8 million in accounts payable, accrued expenses and other current liabilities, partially offset by a $2.0 million increase in prepaid
expenses and other current assets. The increase in accounts payable, accrued expenses and other current liabilities was largely due to an increase of preclinical trial-related expenses. The increase in prepaid expenses and other current assets was
primarily due to the payment of preclinical activities in advance of the related research and development. During the year ended
December 31, 2015, operating activities used $4.2 million of cash, primarily resulting from our net loss of $6.7 million, partially offset by non-cash charges of $0.9 million due primarily to $0.7 million of equity-based
compensation expense, and cash provided by changes in our operating assets and liabilities of $1.6 million. Net cash provided by changes in our operating assets and liabilities during the year ended December 31, 2015 consisted of a
$1.9 million increase in accounts payable, accrued expenses and other current liabilities, partially offset by a $0.3 million increase in prepaid expenses and other current assets. The increase in accounts payable, accrued expenses and
other current liabilities was largely due to an increase of preclinical trial-related expenses. The increase in prepaid expenses and other current assets was primarily due to the payment of preclinical activities in advance of the related research
and development. Investing activities During the year ended December 31, 2017, investing activities provided $10.5 million of cash, consisting primarily of the net
proceeds on the sale and maturity of available-for-sale securities partially offset by purchases of property and equipment.  97




---

##### Table of Contents

During the year ended December 31, 2016, investing activities used $4.2 million of
cash, consisting primarily of net purchases of investments and to a lesser extent the acquisition of property and equipment. During the
year ended December 31, 2015, investing activities used $26.8 million of cash, consisting primarily of net purchases of investments. We expect that purchases of property and equipment will increase over the next several years resulting from our move into a new office and
laboratory facility in early 2018. Financing activities During the year ended December 31, 2017, net cash provided by financing activities was $77.1 million, primarily due to the proceeds from
our sale of Series 1 and 2 Senior Preferred Units of $25.0 million and $55.0 million, respectively, partially offset by payments made in connection with our initial public offering. During the year ended December 31, 2016, net cash provided by financing activities was $3.4 million, due to the proceeds from our
sale of Redeemable Preferred Units. During the year ended December 31, 2015, net cash provided by financing activities was
$51.6 million, due to the proceeds from our sales of Redeemable Preferred Units of $6.8 million and net proceeds of $44.8 million from the issuance of non-controlling interests in our consolidated subsidiary Solid GT. Funding requirements We expect
our expenses to increase substantially in connection with our ongoing development activities related to SGT-001. In addition, we expect to incur additional costs associated with operating as a public company. We expect that our expenses will
increase substantially if and as we:  

seek to resolve the partial and full clinical holds on the Phase I/II clinical trial for SGT-001 and, if and when lifted, resume our clinical development of SGT-001;  

move other current or future product candidates into clinical trials;  

continue research and preclinical development of our other product candidate;  

seek to identify additional product candidates;  

seek marketing approvals for our product candidates that successfully complete clinical trials, if any;  

establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;  

arrange for manufacture of larger quantities of our product candidates for clinical development and potential commercialization;  

maintain, expand and protect our intellectual property portfolio;  

hire and retain additional clinical, quality control and scientific personnel;  

build out new facilities or expand existing facilities to support our ongoing development activity;  

acquire or in-license other drugs and technologies; and  

add operational, financial and management information systems and personnel. On
January 30, 2018, we completed our initial public offering in which we sold 8,984,375 shares of common stock, including shares of common stock issued upon the exercise in full of the underwriters over-allotment option, at a public
offering price of $16.00 per share, resulting in net proceeds of $129.3 million, after deducting underwriting discounts and commissions and offering expenses.  98




---

##### Table of Contents

On October 26, 2017, we completed the sale of 4,886,000 Series 2 Senior Preferred Units
at a price of $11.26 per unit resulting in net proceeds of $55.0 million. As of December 31, 2017, we had cash, cash equivalents and
available-for-sale securities of $69.1 million. We believe that our cash, cash equivalents and available-for-sale securities as of December 31, 2017, together with the net proceeds of $129.3 million from our recently completed initial
public offering, will enable us to fund our operating expenses and capital expenditure requirements until the end of 2019. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner
than we currently anticipate. Because of the numerous risks and uncertainties associated with the development of SGT-001 and other
product candidates and programs and because the extent to which we may enter collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and
operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:  

our ability to favorably resolve the partial and full clinical holds on the Phase I/II clinical trial of SGT-001 and, if so resolved, the timing of such resolution;  

the progress and results of our Phase I/II clinical trial and future clinical trials of SGT-001 and our other product candidates;  

the costs, timing and outcome of regulatory review of SGT-001 and our other product candidates;  

the scope, progress, results and costs of drug discovery, laboratory testing, manufacturing, preclinical development and clinical trials for other product candidates that we may pursue in the future, if any;  

the costs associated with our manufacturing process development and evaluation of third-party manufacturers;  

the costs associated with constructing and validating our own manufacturing facility;  

revenue, if any, received from commercial sale of SGT-001 or other product candidates, should any of our product candidates receive marketing approval;  

the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims;  

the outcome of any lawsuits filed against us;  

the terms of our current and any future license agreements and collaborations; and  

the extent to which we acquire or in-license other product candidates, technologies and intellectual property. We intend to supply our clinical development program for SGT-001 with drug product produced at a cGMP compliant facility located at one of our
CDMO partners. We intend to establish the capability and capacity to supply SGT-001 at commercial scale from multiple sources, including potentially building our own GMP facility to ensure redundancy and reliability. We expect that such a facility
would require capital expenditures of between $35.0 million to $45.0 million to commence operations. We expect to finalize plans to potentially build our own GMP facility after we have initial data from our Phase I/II clinical trial for
SGT-001. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive
and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain
marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if
ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.  99




---

##### Table of Contents

Adequate additional funds may not be available to us on acceptable terms, or at all. We do
not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity securities, our existing stockholders ownership interest may be diluted. Any debt or preferred equity
financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely
impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute existing stockholders ownership interests. If we raise additional funds through licensing agreements and strategic collaborations with third parties, we may have to relinquish valuable
rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds, we may be required to delay, limit, reduce and/or
terminate development of our product candidates or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Contractual obligations and commitments The following table summarizes our contractual obligations at December 31, 2017 and the effects that such obligations are expected to have
on our liquidity and cash flows in future periods:  Payments due by period(in thousands)

Total


Less Than1 Year


1 - 3Years


3 - 5Years


More Than5 YearsOperating lease commitments (1)


$
783


$
783


$



$



$
  (1)
Represents minimum payments due for our lease of office and laboratory space in Cambridge, Massachusetts under an operating lease agreement that, as amended, expires in February 2018 as well as minimum payments for our
lease of additional office and laboratory space in Cambridge, Massachusetts, for which we entered into a lease in May 2017 and amended during the third and fourth quarters of 2017, which extends through April 2018. Amounts in the table above exclude
payments for (a) laboratory space in Cambridge, Massachusetts, for which we entered into a lease in January 2018 and for which the initial lease term is approximately four years and the minimum rent commitment due over the initial term is
approximately $3.8 million and (b) office space in Cambridge, Massachusetts, for which we entered into a lease in January 2018 and for which the lease term is through February 2022 and the minimum rent commitment due over the term is approximately
$4.6 million. Under various agreements with third-party licensors, we have agreed to make milestone payments and pay royalties to third
parties based on specific milestones. We have not included any such contingent payment obligations in the table above as the amount, timing and likelihood of such payments are not known. See BusinessStrategic partnerships and
collaborations/licenses. We enter into contracts in the normal course of business with CROs and CMOs for clinical trials,
preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30 days and, as a result,
are not included in the table of contractual obligations above. Internal control over financial reporting During the preparation of our consolidated financial statements as of and for the years ended December 31, 2016 and 2015, we identified
material weaknesses in our internal control over financial reporting. A companys internal control over financial reporting is a process designed by, or under the supervision of, a companys principal executive and principal financial
officers, or persons performing similar functions, and effected by a  100




---

##### Table of Contents

companys board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in
accordance with generally accepted accounting principles. Under standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. The material weaknesses that we identified were as follows:  

We did not design or maintain an effective control environment commensurate with our financial reporting requirements. We lacked a sufficient number of professionals with an appropriate level of accounting knowledge,
training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, the limited personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in
pursuit of our financial reporting objectives, as demonstrated by, among other things, our insufficient segregation of duties in our finance and accounting functions. This material weakness contributed to the additional material weaknesses detailed
below.  

We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and
review of account reconciliations and journal entries. Additionally, we did not design and maintain controls over the appropriate cut-off, classification and presentation of accounts and disclosures in the financial statements.  

We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. Specifically, we did not design and maintain controls to analyze, account for
and disclose complex transactions, including variable interest entities, preferred units, the preferred unit tranche right and equity-based compensation. We are in the process of implementing measures designed to improve our internal control over financial reporting and remediate the control
deficiencies that led to the material weaknesses, including hiring additional finance and accounting personnel and initiating design and implementation of our financial control environment, including the establishment of formal accounting policies
and procedures, financial reporting controls and controls to account for and disclose complex transactions. We, and our independent
registered public accounting firm, were not required to perform an evaluation of our internal control over financial reporting in accordance with the transition period established by rules of the SEC for newly public companies. Accordingly, we
cannot assure our stockholders that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial
reporting as required by reporting requirements under Section 404. Off-balance sheet arrangements We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. Recently issued accounting pronouncements We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial
statements appearing at the end of this Annual Report on Form 10-K, such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our operations.  101




---

##### Table of Contents

Emerging growth company status The JOBS Act permits an emerging growth company such as us to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to opt out of this provision and, as a result, we will comply with new or revised accounting standards
when they are required to be adopted by public companies that are not emerging growth companies.  Item 7A.
Quantitative and Qualitative Disclosures About Market Risk. Interest Rate Risk We are exposed to market risk related to changes in interest rates. As of December 31, 2017, our available-for-sale securities consisted
of corporate bond securities and U.S. government agency securities that have contractual maturities of one year or less. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S.
interest rates. However, because of the short-term nature of our portfolio, an immediate 10% change in market interest rates would not have a material impact on the fair market value of our investment portfolio or on our financial position or
results of operations. Inflation Risk We do
not believe that inflation had a material effect on our business, financial condition or results of operations in the last three years.  Item 8.
Financial Statements and Supplementary Data. The information required by this Item 8 is included
at the end of this Annual Report on Form 10-K beginning on page F-1.  Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. Change in our public accounting firm In September 2016, we dismissed Katz, Nannis + Solomon, P.C., or KN+S, as our independent accountants. The decision to dismiss KN+S as our
independent registered public accounting firm was approved by the board of managers of Solid Biosciences, LLC. KN+S had reported on our consolidated financial statements as of and for the year ended December 31, 2015. The report of KN+S on our
2015 consolidated financial statements did not contain any adverse opinion or disclaimer of opinion, nor was such report qualified or modified as to uncertainty, audit scope or accounting principles. During the year ended December 31, 2015 and through the date of dismissal, there were no disagreements between us and KN+S on any matter
of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of KN+S, would have caused it to make reference to the subject matter of the disagreement
in connection with its reports. None of the reportable events described under Item 304(a)(1)(v) of Regulation S-K occurred during
the years ended December 31, 2015 and through the date of dismissal of KN+S. We engaged PricewaterhouseCoopers LLP, or PwC, as our
independent registered public accounting firm on March 6, 2017 to audit our consolidated financial statements as of and for the years ended December 31, 2016 and 2015. During the year ended December 31, 2016 and in the subsequent interim period through March 31, 2017, other than in the normal course
of the audit, neither we nor anyone on our behalf consulted with PwC regarding  102




---

##### Table of Contents

either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial
statements, and neither a written report was provided to us or oral advice was provided to us that PwC concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issue; or
(ii) any matter that was either the subject of a disagreement or reportable event as defined in Regulation S-K, Item 304(a)(1)(iv) and Item 304(a)(1)(v), respectively. We delivered a copy of this disclosure to KN+S and requested that they furnish us a letter addressed to the SEC stating whether they agree
with the above statements. In their letter to the SEC dated July 24, 2017, attached as Exhibit 16.1 to the registration statement filed with the SEC on December 29, 2017, KN+S stated that they agreed with the statements above concerning their
firm. Disagreements with accountants on accounting and financial disclosure None  Item 9A.
Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our
disclosure controls and procedures as of December 31, 2017. The term disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means
controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the SECs rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files
or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding
required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating
the cost-benefit relationship of possible controls and procedures. Management identified material weaknesses in our internal control over
financial reporting, which is an integral component of our disclosure controls and procedures. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in
the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a
result, our stock price. In connection with the preparation of our consolidated financial statements as of and for the years ended
December 31, 2016 and 2015, we identified material weaknesses in our internal control over financial reporting. The material weaknesses we identified were as follows:  

We did not design or maintain an effective control environment commensurate with our financial reporting
requirements. We lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, the limited
personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other things, our insufficient segregation of duties in our  103




---

##### Table of Contents

finance and accounting functions. This material weakness contributed to the additional material weaknesses detailed below.  

We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and
review of account reconciliations and journal entries. Additionally, we did not design and maintain controls over the appropriate cut-off, classification and presentation of accounts and disclosures in the financial statements.  

We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. Specifically, we did not design and maintain controls to analyze, account for
and disclose complex transactions, including variable interest entities, preferred units, the preferred unit tranche right and equity-based compensation. These material weaknesses also resulted in a restatement of our previously issued 2015 annual consolidated financial statements and
adjustments to our 2016 annual consolidated financial statements, which were recorded prior to their issuance. We are in the process of
implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses, including hiring additional finance and accounting personnel and initiating design
and implementation of our financial control environment, including the establishment of formal accounting policies and procedures, financial reporting controls and controls to account for and disclose complex transactions. Based on the evaluation of our disclosure controls and procedures as of December 31, 2017, due to the material weaknesses described
above, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting Other than in connection with commencing the implementation of the remediation plan outlined above, there were no changes in our internal control over
financial reporting identified in connection with the evaluation of such internal control required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended December 31, 2017 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting. Managements Annual Report on Internal
Control over Financial Reporting This Annual Report on Form 10-K does not include a report of managements assessment regarding internal control
over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.  Item 9B.
Other Information. Not applicable.  104




---

##### Table of Contents

PART III  Item 10.
Directors, Executive Officers and Corporate Governance. Set forth below are the names,
ages and positions of our current executive officers and directors as of March 19, 2018.  Name

Age


Position(s) heldExecutive OfficersIlan Ganot


44


Co-founder, Chief Executive Officer and DirectorGilad Hayeem


50


Co-founder, President and DirectorAlvaro Amorrortu


46


Chief Operating OfficerCarl Morris, Ph.D.


48


Chief Scientific OfficerJoel Schneider, Ph.D.


33


Chief Technology Officer and Head of Exploratory Research and DevelopmentJorge A. Quiroz, M.D.


48


Chief Medical OfficerJennifer Ziolkowski


44


Chief Financial Officer, Treasurer and Assistant SecretaryNon-Employee DirectorsAndrey Zarur, Ph.D.


47


Co-founder and Chairman of the Board of DirectorsMatthew Arnold


48


DirectorRobert Huffines


52


DirectorAdam Koppel, M.D., Ph.D.


48


DirectorRajeev Shah


40


DirectorAdam Stone


38


DirectorLynne Sullivan


52


Director Executive officers Ilan Ganot is one of our co-founders and has served as our Chief Executive Officer and as a member of our board of directors since
our inception in 2013. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase & Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011,
Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008, at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A.
from London Business School and holds law and business degrees from the Interdisciplinary Center Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces. He is qualified to serve on our
board of directors because of his personal dedication to improving treatments available for DMD patients and his extensive leadership experience in the financial sector. Gilad Hayeemis one of our co-founders and has served as our President and as a member of our board of directors since our inception in
2013. Mr. Hayeem also has served as Chief Executive Officer of Waverly Capital, an equity and venture capital firm, since January 2012. Mr. Hayeem received his M.B.A. from City University of London and his undergraduate degree from
the University of Leeds. Mr. Hayeem is qualified to serve on our board of directors because of his extensive knowledge of our company based on his role as co-founder and President and his extensive leadership experience. Alvaro Amorrortu has served as our Chief Operating Officer since January 2017. Mr. Amorrortu served as our Senior Vice
President of Operations from November 2015 to December 2016. Prior to joining us, he served as Vice President of Consulting for IMS Health (now IQVIA), a healthcare oriented services and technology company, from July 2015 to November 2015
and Vice President of Campbell Alliance (now InVentiv Health Consulting), a management consulting firm serving the pharmaceutical and biotech industry, from July 2012 to June 2015. He was at the Monitor Group (now Monitor Deloitte), a
management consulting firm, from April 2003 to May 2012 where he held various positions, including Associate Partner. From 1995 to 2000,  105




---

##### Table of Contents

Mr. Amorrortu gained significant experience in project engineering and managing food-processing manufacturing facilities through various positions at Molinos Rio de la Plata and Trigalia
(subsidiaries of Bunge Group and Cargill, respectively). Mr. Amorrortu received his M.B.A. from The Wharton School of the University of Pennsylvania and received an M.S. from the Instituto Tecnologico de Buenos Aires, Argentina. Carl Morris, Ph.D. has served as our Chief Scientific Officer since June 2017, and previously served as our Senior Vice President
of Research and Development from September 2015 to June 2017. Prior to joining us, Dr. Morris held various leadership positions within Pfizer Inc.s Rare Disease Research Unit from January 2010 to August 2015, including serving as a
Senior Director, Director and Senior Principal Scientist. Prior to Pfizer, Dr. Morris held various positions within the Tissue Repair unit at Wyeth Pharmaceuticals, Inc., a pharmaceutical company acquired by Pfizer. Dr. Morris
was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit. He is also co-founder and a member of the board of directors of Breed Nutrition Inc. Dr. Morris holds a B.A.
in Biology from Franklin Pierce College and a Ph.D. in Physiology from UCLA. Joel Schneider, Ph.D.has served as our Chief
Technology Officer and Head of Exploratory Research and Development since June 2017. Dr. Schneider also served as an Analyst from March 2014 to March 2015, a Director from March 2015 to January 2017 and our Vice President of Research and
Development from January 2017 to June 2017. Prior to joining Solid, Dr. Schneider completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology from January 2013 to 2014. He holds a Ph.D. in
Cell Biology and Molecular Medicine from Rutgers University and a B.A. in Biology from Brandeis University. Jorge A. Quiroz, M.D.
has served as our Chief Medical Officer since January 2016. Prior to joining us, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at F. Hoffmann-La Roche AG, a multinational
healthcare company, from 2014 to 2015 and, prior to that, as Head of Psychiatry from 2012 to 2014 and Translational Medicine Leader from 2009 to 2011 at Hoffmann-La Roche. From 2007 to 2009, he served as the Director of Johnson &
Johnsons Pharmaceutical Research & Development LLC and from 2005 to 2007 he served as its Associate Director. Dr. Quiroz holds a medical degree from the Pontifical Catholic University of Chile and he completed his medical
training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the NIH in Bethesda, Maryland from February 2001 to May 2005. He is board certified in Psychiatry by the National Commission for
Certification of Medical Specialties. He also holds an M.B.A. dual degree from Columbia University and the London Business School. Jennifer Ziolkowskihas served as our Chief Financial Officer, Treasurer and Assistant Secretary since May 2017. Prior to joining us,
she served as the Head of Sales Operations, North America for Philips Healthcare, a healthcare company, from 2014 to 2017 and as its Senior Director of Finance, North America from 2012 to 2014. Ms. Ziolkowski served as Controller of Medical
Consumables and Sensors from 2010 to 2012, Director of Finance of Imaging Systems from 2008 to 2010, Senior Director of Finance and Corporate Controller from 2007 to 2008 at TransMedics, Inc., a medical device company, and held various finance and
corporate development leadership positions at Cytyc Corporation, a medical technology company, from 2001 to 2007. From 1996 to 2001, Ms. Ziolkowski gained significant experience at PricewaterhouseCoopers LLP where she served as a Senior
Transaction Services Consultant and as Audit Senior and Staff in the Boston Technology Group. Ms. Ziolkowski holds a B.S. in Accounting from Boston College and is a Certified Public Accountant. Non-employee directors Andrey
Zarur, Ph.D. is one of our co-founders and has served as the Chairman of our board of directors since our inception in 2013. Dr. Zarur co-founded GreenLight Biosciences Inc., a biotechnology company, in August 2008, and currently
serves as its Chairman and Chief Executive Officer. From January 2006 to August 2014, he served as Managing General Partner of Kodiak Venture Partners, a venture capital firm. Dr. Zarur is  106




---

##### Table of Contents

also Chairman of the Board for Lumicell Inc. Dr. Zarur holds an M.S. and a Ph.D. from Massachusetts Institute of Technology and an undergraduate degree from Universidad Nacional
Autónoma de México. Mr. Zarur is qualified to serve on our board of directors based on his over 20 years of experience in leading companies from clinical-stage drug development to global commercialization. Matthew Arnold is a founding member of Solid and has served as a member of our board of directors since our inception in
2013. A former energy executive, since 2009, Mr. Arnold has been actively working with startup businesses in the United Kingdom and Europe, primarily in the technology and clean tech sectors. He holds an M.S. from the University of
Virginia and a B.A. from Duke University. Mr. Arnold is qualified to serve on our board of directors because of his extensive management and board experience with startup companies and his background in finance. Robert Huffineshas served as a member of our board of directors since December 2013. Mr. Huffines joined J.P. Morgan, a leading
global financial services firm, in 1992 and currently serves as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions,
including serving as Co-Head of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines received an M.B.A. from the University of Virginia and a B.A. from the University of
North Carolina. Mr. Huffines is qualified to serve on our board of directors based on his over 25 years of experience advising healthcare companies and his leadership experience. Adam Koppel, M.D., Ph.D.has served as a member of our board of directors since October 2017. Dr. Koppel rejoined Bain Capital, a
global investment firm, in 2016 as a Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. During the period from mid-2014 to
mid-2016, Dr. Koppel worked at Biogen Inc., or Biogen, a biotechnology company, where he served as EVP of Corporate Development and Chief Strategy Officer. Prior to joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at
McKinsey & Co., a management consulting firm, where he served a variety of healthcare companies. Dr. Koppel currently serves on the board of directors of Trevena, Inc. and Dicerna Pharmaceuticals, Inc., both public companies.
Dr. Koppel received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. He also received an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated
magna cum laude from Harvard University with an A.B. and A.M. in History and Science. Dr. Koppel is qualified to serve on our board of directors because of his extensive leadership experience, his public company board experience and his
experience working in the healthcare sector. Rajeev Shah has served as a member of our board of directors since March 2017.
Mr. Shah has been Managing Director and Portfolio Manager at RA Capital Management, LLC, or RA Capital, an investment management company. Prior to joining RA Capital in 2004, Mr. Shah was a Senior Project Leader at Altus Pharmaceuticals
Inc., a spin-off of Vertex Pharmaceuticals Inc., from 2001 to 2004. Mr. Shah is currently a member of the board of directors of Ra Pharmaceuticals, Inc. and Kalvista Pharmaceuticals, Inc., both public companies. Mr. Shah holds a B.A. in
Chemistry from Cornell University. Mr. Shah is qualified to serve on our board of directors because of his extensive leadership experience, his public company board experience and his experience investing in life science companies. Adam Stonehas served as a member of our board of directors since November 2015. Mr. Stone is currently the Chief Investment
Officer of Perceptive Advisors, a life science focused hedge fund, where he has worked since May 2006. Mr. Stone received a B.A. from Princeton University. Mr. Stone is qualified to serve on our board of directors because of his extensive
experience developing early-stage biotech and health care companies. Lynne Sullivanhas served as a member of our board of
directors since November 2015. Since September 2016, Ms. Sullivan has served as Biogens Senior Vice President of Finance, where she also served as Vice President of Tax and Corporate Finance from February 2015 to March 2016 and Vice
President of Tax from  107




---

##### Table of Contents

April 2008 to February 2015. Ms. Sullivan is currently a member of the board of directors of resTORbio, Inc., a public company. She received an M.S. in Taxation from Bentley University and a
B.S.B.A. from Suffolk University. Ms. Sullivan is a Certified Public Account for over 20 years. Ms. Sullivan is qualified to serve on our board of directors because of her extensive experience in public accounting and financial expertise. There are no family relationships among any of our directors or executive officers. Scientific Advisory Board We have
established a scientific advisory board comprised of a world-class team of experts, which includes leading immunologists, molecular biologists, clinicians and gene therapy researchers. We regularly seek advice and input from these experienced
leaders on matters related to our research and development programs. Our Scientific Advisory Board currently consists of Jeffrey Chamberlain, Ph.D. (University of Washington), Chairman of our Scientific Advisory Board, Jeff Bluestone, Ph.D.
(University of California, San Francisco), Ronald D. Cohn, M.D. (Hospital for Sick Children), Dongsheng Duan, Ph.D. (University of Missouri), Michael Lawlor, M.D., Ph.D. (Medical College of Wisconsin), Carrie Miceli, Ph.D. (University of California,
Los Angeles), Geoffrey Slaff, Ph.D. and Lawrence A. Turka, M.D. (Massachusetts General Hospital). James M. Wilson, M.D., Ph.D., the former head of our Scientific Advisory Board, resigned on January 11, 2018 citing his emerging safety concerns
about the possible risks of high systemic dosing of AAV. Section 16(a) beneficial ownership reporting compliance Section 16(a) of the Exchange Act requires our directors and executive officers and holders of more than 10% of our common stock to file
with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. These Section 16 reporting persons are required by SEC regulation to furnish us with copies of all Section 16(a)
forms they file. However, during the fiscal year ended December 31, 2017, we did not have any class of equity security registered under Section 12 of the Exchange Act; accordingly, no reports were required to be filed pursuant to
Section 16(a) by these Section 16 reporting persons with respect to our common stock during that fiscal year. Audit Committee Our board of directors has established an audit committee, which operates under a charter that has been approved by our board of directors. Our
audit committee consists of Ms. Sullivan, Dr. Koppel and Mr. Shah, with Ms. Sullivan serving as chair of the audit committee. Our board of directors has determined that each of these individuals meets the independence
requirements of the Sarbanes-Oxley Act, Rule 10A-3 under the Exchange Act, and the applicable listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial statements in accordance with Nasdaq audit
committee requirements. In arriving at this determination, the board has examined each audit committee members employment and other experience. Our board of directors has determined that Ms. Sullivan qualifies as an audit committee
financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq listing rules. In making this determination, our board has considered Ms. Sullivans formal education and previous and
current experience in financial roles. Both our independent registered public accounting firm and management periodically meet privately with our audit committee. The functions of our audit committee include, among other things:  

evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;  

reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;  108




---

##### Table of Contents



monitoring the rotation of partners of our independent auditors on our engagement team as required by law;  

prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate
action to oversee the independence of our independent auditor;  

reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption Managements Discussion and Analysis of Financial Condition and Results of
Operations, and discussing the statements and reports with our independent auditors and management;  

reviewing with our independent auditors and management any significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness
of our financial controls;  

reviewing with management and our auditors any earnings announcements and other public announcements regarding material financial developments;  

establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters;  

preparing the audit committee report that the SEC requires in our annual proxy statement;  

reviewing and providing oversight of any related-person transactions in accordance with our related-person transaction policy and reviewing and monitoring compliance with legal and regulatory requirements, including our
code of business conduct and ethics;  

reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented;  

reviewing on a periodic basis our investment policy; and  

reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter. Our board of directors has determined that the composition and functioning of our audit committee complies with all applicable requirements of
the Sarbanes-Oxley Act, and all applicable SEC and Nasdaq rules and regulations. Code of business conduct and ethics We have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, that applies to our directors, executive officers and employees,
including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Conduct is available on the Investor Relations portion of our
website, www.solidbio.com. The nominating and corporate governance committee of our board of directors is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive
officers and directors. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers of, any provision of the Code of Conduct.  Item 11.
Executive Compensation. Compensation of our Named Executive Officers The following information describes the material elements of compensation awarded to, earned by or paid to each of our named executive
officers, or the Named Executive Officers. The Named Executive Officers for the year ended December 31, 2017 are:  

Ilan Ganot, our Chief Executive Officer;  109




---

##### Table of Contents



Dr. Jorge A. Quiroz, our Chief Medical Officer; and  

Jennifer Ziolkowski, our Chief Financial Officer. Summary Compensation Table for Fiscal Year 2017 The following table contains information about the compensation paid to or earned by each of our Named Executive Officers during
the most recently completed fiscal year.  Name and Principal Position

Year


Salary($) (1)


Bonus($) (2)


StockAwards ($)(3)


All OtherCompensation($)


Total ($)Ilan Ganot,


2017



400,000



200,000











600,000Chief Executive OfficerJorge A. Quiroz, M.D.,


2017



360,500



144,200



786,202



4,420
(4)


1,295,322Chief Medical OfficerJennifer Ziolkowski,


2017



176,060
(5)


124,700
(6)


1,119,000



420
(7)


1,420,180Chief Financial Officer  (1)
For 2018, base salary amounts for our Named Executive Officers were increased as follows: Mr. Ganot: $450,000; Dr. Quiroz: $375,000; and Ms. Ziolkowski: $300,000. (2)
Represents annual discretionary bonuses paid to the Named Executive Officers in respect of performance during the fiscal year ended December 31, 2017. (3)
The amount in this column represents the aggregate grant date fair value of the award as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718. The assumptions used
in calculating the grant date fair value of the award reported in this column are set forth in Note 12 to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. (4)
Represents compensation for mobile phone subsidies, gym subsidies and a taxable gift provided by the Company, including an additional payment in respect of income taxes imposed upon Dr. Quiroz in connection with
the taxable gift. (5)
Ms. Ziolkowski commenced employment with us in May 2017. This amount represents the portion of the year during which she was employed with us. (6)
Includes a $50,000 signing bonus paid to Ms. Ziolkowski in connection with the commencement of her employment with us. (7)
Represents compensation for mobile phone subsidies provided by the Company. Employment Agreement with
Mr. Ganot On December 27, 2013, we entered into an employment agreement with Mr. Ganot. Mr. Ganots
employment agreement provided for an initial annual base salary of $300,000 as well as an entitlement to an annual incentive bonus in an amount determined by our board of managers. Mr. Ganots employment with us is at will, although the
agreement requires that either we or Mr. Ganot provide the other party at least six months prior notice of intention to terminate Mr. Ganots employment. However, we may terminate Mr. Ganots employment immediately for
cause as defined in the employment agreement. Other than the foregoing notice period, Mr. Ganots employment agreement does not provide for any severance payments or benefits upon a termination of his employment with us.
Mr. Ganot is subject to certain restrictive covenants during the term of his employment and for the one-year period following termination, including employee and consultant non-solicitation and non-hire restrictions and non-competition
provisions. Offer Letter with Dr. Quiroz On November 17, 2015, we entered into an offer letter with Dr. Quiroz. Dr. Quirozs offer letter provided for an initial
annual base salary of $350,000 as well as an entitlement to an annual incentive bonus of up to 40%  110




---

##### Table of Contents

of his base salary based upon achievement of individual and company-wide goals established by our board of managers in its sole discretion. Under the offer letter, Dr. Quiroz received a signing bonus of $100,000, 50% of which he was required to repay if he resigned his
employment other than for good reason (as defined in his offer letter) prior to the second anniversary of his employment commencement date. In addition, we agreed to assume certain obligations of Dr. Quirozs prior employer
with respect to Dr. Quirozs graduate business school education, a leased apartment and a leased vehicle, up to a maximum of $250,000 in the aggregate. If Dr. Quiroz resigned his employment other than for good reason prior to the
second anniversary of his employment commencement date, he would have been required to repay 50% of the assumed obligations. We also agreed to reimburse Dr. Quiroz up to $120,000 in relocation expenses, plus an additional amount equal to the
income taxes imposed on Dr. Quiroz in connection with such reimbursement. In the event Dr. Quirozs employment is
terminated without cause (as defined in his offer letter) or Dr. Quiroz resigns for good reason (as defined in his offer letter), then, subject to his execution and non-revocation of a release of claims, he will receive
continued payment of his base salary until the earlier of (i) six months following termination, and (ii) the date he obtains full-time employment. If his employment is terminated (by us for cause or by Dr. Quiroz for
good reason) within 12 months following a change of control, Dr. Quiroz will receive an additional payment equal to 20% of his then current base salary. Dr. Quiroz is subject to certain restrictive covenants during the term of
his employment and for the one-year period following termination, including employee and consultant non-solicitation and non-hire restrictions, customer non-solicitation and non-competition provisions. Offer Letter with Ms. Ziolkowski On April 17, 2017, we entered into an offer letter with Jennifer Ziolkowski, our Chief Financial Officer. Ms. Ziolkowskis
agreement provided for an initial annual base salary of $280,000 and an annual incentive bonus of up to 40% of her base salary based upon achievement of individual and company-wide goals established by our board. Ms. Ziolkowskis agreement
also provided for a one-time signing bonus of $50,000. Ms. Ziolkowskis agreement provided for a grant of 150,000 Series D
common units of Solid Biosciences, LLC. The units subject to these awards vest 25% on the first anniversary of Ms. Ziolkowskis start date and then in semi-annual installments over the 36-month period thereafter. In the event that we are
acquired by a third party and Ms. Ziolkowskis employment is terminated by us without Cause (as defined in her employment agreement) within 12 months of the event, (A) Ms. Ziolkowski is entitled to receive continued
payment of her base salary until the earlier of (i) three months following termination and (ii) the date she obtains full-time employment, and (B) all of Ms. Ziolkowskis outstanding unvested equity awards will become fully
vested. Ms. Ziolkowski is subject to certain restrictive covenants during the term of her employment and for the one-year period
following termination, including employee and consultant non-solicitation and non-hire restrictions, customer non-solicitation and non-competition provisions.  111




---

##### Table of Contents

Stock Awards 2017 Outstanding Equity Awards at Fiscal Year-End The following table sets forth information regarding equity awards held by our Named Executive Officers as of December 31, 2017.  Stock AwardsName

Number of sharesor units that havenot vested (#)


Market value ofshares or units thathave not vested ($)(1)Ilan Ganot






Jorge A. Quiroz, M.D.


225,887
(2)


789,68045,184
(3)


212,81745,184
(4)


573,385Jennifer Ziolkowski


150,000
(5)


484,50050,000
(6)


634,500  (1)
Calculated based on an independent third-party valuation. (2)
Represents Series D common units of Solid Biosciences, LLC granted on January 4, 2016. 25% of award vests on each of the first four anniversaries of grant date subject to continued employment through each vesting
date. Pursuant to his award agreement, 100% of the units vest if Dr. Quirozs employment is terminated without cause during the 12-month period after a change in control (as such terms are defined in his offer letter). (3)
Represents Series D common units of Solid Biosciences, LLC, with 11,296 vesting on September 12, 2018, and an additional 11,296 units vesting on each anniversary thereafter, subject to continued service through the
vesting date and in no event will more than 45,184 units become vested units. Pursuant to his award agreement, 100% of the units vest if Dr. Quirozs employment is terminated without cause during the
12-month period after a change in control (as such terms are defined in his offer letter). (4)
Represents Series D common units of Solid Biosciences, LLC, with 11,296 vesting on the one-year anniversary of the date upon which the first dosing of a patient occurs in a clinical trial conducted by us, and an
additional 5,648 units on each semi-annual anniversary thereafter, subject to continued employment through the vesting date and in no event will more than 45,184 units become vested units. Pursuant to his award agreement, 100% of the units vest if
Dr. Quirozs employment is terminated without cause during the 12-month period after a change in control (as such terms are defined in his offer letter), provided that the first dosing condition is satisfied. If the dosing date has not
occurred by December 7, 2027, all of the units become vested, subject to his continued employment through such date. (5)
Represents Series D common units of Solid Biosciences, LLC, with 37,500 units vesting on May 15, 2018, and an additional 18,250 units vesting on each semi-annual anniversary thereafter. Pursuant to her offer
letter, 100% of the units vest if Ms. Ziolkowskis employment is terminated without cause during the 12-month period after a change in control (as such terms are defined in her offer letter). (6)
Represents Series D common units of Solid Biosciences, LLC, with 12,500 units vesting on the one-year anniversary of the date upon which we successfully complete an equity financing of $50 million or more at a price per
unit not less than the price at which units were sold in the prior equity financing, and an additional 6,250 units on each semi-annual anniversary thereafter, subject to continued employment through the vesting date and in no event will more than
50,000 units become vested units. Pursuant to her offer letter, 100% of the units vest if Ms. Ziolkowski employment is terminated without cause during the 12-month period after a change in control (as
such terms are defined in her offer letter), provided that the equity financing condition is satisfied (as such term is defined in her award agreement). If the equity financing condition has not occurred by December 7, 2027, all of the units
become vested, subject to her continued employment through such date. On February 14, 2018, we granted a stock option
to Dr. Quiroz for the right to buy 47,061 shares of our common stock and a stock option to Ms. Ziolkowski for the right to buy 66,852 shares of our common  112




---

##### Table of Contents

stock. The options have an exercise price of $26.23 per share, vest in four equal installments beginning on February 14, 2019 and expire on February 14, 2028. Equity Incentive Plans Solid Biosciences, LLC
Amended and Restated Equity Incentive Plan Prior to the closing of our initial public offering, Solid Biosciences, LLC maintained
its Amended and Restated Equity Incentive Plan, or the Existing Plan, under which Solid Biosciences, LLC granted Series D Common Units to its employees, consultants and other service providers. The Existing Plan was frozen in connection with our
initial public offering. No further awards will be granted under the Existing Plan, but awards granted prior to the freeze date will continue in accordance with their terms and the terms of the Existing Plan. 2018 Omnibus Incentive Plan Prior
to our initial public offering, the board of managers of Solid Biosciences, LLC adopted the Solid Biosciences Inc. 2018 Omnibus Incentive Plan, or 2018 Plan, contingent upon the consummation of our initial public offering. The unitholders of Solid
Biosciences, LLC approved the 2018 Plan contingent upon the consummation of our initial public offering. The material terms of the 2018
Plan are summarized below. The following summary is qualified in its entirety by reference to the complete text of the 2018 Plan, a copy of which was filed as Exhibit 99.1 to our registration statement on Form S-8 filed with the SEC on
January 29, 2018, and is incorporated herein by reference. Administration of the plan The board of managers of Solid Biosciences, LLC appointed the compensation committee of our board of directors as the committee under the 2018
Plan with the authority to administer the 2018 Plan. We refer to our board of directors or compensation committee, as applicable, as the Administrator. The Administrator is authorized to grant awards to eligible employees, consultants and
non-employee directors. Number of authorized shares and award limits The aggregate number of our shares of common stock that may be issued or used for reference purposes under the 2018 Plan may not exceed
5,001,000 shares (subject to adjustment as described below). Our shares of common stock that are subject to awards will be counted against the overall limit as one share for every share granted or covered by an award. If any award is cancelled,
expires or terminates unexercised for any reason, the shares covered by such award will again be available for the grant of awards under the 2018 Plan, except that any shares that are not issued as the result of a net exercise or settlement or that
are used to pay any exercise price or tax withholding obligation will not be available for the grant of awards. Shares of common stock that we repurchase on the open market with the proceeds of an option exercise price also will not be available for
the grant of awards. Awards that may be settled solely in cash will not be deemed to use any shares. The maximum number of our shares of
common stock that may be granted pursuant to awards under the 2018 Plan during any fiscal year to any non-employee director is 1,000,200 shares. The foregoing individual participant limit is cumulative; that is, to the extent that shares of common
stock that may be granted to an individual in a fiscal year are not granted, the number of shares of common stock that may be granted to such individual is increased in the subsequent fiscal years during the term of the 2018 Plan until used. The Administrator will, in accordance with the terms of the 2018 Plan, make appropriate adjustments to the above aggregate and individual
limits (other than cash limitations), to the number and/or kind of shares or other  113




---

##### Table of Contents

property (including cash) underlying awards and to the purchase price of shares underlying awards, in each case, to reflect any change in our capital structure or business by reason of any stock
split, reverse stock split, stock dividend, combination or reclassification of shares, any recapitalization, merger, consolidation, spin off, split off, reorganization or any partial or complete liquidation, any sale or transfer of all or part of
our assets or business, or any other corporate transaction or event that would be considered an equity restructuring within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718. In addition, the
Administrator may take similar action with respect to other extraordinary events. Eligibility and participation All of our current and prospective employees and consultants, as well as our non-employee directors, are eligible to be granted non-qualified
stock options, restricted stock, performance-based cash awards and other stock-based awards under the 2018 Plan. Only our and our subsidiaries employees are eligible to be granted incentive stock options, or ISOs, under the 2018 Plan.
Eligibility for awards under the 2018 Plan is determined by the Administrator in its discretion. In addition, each member of our board of directors who is not an employee of the company or any of our affiliates is expected to be eligible to receive
awards under the 2018 Plan. Types of awards Stock options. The 2018 Plan authorizes the Administrator to grant ISOs to eligible employees and non-qualified stock options to
purchase shares to employees, consultants, prospective employees, prospective consultants and non-employee directors. The Administrator will determine the number of shares of common stock subject to each option, the term of each option, the exercise
price (which may not be less than the fair market value of the shares of common stock at the time of grant, or 110% of fair market value in the case of ISOs granted to 10% stockholders), the vesting schedule and the other terms and conditions of
each option. Options will be exercisable at such times and subject to such terms as are determined by the Administrator at the time of grant. The maximum term of options under the 2018 Plan is ten years (or five years in the case of ISOs granted to
10% stockholders). Upon the exercise of an option, the participant must make payment of the full exercise price (a) in cash or by check, bank draft or money order; (b) solely to the extent permitted by law and authorized by the
Administrator, through the delivery of irrevocable instructions to a broker, reasonably acceptable to us, to promptly deliver to us an amount equal to the aggregate exercise price; or (c) on such other terms and conditions as may be acceptable
to the Administrator (including, without limitation, the relinquishment of options or by payment in full or in part in the form of shares of common stock). Restricted stock. The 2018 Plan authorizes the Administrator to grant restricted stock. Recipients of restricted stock will be required
to enter into an agreement with us subjecting the restricted stock to transfer and other restrictions and providing the criteria or dates on which such awards vest and such restrictions lapse. The restrictions on restricted stock may lapse and the
awards may vest over time, based on performance criteria or other factors, as determined by the Administrator at the time of grant. Except as otherwise determined by the Administrator, a holder of restricted stock has all of the attendant rights of
a stockholder including the right to receive dividends, if any, subject to and conditioned upon vesting and restrictions lapsing on the underlying restricted stock, the right to vote shares and, subject to and conditioned upon the vesting and
restrictions lapsing for the underlying shares, the right to tender such shares. However, the Administrator may in its discretion provide at the time of grant that the right to receive dividends on restricted stock will not be subject to the vesting
or lapsing of the restrictions on the restricted stock. Other stock-based awards. The 2018 Plan authorizes the Administrator to
grant awards of shares of common stock and other awards that are valued in whole or in part by reference to, or are payable in or otherwise based on, shares of common stock, including, but not limited to, shares of common stock awarded purely as a
bonus and not subject to any restrictions or conditions; shares of common stock in payment of the amounts due under an incentive or performance plan sponsored or maintained by us or an affiliate; stock appreciation rights; stock equivalent units;
restricted stock units; performance awards entitling participants to receive a number of  114




---

##### Table of Contents

shares of common stock (or cash in an equivalent value) or a fixed dollar amount, payable in cash, stock or a combination of both, with respect to a designated performance period; or awards
valued by reference to book value of our shares of common stock. In general, other stock-based awards that are denominated in shares of common stock will include the right to receive dividends, if any, subject to and conditioned upon vesting and
restrictions lapsing on the underlying award, but the Administrator may in its discretion provide at the time of grant that the right to receive dividends on a stock-denominated award will not be subject to the vesting or lapsing of the restrictions
on the performance award. Performance-based cash awards. The 2018 Plan authorizes the Administrator to grant cash awards that are payable or
otherwise based on the attainment of pre-established performance goals during a performance period. These performance goals will be based on the attainment of a certain target level of, or a specified increase in (or decrease where noted), criteria
selected by the Administrator. Such performance goals may be based upon the attainment of specified levels of company, affiliate,
subsidiary, division, other operational unit, business segment or administrative department performance relative to the performance of other companies. The Administrator may designate additional business criteria on which the performance goals may
be based or adjust, modify or amend those criteria. Unless the Administrator determines otherwise, the Administrator will disregard and exclude the impact of special, unusual or non-recurring items, events, occurrences or circumstances; discontinued
operations or the disposal of a business; the operations of any business that we acquire during the fiscal year or other applicable performance period; or a change in accounting standards required by generally accepted accounting principles or
changes in applicable law or regulations. Effect of certain transactions; Change in control In the event of a change in control, as defined in the 2018 Plan, except as otherwise provided by the Administrator, unvested awards will not
vest. Instead, the Administrator may, in its sole discretion, provide that outstanding awards will be: assumed and continued; purchased based on the price per share paid in the change in control transaction (less, in the case of options and stock
appreciation rights, or SARs, the exercise price), as adjusted by the Administrator for any contingent purchase price, escrow obligations, indemnification obligations or other adjustments to the purchase price; and/or in the case of stock options or
other stock-based appreciation awards where the change in control price is less than the applicable exercise price, cancelled. However, the Administrator may in its sole discretion provide for the acceleration of vesting and lapse of restrictions of
an award at any time including in connection with a change in control. Non-transferability of awards Except as the Administrator may permit, at the time of grant or thereafter, awards granted under the 2018 Plan are generally not transferable
by a participant other than by will or the laws of descent and distribution. Shares of common stock acquired by a permissible transferee will continue to be subject to the terms of the 2018 Plan and the applicable award agreement. Term Awards under the 2018 Plan may not
be made after December 18, 2027, but awards granted prior to such date may extend beyond that date. Amendment and termination Subject to the rules referred to in the balance of this paragraph, our board of directors or the Administrator (to the extent permitted by law)
may at any time amend, in whole or in part, any or all of the provisions of the 2018 Plan, or suspend or terminate it entirely, retroactively or otherwise. Except as required to comply with  115




---

##### Table of Contents

applicable law, no such amendment, suspension or termination may reduce the rights of a participant with respect to awards previously granted without the consent of such participant. In addition,
without the approval of stockholders, no amendment may be made that would: increase the aggregate number of shares of common stock that may be issued under the 2018 Plan; increase the maximum individual participant share limitations for a fiscal
year or year of a performance period; change the classification of individuals eligible to receive awards under the 2018 Plan; extend the maximum term of any option; reduce the exercise price of any option or SAR or cancel any outstanding
in-the-money option or SAR in exchange for cash; substitute any option or SAR in exchange for an option or SAR (or similar other award) with a lower exercise price; alter the performance goals; or require stockholder approval in order
for the 2018 Plan to continue to comply with Section 162(m) or Section 422 of the Internal Revenue Code of 1986, as amended, or the Code. Registration of shares On
January 29, 2018, we filed a registration statement on Form S-8 under the Securities Act of 1933, as amended, or the Securities Act, to register the full number of shares of common stock that will be available for issuance under the 2018 Plan,
as described in the section titled Number of authorized shares and award limits above. Non-employee director compensation Prior to our initial public offering, we did not have a formal policy with respect to compensation payable to our non-employee managers for
service as managers. During 2017, except for the Chairman of our Board, our non-employee managers did not receive any cash compensation for their services as managers or as board committee members. In 2017, Dr. Zarur received aggregate cash
compensation of $352,333 for his services as Chairman. None of our non-employee managers received any equity award grants in 2017. The
table below shows the compensation paid to our non-employee managers during 2017.  Name

FeesEarned orPaid inCash ($)


StockAwards($) (1)


All OtherCompensation($)


Total ($)Andrey Zarur, Ph.D.


200,000
(2)






152,333
(2)


352,333
(2)Robert Huffines














Lynne Sullivan














Matthew Arnold














Adam Stone














Rajeev Shah














Adam Koppel, M.D., Ph.D.














  (1)
As of December 31, 2017, none of our non-employee managers held any equity awards or unvested units. (2)
Represents advisory fees paid to Dr. Zarur in exchange for services as Chairman of our board of managers, including an approximately $150,000 discretionary bonus paid to Dr. Zarur in respect of performance
during the fiscal year ended December 31, 2017 and an additional $2,333 representing a taxable gift provided by the Company. Following the closing of our initial public offering in January 2018, we implemented a director compensation program pursuant to which our
non-employee directors receive the following compensation for their service on our board of directors:  

An annual retainer of $35,000;  

An additional annual retainer of $15,000 for serving as chair or $7,500 for serving as a member of the Audit Committee;  116




---

##### Table of Contents



An additional annual retainer of $10,000 for serving as chair or $5,000 for serving as a member of the Compensation Committee;  

An additional annual retainer of $8,000 for serving as chair or $4,000 for serving as a member of the Nominating and Corporate Governance Committee; and  

An annual grant of restricted stock made under the 2018 Plan having a fair market value of $50,000, all of which will vest on the earlier to occur of the one-year anniversary of the grant date and immediately prior to
the first annual meeting of our stockholders occurring after the grant date subject, in all cases, to each such directors continued service as a member of the Board from the grant date to the applicable vesting date. Compensation committee interlocks and insider participation None of the current members of our compensation committee has ever been an executive officer or employee of ours. None of our executive
officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our board of directors or
compensation committee.  Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. Security Ownership of Certain Beneficial Owners and Management The following table sets forth information regarding the beneficial ownership of our common stock as of March 15, 2018 by (i) each
person whom we know to beneficially own more than 5% of our outstanding common stock (a 5% stockholder), (ii) each director, (iii) each named executive officer and (iv) all current directors and executive officers as a
group. Unless otherwise indicated, the address of each executive officer and director is c/o Solid Biosciences, 141 Portland Street, Fifth Floor, Cambridge, MA 02139. The number of shares of common stock beneficially owned by each stockholder is determined under rules issued by the SEC regarding
the beneficial ownership of securities. This information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership of shares of our common stock includes (1) any shares as to which the
person or entity has sole or shared voting power or investment power and (2) any shares as to which the person or entity has the right to acquire beneficial ownership within 60 days after March 15, 2018. The percentage of beneficial
ownership in the table below is based on 35,476,892 shares of common stock deemed to be outstanding as of March 15, 2018.  117




---

##### Table of Contents

Unless otherwise indicated below, and subject to community property laws where applicable,
to our knowledge, all persons named in the table have sole voting and investment power with respect to their shares of common stock.  Name of Beneficial Owner

Number of SharesBeneficiallyOwned


Percentage ofShares BeneficiallyOwned5% Stockholders:JPMC Strategic Investments II
Corporation (1)


3,031,601



8.5
%Perceptive Life Sciences Master Fund
LTD (2)


3,927,222



11.1
%Biogen New Ventures Inc. (3)


1,772,486



5.0
%BCLS SB Investco, LP (4)


1,989,444



5.6
%Entities affiliated with RA Capital Management, LLC (5)


2,689,444



7.6
%Named Executive Officers and Directors:Ilan Ganot (6)


1,443,040



4.1
%Gilad Hayeem (7)


3,578,399



10.1
%Jorge A. Quiroz, M.D.


268,342



*Jennifer Ziolkowski


169,700



*Andrey Zarur, Ph.D.


691,205



1.9
%Matthew Arnold


3,396,293



9.6
%Robert Huffines






*Adam Koppel, M.D., Ph.D. (8)


1,989,444



5.6
%Rajeev Shah (5)


2,689,444



7.6
%Adam Stone (9)






*Lynne Sullivan






*All current directors and executive officers as a group (14 persons)


14,664,804



41.3
%  *
Less than one percent. (1)
Consists of shares held by JPMC Strategic Investments II Corporation, or JPMC Strategic Investments. The address of JPMC Strategic Investments is 270 Park Avenue, New York, NY 10017. (2)
Consists of shares held by Perceptive Life Sciences Master Fund LTD, or Perceptive, including 1,000,000 shares that Perceptive purchased in connection with the closing of our initial public offering. Perceptive Advisors
LLC is the advisor of Perceptive, and Joseph Edelman is the managing member of Perceptive Advisors LLC. Perceptive Advisors LLC and Mr. Edelman may be deemed to beneficially own the shares held by Perceptive. The address of Perceptive is 51
Astor Place, 10th Floor, New York, NY 10003. Perceptive reports that it holds shared voting power and shared dispositive power with respect to all shares held by it. (3)
Consists of shares held by Biogen New Ventures Inc., or Biogen New Ventures. Biogen New Ventures is a wholly owned subsidiary of Biogen MA Inc., which is a wholly owned subsidiary of Biogen Inc. The address of Biogen
New Ventures is 250 Binney Street, Cambridge, MA 02142. (4)
Consists of shares held by BCLS SB Investco, LP (BCLS), including 300,000 shares that BCLS purchased in connection with the closing of our initial public offering. The governance, investment strategy and
decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, a member of our board of directors. As a result, each of Bain Capital
Life Sciences Investors, LLC, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by BCLS. The address of BCLS is c/o Bain Capital Life Sciences, LP, 200 Clarendon Street, Boston,
Massachusetts 02116. (5)
Consists of (a) 1,368,981 shares held by RA Capital Healthcare Fund, L.P. (RA Capital Fund),
(b) 320,463 shares held by Blackwell Partners LLCSeries A (Blackwell) and (c) 1,000,000 shares that RA Capital Fund and Blackwell purchased in connection with the closing of our initial public offering. RA Capital
Management, LLC (RA Capital) is the general partner of RA Capital Fund and the investment  118




---

##### Table of Contents

manager to Blackwell. Investment decisions with respect to the shares held by RA Capital Fund and Blackwell are made by a portfolio management team at RA Capital of which Rajeev Shah, a member of
our board of directors, is a member. Mr. Shah disclaims beneficial ownership of all shares held by RA Capital Fund and Blackwell, except to the extent of his pecuniary interest therein. The address for each of RA Capital Fund, Blackwell, and RA
Capital is c/o 20 Park Plaza, Suite 1200, Boston, MA 02116. Entities affiliated with RA Capital report that they hold shared voting power and shared dispositive power with respect to all shares held by them. (6)
Consists of (a) 1,091,495 shares held by Mr. Ganot as an individual, (b) 60,631 shares held by Mr. Ganot and Ms. Ganot as joint tenants with right of survivorship and (c) 290,914 shares
held by Mr. Adam Ganot and Ms. Ganot, as trustees for the Ilan Ganot 2017 Irrevocable Trust. Excludes 1,593,755 shares held by The Popps Trust for which Mr. Ganot and Mr. Hayeem act as trustees, but as to which Mr. Ganot has
no pecuniary interest. (7)
Consists of (a) 1,984,644 shares held by Mr. Hayeem as an individual and (b) 1,593,755 shares held by The Popps Trust, a trust established for the benefit of Mr. Hayeems family for which
Mr. Hayeem is the Investment Advisor. In connection with estate planning activities, Mr. Hayeem sold units of the Company equivalent to approximately 353,050 shares to a sub-trust of an employee-benefit trust established by a former
employer of Mr. Hayeem. Such sub-trust has as its beneficiaries Mr. Hayeem and his family. Because Mr. Hayeem does not exercise investment or voting control of the shares held by such sub-trust, such shares do not appear in the table
above. (8)
Consists of shares held by BCLS. Dr. Koppel is a manager of Bain Capital Life Sciences Investors, LLC and as a result, by virtue of the relationships described in footnote (4) above, may be deemed to share
beneficial ownership of the shares held by BCLS. The address of Dr. Koppel is c/o Bain Capital Life Sciences, LP, 200 Clarendon Street, Boston, Massachusetts 02116. (9)
Mr. Stone is Chief Investment Officer of Perceptive Advisors LLC. Mr. Stone disclaims beneficial ownership of the shares held by Perceptive. The address of Mr. Stone is 51 Astor Place, 10th Floor,
New York, NY 10003. Securities Authorized for Issuance under Equity Compensation Plans The following table provides information about our equity compensation plans as of December 31, 2017. As of December 31, 2017, we had
only one equity compensation plan, the Existing Plan.  Plan Category

(a)Number ofsecuritiesto be issued uponthe exercise 
ofoutstandingoptions,warrants andrights


(b)Weighted-averageexercise priceof outstandingoptions,warrantsand 
rights


(c)Number of securitiesremaining availablefor future issuanceunder equitycompensation 
plans(excluding securitiesreflected in column(a))Equity compensation plans approved by security holders


N/A



N/A



750,956Equity compensation plans not approved by security holders










Total










750,956 In connection with our initial public offering, we ceased granting awards under the Existing Plan and
implemented the 2018 Omnibus Equity Incentive Plan. As described above under Item 11. Executive CompensationEquity Incentive Plans2018 Omnibus Incentive Plan, in connection with the closing of our initial public offering, our
board of directors and stockholders approved a new equity compensation plan, the 2018 Plan, which provides for the reservation of 5,001,000 shares of common stock for equity awards.  119




---

##### Table of Contents

Item 13.
Certain Relationships and Related Transactions, and Director Independence. In addition
to the executive officer and director compensation arrangements discussed above under Compensation of our executive officers and directors, we describe transactions since January 1, 2017 to which we have been or will be a
participant, in which the amount involved in the transaction exceeds or will exceed $120,000 and in which any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock, or 5% Security Holders, or
any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest. Equity financings Solid Biosciences, LLC On March 29, 2017, Solid Biosciences, LLC entered into a unit purchase agreement, or the Senior Preferred Unit Purchase
Agreement, which provided for the sale of 2,500,000 of its Series 1 Senior Preferred Units to certain investors at a price of $10.00 per unit for an aggregate purchase price of $25.0 million. 625,000 of such units were sold to affiliates
of RA Capital for an aggregate price of $6.3 million. Mr. Shah, a member of our board of directors, is a Portfolio Manager and Managing Director at RA Capital. 249,999 of Series 1 Senior Preferred Units were sold to affiliates of
Perceptive Advisors for an aggregate price of $2.5 million. Mr. Stone, a member of our board of directors, is the Chief Investment Officer of Perceptive Advisors, and Perceptive Advisors is a 5% Security Holder. 166,667 of such units
were sold to an affiliate of Biogen for an aggregate price of $1.7 million. Ms. Sullivan, a member of our board of directors, is the Senior Vice President of Finance of Biogen, and Biogen is a 5% Security Holder. The Senior Preferred Unit Purchase Agreement, as amended on September 1, 2017, additionally provided that the holders of the Series 1
Senior Preferred Units were required to purchase $25.0 million of Series 2 Senior Preferred Units, in the event Solid Biosciences, LLC achieve certain preclinical milestones. In addition, at their option, the holders had the ability to purchase the
Series 2 Senior Preferred Units at any time prior to December 1, 2017. On October 26, 2017, the Senior Preferred Unit Purchase Agreement was further amended to provide for the sale of 4,886,000 Series 2 Senior Preferred Units at a purchase
price of $11.26 per unit for an aggregate purchase price of $55.0 million. As part of this Series 2 Preferred Financing, which closed on October 26, 2017, 1,110,470 of such units were sold to affiliates of RA Capital for an aggregate price of
$12.5 million, 444,180 of such units were sold to an affiliate of Perceptive Advisors for an aggregate price of $5.0 million, 296,120 of such units were sold to an affiliate of Biogen for an aggregate price of $3.3 million, 1,110,470 of such
units were sold to an affiliate of Bain Capital Life Sciences for an aggregate price of $12.5 million and 222,080 of such units were sold for an aggregate price of $2.5 million to each of Mr. Arnold and Mr. Hayeem, members of our
board of directors. Dr. Koppel, a member of our board of directors, is a Managing Director of Bain Capital Life Sciences, and Bain Capital Life Sciences is a 5% Security Holder. As a result of the Corporate Conversion, the holders of the Series 1 and 2 Senior Preferred Units became holders of shares of our common
stock. J.P. Morgan Securities, LLC, acted as placement agent in connection with our offering of securities under the Senior Preferred
Unit Purchase Agreement and received customary placement agent fees for its services. Mr. Huffines is an employee of J.P. Morgan Securities, LLC. JPMC Strategic Investments II Corporation, a 5% Security Holder, is an affiliate of J.P. Morgan
Securities, LLC. Solid GT, LLC On March 29, 2017, pursuant to a merger agreement between Solid Biosciences, LLC and Solid GT, or the Merger Agreement, the operations of
Solid GT were merged into Solid Biosciences, LLC and all outstanding units of Solid GT, including those held by related persons, were converted into units of Solid Biosciences, LLC. See Merger and recapitalization below.  120




---

##### Table of Contents

As result of the Corporate Conversion, the holders of Series D Common Units of Solid
Biosciences, LLC became holders of shares of our common stock. Merger and recapitalization Solid Biosciences, LLC historically owned 100% of the voting units of its wholly owned subsidiary, Solid GT. Solid GT was organized in Delaware
in August 2014. In November 2015, Solid GT issued voting units to new investors (as discussed above under Equity financingsSolid GT, LLC), which decreased voting ownership by Solid Biosciences, LLC of Solid GT to 77%. On
March 29, 2017, pursuant to the Merger Agreement, Solid Biosciences, LLC merged the operations of Solid GT into the company and Solid GT ceased to exist as a separate legal entity. In connection with the merger, units of the company and units
of Solid GT were converted into new series of units of the company. Units of the company and Solid GT that were held by our executive officers, directors and 5% Security Holders were converted on the same basis as all other holders of such units as
forth in the Merger Agreement and the LLC Agreement. Limited liability company agreement of Solid Biosciences, LLC Solid Biosciences, LLC was party to the LLC Agreement with its members. The LLC Agreement terminated upon the Corporate Conversion. Under the
terms of the LLC Agreement, Series A Common Unit holders were entitled to designate two individuals to serve on our board of managers. Pursuant to this provision, the two board appointees were Mssrs. Arnold and Huffines. Mr. Huffines is an
employee of J.P. Morgan Securities LLC, a participating underwriter in our initial public offering. An affiliate of J.P. Morgan Securities LLC owned in excess of 10% of our issued and outstanding common stock immediately prior to our initial public
offering. See UnderwritingConflicts of Interest in our prospectus filed with the SEC filed on January 29, 2018 for a description of services that the underwriters provided to us in connection with our initial public offering. As result of the Corporate Conversion, the holders of Series A Common Units of Solid Biosciences, LLC became holders of shares of our
common stock. Amended and restated registration rights agreement We are party to an Amended and Restated Registration Rights Agreement, or the Registration Rights Agreement, dated March 29, 2017, with
certain of our stockholders, or the Investors, which includes our 5% Security Holders and entities affiliated with certain of our directors. The Registration Rights Agreement provides for demand and piggyback registration rights for the Investors. Demand registration rights Beginning six months after the date of the prospectus for our initial public offering, the Investors are entitled to demand registration
rights. Under the terms of the Registration Rights Agreement, we will be required, upon the written request of Investors holding at least 20% of the securities eligible for registration then outstanding, to file a registration statement and use our
best efforts to effect as soon as practicable the registration of such shares. We are required to effect only two demand registrations pursuant to the Registration Rights Agreement. However, if we become eligible to register the sale of securities
on Form S-3 under the Securities Act, the Investors have the right to demand unlimited registrations under the Registration Rights Agreement (but not to exceed two registrations on Form S-3 in any calendar year) provided that the
securities for sale on Form S-3 have an aggregate price to the public of at least $2.0 million. Piggyback registration rights If we register any of our equity securities either for our own account or for the account of other security holders, the Investors
are entitled to piggyback registration rights and may include their shares in the registration.  121




---

##### Table of Contents

The underwriters may advise us to limit the number of shares included in any underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not
jeopardize the success of the offering. If this occurs, the aggregate number of securities held by the Investors that may be included in the underwriting will be allocated among all requesting Investors in proportion to the amount of securities
sought to be sold by each Investor. Fees; Indemnification Under the Registration Rights Agreement, we are responsible, subject to certain exceptions, for the expenses of any registration of securities
pursuant to the agreement, other than underwriting discounts and commissions. The Registration Rights Agreement contains customary
cross-indemnification provisions, under which we are obligated to indemnify the Investors in the event of material misstatements or omissions in the registration statement or any violation of the Securities Act, Exchange Act, state securities law or
any rule or regulation promulgated thereunder attributable to us, and they are obligated to indemnify us, severally and not jointly, for material misstatements, omissions or any violation of the Securities Act, Exchange Act, state securities law or
any rule or regulation promulgated thereunder attributable to them. Termination of registration rights The demand registration rights and the piggyback registration rights granted under the Registration Rights Agreement will terminate, with
respect to each Investor, as of the date when all registrable securities held by and issued to such Investor may be sold under Rule 144 under the Securities Act, provided such Investor owns less than 1% of the outstanding common stock of the
Company. Corporate conversion In
connection with our Corporate Conversion, Solid Biosciences, LLC unitholders received 26,498,559 shares of common stock (including 1,132,425 shares of restricted stock) for all units held immediately prior to the Corporate Conversion. The
existing units held by our executive officers, directors and 5% Security Holders were converted on the same basis as all other holders of such units. Equity grants to executive officers and directors Solid Biosciences, LLC On
March 29, 2017, Solid Biosciences, LLC granted 50,000 Series D Common Units to Dr. Morris. On May 31, 2017, Solid Biosciences, LLC granted 150,000 Series D Common Units to Ms. Ziolkowski. On September 12, 2017, Solid
Biosciences, LLC granted 45,184 Series D Common Units to Dr. Quiroz and 22,707 Series D Common Units to Mr. Amorrortu. On December 7, 2017, Solid Biosciences, LLC granted 22,706 Series D Common Units to Mr. Amorrortu, 45,184
Series D Common Units to Dr. Quiroz and 50,000 Series D Common Units to Ms. Ziolkowski. No payment was made to Solid in connection with the above grants. As result of the Corporate Conversion, the holders of Series A and D Common Units of Solid Biosciences, LLC became holders of shares of our
common stock. Following our initial public offering, we granted options for the right to buy shares of our common stock to certain of our executive officers. Such grants were approved by independent directors of the Compensation Committee of our
board of directors. For additional detail concerning grants made to our Named Executive Officers, see Item 11. Executive Compensation  2017 Outstanding Equity Awards at Fiscal Year End. Participation in initial public offering In our initial public offering, certain of our 5% stockholders and their affiliates purchased an aggregate of 2,300,000 shares of our common
stock. Each of those purchases was made through the underwriters at the initial  122




---

##### Table of Contents

public offering price of $16.00 per share. The following table sets forth the aggregate number of shares of our common stock that these 5% stockholders and their affiliates purchased in our
initial public offering:  Purchaser
(1)

Shares ofcommon stock


Totalpurchase priceRA Capital Management LLC


1,000,000


$
16,000,000Perceptive Advisors LLC


1,000,000


$
16,000,000BCLS SB Investco, LP


300,000


$
4,800,000  (1)
See Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters for more information about the shares held by the below identified entities. Other arrangements Since November 2016, we have employed Annie Ganot, the wife of Ilan Ganot, as Director, Patient Advocacy. Mr. Ganot is our CEO and a
member of our board of directors. Ms. Ganot receives an annual salary of less than $200,000 and received a signing bonus in connection with the start of her employment. Indemnification agreements We entered
into agreements to indemnify our directors and executive officers in connection with our initial public offering. These agreements require us, among other things, to indemnify these individuals for certain expenses (including attorneys fees),
judgments, fines and settlement amounts reasonably incurred by such persons in any action or proceeding, including any action by or in our right, on account of any services undertaken by any such person on behalf of our company or that persons
status as a member of our board of directors to the maximum extent allowed under Delaware law. Policy for approval of related-person transactions We have adopted a written related-person transaction policy that sets forth our procedures for the identification, review,
consideration and approval or ratification of any transaction, arrangement or relationship in which we are a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or 5% stockholders (or
their immediate family members), each of whom we refer to as a related person, has a direct or indirect material interest. If
a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a related-person transaction, the related person must report the proposed related-person transaction to our general counsel.
The policy calls for the proposed related-person transaction to be reviewed by and if deemed appropriate approved by, the audit committee of our board of directors. Whenever practicable, the reporting, review and approval will occur prior to entry
into the transaction. If advance review and approval is not practicable, the audit committee will review and, in its discretion, may ratify the related-person transaction. The policy also permits the chair of the audit committee to review, and if
deemed appropriate approve, proposed related-person transactions that arise between audit committee meetings, subject to ratification by the audit committee at its next meeting. Any related-person transactions that are ongoing in nature will be
reviewed annually. A related-person transaction reviewed under the policy will be considered approved or ratified if it is authorized by
the audit committee after full disclosure of the related persons interest in the transaction. As appropriate for the circumstances, the committee will review and consider:  

the related persons interest in the related-person transaction;  

the approximate dollar amount involved in the related-person transaction;  123




---

##### Table of Contents



the approximate dollar amount of the related persons interest in the transaction without regard to the amount of any profit or loss;  

whether the transaction was undertaken in the ordinary course of our business;  

whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;  

the purpose of, and the potential benefits to us of, the related-person transaction; and  

any other information regarding the related-person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular
transaction. The audit committee may approve or ratify the transaction only if the audit committee determines that, under
all of the circumstances, the transaction is not inconsistent with our best interests. The audit committee may impose any conditions on the related-person transaction that it deems appropriate. The policy provides that transactions involving compensation of executive officers will be reviewed and approved by the compensation committee
of our board of directors in the manner specified in its charter. Director independence Applicable Nasdaq rules require a majority of a listed companys board of directors to be comprised of independent directors within one
year of listing. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed companys audit, compensation and nominating and corporate governance committees be independent under the Exchange Act. Audit
committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and compensation committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. The Nasdaq
independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various
types of business dealings with us. In addition, under applicable Nasdaq rules, a director will only qualify as an independent director if, in the opinion of the listed companys board of directors, that person does not have a
relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company
may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any
of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule 10C-1, the board must consider, for each member of a compensation committee of
a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that directors ability to be independent from management in connection with the duties of a
compensation committee member, including, but not limited to: (1) the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and (2) whether the director is
affiliated with the company or any of its subsidiaries or affiliates. Our board of directors has determined that all members of the board
of directors, except Ilan Ganot, Gilad Hayeem and Andrey Zarur, are independent directors, as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the relationships that each such non-employee
director has with our Company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our common stock by each non-employee director. The composition of our committees currently complies with all applicable independence requirements of Nasdaq and the rules and regulations of the SEC.  124




---

##### Table of Contents

Item 14.
Principal Accounting Fees and Services. Auditors fees The following table represents aggregate fees billed to us by PwC for the fiscal years ended December 31, 2017 and 2016:  2017


2016Audit fees

$
1,234,500


$
495,750Audit-related fees






Tax fees


131,727



All other fees


1,800



Total

$
1,368,027


$
495,750 The services rendered by PwC in connection with the fees presented above were as follows: Audit Fees Audit fees consist of amounts
for professional services rendered for audit and quarterly reviews of our financial statements and review of our registration statement on Form S-1. Tax Fees Tax fees consist of fees for
professional services related to tax compliance and consultations. All other fees All other fees include license fees for a web-based accounting research tool. Pre-approval policies The audit
committee has not adopted policies and procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm and, consequently, all audit and non-audit services are pre-approved by the whole
audit committee or the chair of the audit committee.  125




---

##### Table of Contents

PART IV  Item 15.
Exhibits, Financial Statement Schedules. (1) Financial Statements:  PageReport of Independent Registered Public Accounting Firm


F-1Consolidated Balance Sheets at December 31, 2017 and 2016



F-2Consolidated Statements of Operations for the Years Ended December 
31, 2017, 2016 and 2015


F-3Consolidated Statements of Comprehensive Loss for the Years Ended December 31,
 2017, 2016 and 2015


F-4Consolidated Statements of Redeemable Preferred Units and Members Deficit
 for the Years Ended December 31, 2017, 2016 and 2015


F-5Consolidated Statements of Cash Flows for the Years Ended December 
31, 2017, 2016 and 2015


F-6Notes to Consolidated Financial Statements


F-7 (2) Financial Statement Schedules: All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the
financial statements or the notes thereto. (3) Exhibits. The following is a list of exhibits filed as part of this Annual Report on Form
10-K.  ExhibitNumber

Description2.1

Agreement and Plan of Merger, dated March 29, 2017, by and between Solid Biosciences, LLC and Solid GT, LLC (incorporated by reference to Exhibit
 2.1 to the Registration Statement on Form S-1 filed on December 29, 2017).2.2*

Plan of Conversion, dated January 25, 2018.2.3*

Agreement and Plan of Merger, dated January 25, 2018, by and among Solid Biosciences Inc., Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, BCLS Solid Bio, Inc., Foresite Capital Fund
 III, L.P. and FC Fund III Solid Holdings, Inc.3.1

Certificate of Incorporation of Solid Biosciences Inc. (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed
 on January 29, 2018).3.2

Bylaws of Solid Biosciences Inc. (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-8 filed on January 29, 2018).4.1

Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed on December 29, 2017).10.1

Amended and Restated Registration Rights Agreement dated March 29, 2017 by and among Solid Biosciences, LLC and certain investors (incorporated
 by reference to Exhibit 10.17 to the Registration Statement on Form S-1 on December 29, 2017).10.2

Employment Agreement, dated as of December 27, 2013, by and between Solid Ventures, LLC and Ilan Ganot (incorporated by reference to Exhibit
 10.1 to the Registration Statement on Form S-1 filed on December 29, 2017).10.3

Offer Letter, dated as of November 17, 2015, by and between Solid GT, LLC and Jorge A. Quiroz, M.D. (incorporated by reference to Exhibit 10.2
 to the Registration Statement on Form S-1 filed on December 29, 2017).10.4

Offer Letter, dated as of April 17, 2017, by and between Solid Biosciences, LLC and Jennifer Ziolkowski (incorporated by reference to Exhibit
 10.3 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).  126




---

##### Table of Contents

10.5

Amendment to Offer Letter, dated November 17, 2017, by and between Solid Biosciences, LLC and Jennifer Ziolkowski (incorporated by reference
 to Exhibit 10.19 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).10.6

Advisory Agreement, dated as of December 18, 2013, by and between Solid Ventures, LLC and Andrey Zarur (incorporated by reference to Exhibit
 10.4 to the Registration Statement on Form S-1 filed on December 29, 2017).10.7*

Solid Biosciences, LLC Amended and Restated Equity Incentive Plan and form of unit restriction agreement.10.8

Solid Biosciences Inc. 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 filed
 on January 29, 2018).10.9

Form of Incentive Stock Option Agreement under 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement
 on Form S-1 filed on December 29, 2017).10.10

Form of Nonqualified Stock Option Agreement under 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registration
 Statement on Form S-1 filed on December 29, 2017).10.11

Form of Restricted Stock Agreement under 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registration Statement
 on Form S-1 filed on December 29, 2017).10.12#

Exclusive Patent License Agreement, dated as of October 16, 2015, by and between Solid GT, LLC and the University of Washington (incorporated
 by reference to Exhibit 10.10 to the Registration Statement on Form S-1 filed on December 29, 2017).10.13#

Patent License Agreement, dated as of March 10, 2016, by and between Solid GT, LLC and the Regents of the University of Michigan (incorporated
 by reference to Exhibit 10.11 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).10.14#

License Agreement, dated as of October 15, 2015, by and between Solid GT, LLC and The Curators of the University of Missouri (incorporated by
 reference to Exhibit 10.12 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).10.15#

Cell Line License Agreement, dated as of November 
20, 2016, by and between Solid Biosciences, LLC and Life Technologies Corporation (incorporated by reference to Exhibit 10.13 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).10.16#

License Agreement, dated as of June 
23, 2016, by and between Solid GT, LLC and the President and Fellows of Harvard College (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 filed on December 29, 2017).10.17#

License Agreement, dated as of August 3, 2017, by and between Solid Biosciences, LLC and the President and Fellows of Harvard College (incorporated
 by reference to Exhibit 10.15 to the Registration Statement on Form S-1 filed on December 29, 2017).10.18

First Amendment to Patent License Agreement, dated as of March 15, 2017, by and between Solid GT, LLC and the Regents of the University of Michigan
 (incorporated by reference to Exhibit 10.16 to Amendment No. 1 to the Registration Statement on Form S-1 filed on January 16, 2018).10.19

Form of Indemnification Agreement for Directors and Officers (incorporated by reference to Exhibit 
10.16 to the Registration Statement on Form S-1 filed on December 29, 2017).10.20*

Sublease, dated as of January 30, 2018, by and between Solid Biosciences, LLC and Twitter, Inc.10.21*

Lease Agreement, dated as of December 22, 2017, by and between Solid Biosciences, LLC and ARE-MA Region No. 59, LLC.  127




---

##### Table of Contents

16.1

Letter from Katz, Nannis + Solomon, P.C., dated as of July 
24, 2017, regarding change in certifying accountant (incorporated by reference to Exhibit 16.1 to the Registration Statement on Form S-1 filed on December 29, 2017).21.1

Subsidiaries of Solid Biosciences Inc. (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 filed on December
 29, 2017).23.1*

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.31.1*

Certification of Chief Executive Officer of the Registrant Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*

Certification of Chief Financial Officer of the Registrant Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1**

Certification of Chief Executive Officer of the Registrant Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2**

Certification of Chief Financial Officer of the Registrant Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.  *
Filed herewith. **
Furnished herewith. 
Indicates management contract or compensatory plan. #
Confidential treatment has been granted as to certain portions, which portions the Registrant has omitted and filed separately with the SEC.  Item 16.
Form 10-K Summary. Not applicable.  128




---

##### Table of Contents

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly
caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.  SOLID BIOSCIENCES INC.Date: March 29, 2018



By:

/s/ Ilan GanotIlan GanotChief Executive Officer and Director
(Principal Executive Officer) Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed
below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.  /s/ Ilan Ganot
Ilan Ganot

Chief Executive Officer and Director
(Principal Executive Officer)

March 29, 2018/s/ Gilad Hayeem
Gilad Hayeem

President and Director

March 29, 2018/s/ Jennifer Ziolkowski
Jennifer Ziolkowski

Chief Financial Officer
(Principal Financial and Accounting Officer)

March 29, 2018/s/ Andrey Zarur, Ph.D.
Andrey Zarur, Ph.D.

Chairman of the Board

March 29, 2018/s/ Matthew Arnold
Matthew Arnold

Director

March 29, 2018/s/ Robert Huffines
Robert Huffines

Director

March 29, 2018/s/ Adam Koppel
Adam Koppel, M.D., Ph.D.

Director

March 29, 2018/s/ Rajeev Shah
Rajeev Shah

Director

March 29, 2018/s/ Adam Stone
Adam Stone

Director

March 29, 2018/s/ Lynne Sullivan
Lynne Sullivan

Director

March 29, 2018  129




---

##### Table of Contents

Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders of Solid Biosciences
Inc.: Opinion on the Financial Statements We
have audited the accompanying consolidated balance sheets of Solid Biosciences, LLC and its subsidiaries (the Company) as of December 31, 2017 and 2016, and the related consolidated statements of operations, of comprehensive loss,
of redeemable preferred units and members deficit and of cash flows for each of the three years in the period ended December 31, 2017, including the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows
for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial
statements are the responsibility of the Companys management. Our responsibility is to express an opinion on the Companys consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB. We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ PricewaterhouseCoopers LLP Boston, Massachusetts March 29, 2018 We have served as the Companys
auditor since 2017.  F-1




---

##### Table of Contents

SOLID BIOSCIENCES, LLC CONSOLIDATED BALANCE SHEETS (In thousands, except unit and per unit data)  December 31,2017


2016AssetsCurrent assets:Cash and cash equivalents

$
52,080


$
7,678Available-for-sale securities


17,014



29,980Prepaid expenses and other current assets


1,499



2,314Restricted cash


65



Total current assets


70,658



39,972Property and equipment, net


2,429



452Restricted cash






165Deferred offering costs


3,106



47Total assets

$
76,193


$
40,636Liabilities, Redeemable Preferred Units and Members DeficitCurrent liabilities:Accounts payable

$
5,066


$
2,984Accrued expenses and other current liabilities


6,205



3,889Total current liabilities


11,271



6,873Total liabilities


11,271



6,873Commitments and Contingencies (Note 13)Redeemable Preferred Units, no units authorized at December 31, 2017 and 60,000,000 units
authorized at December 31, 2016; no units and 17,100,000 units issued and outstanding at December 31, 2017 and 2016, respectively; aggregate liquidation preference of $0 at December 31, 2017






71,649Series 2 Senior Preferred Units, 4,886,000 units authorized at December 31, 2017 and no
units authorized at December 31, 2016; 4,886,000 units issued and outstanding at December 31, 2017 and no units issued and outstanding at December 31, 2016; aggregated liquidation preference of $55,002 at December 31,
2017


55,002



Series 1 Senior Preferred Units, 2,500,000 units authorized at December 31, 2017 and no
units authorized at December 31, 2016; 2,500,000 units issued and outstanding at December 31, 2017 and no units issued and outstanding at December 31, 2016; aggregate liquidation preference of $25,000 at December 31,
2017


25,000



Junior Preferred Units, 4,414,356 units authorized at December 31, 2017 and no units
authorized at December 31, 2016; 4,414,356 units issued and outstanding at December 31, 2017 and no units issued and outstanding at December 31, 2016; aggregate liquidation preference of $42,500 at December 31, 2017


44,177



Members deficitSeries A, B, C and D Common Units, 20,189,509 units and 20,000,000 units authorized at
December 31, 2017 and 2016, respectively; 19,438,552 units and 5,123,917 units issued and outstanding at December 31, 2017 and 2016, respectively


65,014



558Accumulated other comprehensive income (loss)


(13
)


23Accumulated members deficit


(124,258
)


(84,941
)Total members deficit


(59,257
)


(84,360
)Non-controlling interest






46,474Total deficit


(59,257
)


(37,886
)Total liabilities, redeemable preferred units and members deficit

$
76,193


$
40,636 The accompanying notes are an integral part of these consolidated financial statements.  F-2




---

##### Table of Contents

SOLID BIOSCIENCES, LLC CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except unit and per unit data)  Year Ended December 31,2017


2016


2015Revenue

$



$



$
Operating expenses:Research and development


39,905



20,116



4,192General and administrative


14,952



5,460



2,372Total operating expenses


54,857



25,576



6,564Loss from operations


(54,857
)


(25,576
)


(6,564
)Other income (expense):Revaluation of preferred unit tranche rights


459



1,163



(103
)Interest income


219



369



3Other income


1,001



271



Total other income (expense), net


1,679



1,803



(100
)Net loss

$
(53,178
)

$
(23,773
)

$
(6,664
)Net loss attributable to non-controlling interest


(1,060
)


(2,234
)


(287
)Net loss attributable to Solid Biosciences, LLC

$
(52,118
)

$
(21,539
)

$
(6,377
)Decretion (accretion) of preferred units to redemption value


(959
)


4,309



(68
)Redemption of preferred units


15,685







Redemption of redeemable interest from non-controlling interest in Solid GT


(1,925
)






Net loss attributable to common unitholders

$
(39,317
)

$
(17,230
)

$
(6,445
)Net loss per unit attributable to common unitholders, basic and diluted

$
(2.88
)

$
(10.14
)

$
(7.61
)Weighted average common units outstanding, basic and diluted


13,649,485



1,698,904



846,569 The accompanying notes are an integral part of these consolidated financial statements.  F-3




---

##### Table of Contents

SOLID BIOSCIENCES, LLC CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands)  Year Ended December 31,2017


2016


2015Net loss

$
(53,178
)

$
(23,773
)

$
(6,664
)Other comprehensive loss:Unrealized gain (loss) on available-for-sale securities


(36
)


33



(10
)Comprehensive loss


(53,214
)


(23,740
)


(6,674
)Comprehensive loss attributable to non-controlling interest


(1,060
)


(2,234
)


(287
)Comprehensive loss attributable to Solid Biosciences, LLC

$
(52,154
)

$
(21,506
)

$
(6,387
) The accompanying notes are an integral part of these consolidated financial statements.  F-4




---

##### Table of Contents

SOLID BIOSCIENCES, LLC CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED UNITS AND MEMBERS DEFICIT (In thousands except for unit data)  RedeemablePreferredUnits


Amount


Series 2SeniorPreferredUnits


Amount


Series 1SeniorPreferredUnits


Amount


JuniorPreferredUnits


Amount


Series A, B, Cand DCommonUnits


Amount


Accumulatedothercomprehensiveincome (loss)


AccumulatedMembersDeficit


TotalMembersDeficit


Non-controllingInterest


TotalDeficitBalance at December 31, 2014


6,840,000


$
30,781



























4,729,667


$
68






$
(61,266
)

$
(61,198
)

$
2,499


$
(58,699
)Issuance of preferred units


6,840,000



6,840



















































Reclassification of tranche right upon issuance of preferred units






24,008



















































Accretion in redemption value of preferred units






68







































(68
)


(68
)






(68
)Issuance of Series A common units


































305,000























Repurchase of Series A common units


































(18,750
)






















Equity based compensation expense






































140











140



624



764Issuance of non-controlling interest in Solid GT






















































44,752



44,752Unrealized loss on available for sale securities









































$
(10
)






(10
)






(10
)Net loss














































(6,377
)


(6,377
)


(287
)


(6,664
)Balance at December 31, 2015


13,680,000



61,697



























5,015,917



208



(10
)


(67,711
)


(67,513
)


47,588



(19,925
)Issuance of preferred units


3,420,000



3,420



















































Reclassification of tranche right upon issuance of preferred units






10,841



















































Decretion in redemption value of preferred units






(4,309
)






































4,309



4,309







4,309Issuance of Series A common units


































108,000























Equity based compensation expense






































350











350



1,120



1,470Unrealized gain on available for sale securities










































33







33







33Net loss














































(21,539
)


(21,539
)


(2,234
)


(23,773
)Balance at December 31, 2016


17,100,000



71,649



























5,123,917



558



23



(84,941
)


(84,360
)


46,474



(37,886
)Issuance of Series 1 senior preferred units, net of issuance costs of $500 and tranche right of
$459


















2,500,000


$
24,041



































Accretion of Series 1 senior preferred units to redemption value






















959























(959
)


(959
)






(959
)Redemption of preferred units






(15,685
)






































15,685



15,685







15,685Equity based compensation






































5,030











5,030



300



5,330Net loss














































(52,118
)


(52,118
)


(1,060
)


(53,178
)Issuance of Series B common units in exchange for Series A common units


































(1,301,520
)






















Issuance of Series D common units in exchange for Series A common units


































(160,954
)






















Issuance of Series A common units in exchange for redeemable preferred units


(17,100,000
)


(55,964
)


























12,219,299



55,964











55,964







55,964Issuance of junior preferred units in redemption of Class D non-controlling interest in
Solid GT


























4,414,356


$
44,177















(1,925
)


(1,925
)


(42,252
)


(44,177
)Issuance of Series C common units in exchange for Class B non-controlling interest in Solid
GT


































1,635,916



2,053











2,053



(2,053
)


Issuance of Series D common units in exchange for Class C non-controlling interest in Solid
GT


































1,083,205



1,409











1,409



(1,409
)


Issuance of Series D common units


































838,689























Issuance of Series 2 senior preferred units,










4,886,000



55,002











































Unrealized loss on available for sale securities










































(36
)






(36
)






(36
)Balance at December 31, 2017










4,886,000


$
55,002



2,500,000


$
25,000



4,414,356


$
44,177



19,438,552


$
65,014


$
(13
)

$
(124,258
)

$
(59,257
)





$
(59,257
) The accompanying notes are an integral part of these consolidated financial statements.  F-5




---

##### Table of Contents

SOLID BIOSCIENCES, LLC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)  Year Ended December 31,2017


2016


2015Cash flows from operating activities:Net loss

$
(53,178
)

$
(23,773
)

$
(6,664
)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of premium on available for sale securities


206



505



5Equity-based compensation expense


5,330



1,470



764Depreciation expense


448



56



Loss (gain) from revaluation of preferred unit tranche right


(459
)


(1,163
)


103Changes in operating assets and liabilities:Prepaid expenses and other current assets


815



(2,005
)


(309
)Accounts payable


1,579



2,213



585Accrued expenses and other current liabilities


2,035



2,577



1,312Net cash used in operating activities


(43,224
)


(20,120
)


(4,204
)Cash flows from investing activities:Purchases of property and equipment


(2,276
)


(392
)


Proceeds from sales and maturities of available for sale securities


31,621



22,035



Purchases of available for sale securities


(18,897
)


(25,695
)


(26,806
)Changes in restricted cash


100



(165
)


Net cash provided by (used in) investing activities


10,548



(4,217
)


(26,806
)Cash flows from financing activities:Proceeds from issuance of Series 1 Senior preferred units


24,500







Proceeds from issuance of Series 2 Senior preferred units


55,002







Payment of deferred offering costs


(2,424
)






Proceeds from issuance of redeemable preferred units






3,420



6,840Proceeds from issuance of non-controlling interest in Solid GT










44,752Net cash provided by financing activities


77,078



3,420



51,592Net increase (decrease) in cash and cash equivalents


44,402



(20,917
)


20,582Cash and cash equivalents at beginning of period


7,678



28,595



8,013Cash and cash equivalents at end of period

$
52,080


$
7,678


$
28,595Supplemental disclosure of non-cash investing and financing activities:Reclassification of preferred unit tranche liability to preferred units upon settlement





$
10,841


$
24,008Decretion (accretion) to redemption value for redeemable preferred units

$
(959
)

$
4,309


$
(68
)Redemption of preferred units

$
15,685







Redemption of redeemable interest from non-controlling interest in Solid GT

$
(1,925
)






Deferred offering costs included in accounts payable and accrued expenses

$
682


$
47



Property and equipment included in accounts payable

$
265


$
116



Issuance of Series D common units in exchange for Series A common units

$
638







Issuance of Series A common units in exchange for Redeemable preferred units

$
55,964







Issuance of Junior preferred units upon redemption of Class D non-controlling interest in
Solid GT

$
44,177







Issuance of Series C common units in exchange for Class B non-controlling interest in
Solid GT

$
2,053







Issuance of Series D common units in exchange for Class C non-controlling interest in
Solid GT

$
1,409







 The accompanying notes are an integral part of these consolidated financial statements.  F-6




---

##### Table of Contents

SOLID BIOSCIENCES, LLC NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Amounts in thousands, except unit and per unit data) 1. Nature of the Business and Basis of Presentation Nature of Business Solid Biosciences, LLC was
organized in March 2013 under the name SOLID Ventures Management, LLC. In October 2013, the company changed its name to Solid Ventures, LLC and in June 2015, the company changed its name to Solid Biosciences, LLC. The company operated as a Delaware
limited liability company under the name Solid Biosciences, LLC until immediately prior to the effectiveness of its registration statement on Form S-1 on January 25, 2018, at which time it completed a statutory corporate conversion into a
Delaware corporation (the Corporate Conversion) and changed its name to Solid Biosciences Inc. (the Company) In addition, entities formed solely for the purpose of holding membership interests in the Companys limited
liability company were merged with and into the Company. As a result of the Corporate Conversion, all of the Series 1 and 2 Senior Preferred, Junior Preferred Units, Series A, B, C and D Common Units of Solid Biosciences, LLC converted into shares
of common stock of Solid Biosciences Inc. on a one for 0.8485 basis and all of the unit holders of Solid Biosciences, LLC became holders of common stock of Solid Biosciences Inc. The Companys mission is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys. It is
caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and tear. Without functioning dystrophin and
certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. The Companys lead product candidate, SGT-001, is a gene
transfer under development to restore functional dystrophin protein expression in patients muscles. SGT-001 has been granted Rare Pediatric Disease Designation in the United States and Orphan Drug Designations in both the United States
and European Union. The Company filed an Investigational New Drug application, or IND, in September 2017 and initiated a Phase I/II for SGT-001 in the United States during the fourth quarter of 2017. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by
competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product
candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require
significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities. The Companys
product candidates are in development. There can be no assurance that the Companys research and development will be successfully completed, that adequate protection for the Companys intellectual property will be obtained, that any
products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Companys product development efforts are successful, it is uncertain when, if ever, the Company will
generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from, among others, other pharmaceutical and biotechnology companies. In addition, the Company is
dependent upon the services of its employees, partners and consultants. Initial Public Offering in January 2018 On January 30, 2018, the Company completed its initial public offering with the sale of 8,984,375 shares of common stock, including shares
of common stock issued upon the exercise in full of the underwriters over-  F-7




---

##### Table of Contents

allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $129,300, after deducting underwriting discounts and commissions and offering expenses. Liquidity The accompanying consolidated financial
statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Through
December 31, 2017, the Company has funded its operations primarily with proceeds from the sale of redeemable preferred units, including the sale of 4,886,000 Series 2 Senior Preferred Units resulting in net proceeds of $55,002 in the fourth
quarter of 2017. The Company has incurred recurring losses from operations since its inception, including a net loss of $53,178, $23,773 and $6,664 for the years ended December 31, 2017, 2016 and 2015, respectively. In addition, as of
December 31, 2017 and 2016 the Company had an accumulated members deficit of $124,258 and $84,941, respectively. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2017, the Company had cash, cash equivalents and available-for-sale securities of $69,094. The Company believes that its cash, cash
equivalents and available-for-sale securities as of December 31, 2017, together with the net proceeds of $129,300 from its recently completed initial public offering, will enable it to fund its operating expenses and capital expenditure
requirements for at least the next twelve months from the issuance of the financial statements. To execute its business plans, the Company will need
substantial funding to support its continuing operations and pursue its growth strategy. Until the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of public or private
equity, debt financings or other capital sources, potentially including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. Even if the Company is able
to secure the financing, the terms of any financing may adversely affect the holdings or the rights of the Companys stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all
of its research and development programs, pre-clinical and eventual clinical testing or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that
the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. Merger and Recapitalization in March 2017 The
Company had historically owned 100% of the voting units of its wholly owned subsidiary, Solid GT, LLC (Solid GT), and the results of Solid GT are included in the Companys consolidated financial statements. In November 2015, Solid
GT issued voting units to new investors which decreased the Companys voting ownership in Solid GT to 77%. The Company continued to consolidate the results of Solid GT into its financial statements as the Company owned a majority voting
interest in Solid GT and directed the activities of Solid GT. However, because the Company controlled but owned less than 100% of Solid GT, the Company recorded a non-controlling ownership interest at its fair value at inception and recognizes the
net loss or profit attributable to non-controlling interests in the consolidated statements of operations based on a profit and loss sharing arrangement between the Company and the non-controlling interests. The Company also presents the change in
equity related to equity-based compensation issued to Solid GT employees by Solid GT, in non-controlling interest. See Note 12, Equity-Based Compensation, for additional information. On March 29, 2017, the Company merged the operations of Solid GT into the Company and Solid GT ceased to exist as a legal entity. See Note 3, Merger
and Recapitalization, for additional information. The proportionate share of the loss attributed to the non-controlling interest amounted to $1,060,
$2,234 and $287, for the years ended December 31, 2017, 2016 and 2015, respectively.  F-8




---

##### Table of Contents

There was no non-controlling interest at December 31, 2017. The carrying value of the non-controlling
interest was $46,474 at December 31, 2016. The accompanying consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America (GAAP). The accompanying consolidated financial statements include the accounts of Solid Biosciences, LLC and its wholly owned or controlled subsidiaries. All intercompany
accounts and transactions have been eliminated. 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the Companys
consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of
research and development expenses and the valuation of restricted common units and the preferred unit tranche rights. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded
in the period in which they become known. Actual results could differ from the Companys estimates. Cash Equivalents The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Restricted Cash The Company held restricted cash of
$65 in a separate restricted bank account as a security deposit for the lease of the Companys facility as of December 31, 2017. The Company has included the restricted cash of $65 as a current asset as of December 31, 2017. The Company held restricted cash of $100 and $65 in separate restricted bank accounts as a security deposit for the Companys credit card program and for
the lease of the Companys facility, respectively, as of December 31, 2016. The Company has classified these deposits as long-term assets on its balance sheets at such date. Available-for-Sale Securities Available-for-sale
securities consist of investments with original maturities greater than 90 days at acquisition date. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such
available-for-sale securities represent the investment of cash that is available for current operations. The Company classifies all of its investments as
available-for-sale securities. The Companys investments are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a
separate component of members deficit. The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statement of operations. If any
adjustment to fair value reflects a decline in the value of the investment that the Company considers to be other than temporary, the Company reduces the investment to fair value through a charge to the consolidated statement of
operations. No such adjustments were necessary during the periods presented.  F-9




---

##### Table of Contents

Concentration of Credit Risk and of Significant Suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the
Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not
exposed to significant credit risk. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including clinical and
pre-clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance products. Fair
Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to
measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair
value hierarchy, of which the first two are considered observable and the last is considered unobservable:  

Level 1Quoted prices in active markets for identical assets or liabilities.  

Level 2Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or
similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data.  

Level 3Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash
flow methodologies and similar techniques. The Companys cash equivalents and available-for-sale securities are carried at fair value,
determined according to the fair value hierarchy described above. See Note 4, Fair Value of Financial Assets and Liabilities, for additional information. The carrying values of the Companys accounts payable and accrued expenses and
other current liabilities approximate their fair value due to the short-term nature of these liabilities. Deferred Offering Costs The Company capitalizes certain legal and other third-party fees that are directly associated with in-process equity financings as deferred offering costs
until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering
costs will be expensed immediately as a charge to operating expense in the consolidated statements of operations. Deferred offering costs amounted to $3,106 at December 31, 2017 and $47 at December 31, 2016. Property and Equipment Property and equipment are stated
at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory equipment is depreciated over five years. Computer equipment is depreciated over three years.
Computer software is depreciated over two years. Furniture and office equipment are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures
for repairs and maintenance  F-10




---

##### Table of Contents

of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or
loss is included in loss from operations. Impairment of Long-Lived Assets Long-lived assets, comprised of property and equipment, to be held and used are tested for recoverability whenever events or changes in business circumstances
indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations,
significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of
undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of
an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any
impairment losses or disposals on long-lived assets. Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses include salaries, equity-based compensation and benefits of
employees, third-party license fees and other operational costs related to the Companys research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both
pre-clinical studies and clinical trials. Non-refundable pre-payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense as the
goods or services are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. Research Contract Costs and Accruals The Company has
entered into various research and development contracts with research institutions and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company
records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs.
Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Companys estimates. The Companys historical accrual estimates have not been
materially different from the actual costs. Patent Costs All patent-related costs incurred for filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the
expenditure. Amounts incurred are classified as general and administrative expenses. Equity-Based Compensation The Company measures restricted common units granted to employees and directors based on the fair value on the date of grant and recognizes compensation
expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. Generally, the Company issues restricted common units with only service-based
vesting conditions and records the expense for these awards using the straight-line method. The Company has not issued any awards with performance-based vesting conditions.  F-11




---

##### Table of Contents

The Company measures restricted common unit awards granted to consultants and non-employees based on the
fair value of the award on the date of grant. Compensation expense is recognized over the period during which services are rendered by such consultants and nonemployees until completed. At the end of each financial reporting period prior to
completion of the service, the fair value of unvested awards is remeasured using the then-current fair value of the Companys common units. The
Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipients payroll costs are classified or in which the award recipients service payments are
classified. The fair value of each restricted common unit was determined based on a number of objective and subjective factors consistent with the
methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, including the contemporaneous valuations of the Companys common
units, the Companys financial condition and operating results, the material risks related to the Companys business, the Companys stage of development and business strategy and the likelihood of achieving a liquidity event for the
holders of the Companys common units such as an initial public offering given prevailing market conditions. Income Taxes As of December 31, 2017, the Company was treated as a partnership for income tax purposes and was not subject to U.S. federal or state income taxation. As
a result, the Company has not recorded any U.S. federal or state income tax benefits for the net losses incurred in each reporting period or for any earned research and development tax credits. To date, the operating losses incurred by the Company
have been passed through to its members. Segment Data The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Companys singular
focus is on developing treatments through gene therapy and other means for patients with DMD. All of the Companys tangible assets are held in the United States. Comprehensive Loss Comprehensive loss includes net loss,
as well as other changes in members deficit that result from transactions and economic events other than those with members. The Companys only element of other comprehensive income (loss) in all periods presented was unrealized gains
(losses) from available-for-sale securities. Net Loss per Unit The Company applies the two-class method to calculate its basic and diluted net loss per unit attributable to common unitholders, as its preferred units and
certain unvested common units are considered participating securities. The two-class method determines net income (loss) per unit for each class of common and participating securities according to participation rights in undistributed earnings. The
two-class method requires income available to common unitholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.
As holders of the Companys participating securities, which include Redeemable Preferred Units, Series 2 Senior Preferred Units, Series 1 Senior Preferred Units, Junior Preferred Units and certain unvested common units, do not have a
contractual obligation to fund the losses of the Company, the net loss is not allocated between common units and participating securities. The exchange
of Series A Common Units to Series B and Series D Common Units as the result of merger and recapitalization described in Note 3 is treated similar to a stock split for the purposes of presenting
weighted-  F-12




---

##### Table of Contents

average units outstanding. The Companys weighted-average number of common units for the periods prior to such merger and recapitalization, therefore, have been retroactively adjusted to
reflect the exchange of vested Series A Common Units into vested Series B and vested Series D Common Units. Accordingly, for the period subsequent to the Merger and Recapitalization, weighted-average units outstanding include newly issued Series A
Common Units, vested Series B, vested Series D Common Units and Series C Common Units. Although each series of units has different rights, losses are shared equally among each of the series of common units and therefore, net loss per unit is the
same for each series of common units. The Companys basic and diluted net loss per unit are the same because the Company has generated a net loss in
all periods presented and potentially dilutive securities are excluded from diluted net loss per unit because they have an anti-dilutive impact. Preferred Unit Tranche Rights Included in the terms of
the Redeemable Preferred Unit Purchase Agreement was a Redeemable Preferred Unit Tranche Right granted to the holders of the Redeemable Preferred Units. Included in the terms of the Series 1 Senior Preferred Unit Purchase Agreement was a
Series 1 Senior Preferred Unit Tranche Right granted to the holders of the Series 1 Senior Preferred Units. The Redeemable Preferred Unit
Tranche Right and the Series 1 Preferred Unit Tranche Right, together the Tranche Rights, obligate the holders to purchase additional preferred units under certain conditions. The Tranche Rights also provide the holders with the right to
purchase these additional units. The Tranche Rights meet the definition of a freestanding financial instrument as the Tranche Rights are legally detachable and separately exercisable from the Redeemable Preferred Units and the Series 1 Senior
Preferred Units. The Tranche Rights are initially recorded at fair value and are subsequently re-measured at fair value each reporting period. Changes in the fair market value are recognized as a component of other income (expense), net, in the
consolidated statements of operations. Funding from Charitable Organizations The Company has received funding from charitable organizations to perform research and development services to identify therapies for people with DMD. The
amounts received are recognized as services are performed and research expenses are incurred. These are included in other income in the consolidated statements of operations as the arrangement between the Company and the charitable organizations are
not part of the Companys on-going, major or central operations. Any amount received in advance of services performed is recorded in accrued expenses and other current liabilities in the consolidated balance sheets if the services are expected
to be performed within the next twelve months. There was no other income recorded for the year ended December 31, 2015. The Company recognized other
income of $1,001 and $271 for the years ended December 31, 2017 and 2016, respectively, which is included in the consolidated statements of operations. Contingencies Loss contingency provisions are recorded
if the potential loss from any claim, asserted or unasserted, or legal proceeding, is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent the Companys best estimate of
probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company reviews the status of each significant
matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these
matters, accruals are based only on the best information available at the time. As additional information becomes  F-13




---

##### Table of Contents

available, the Company reassesses the potential liability related to pending claims and may change its estimates. These changes in the estimates of the potential liabilities could have a material
impact on the Companys consolidated results of operations and financial position. Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09,
CompensationStock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09). ASU 2016-09 includes multiple provisions intended to simplify various aspects of the accounting for
share-based payments, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross share compensation expense with actual forfeitures recognized as they occur, as well as certain
classifications on the statement of cash flows. The Company elected to early adopt the standard on January 1, 2016. The adoption of ASU 2016-09 had no material impact on the Companys financial position, results of operations or cash
flows. The Company elected to account for forfeitures as they occur rather than apply an estimated forfeiture rate to share-based compensation expense. In August 2014, the FASB issued ASU No. 2014-15,Disclosure of Uncertainties About an Entitys Ability to Continue as a Going Concern
(ASU 2014-15). ASU 2014-15 amends Accounting Standards Codification (ASC) 205-40, Presentation of Financial StatementsGoing Concern, by providing guidance on determining when and how reporting entities must
disclose going-concern uncertainties in their financial statements, including requiring management to perform interim and annual assessments of an entitys ability to continue as a going concern within one year of the date of issuance of the
entitys financial statements and providing certain disclosures if there is substantial doubt about the entitys ability to continue as a going concern. The standard is effective for public companies for annual periods ending after
December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. The Company has adopted this standard for the year ended December 31, 2016 and its adoption had no impact on the Companys financial
position, results of operations, cash flows or disclosures. In May 2014, the FASB issued ASU No. 2014-09,Revenue from Contracts with
Customers, which supersedes the revenue recognition requirements in ASC 605-25,Multiple-Element Arrangements and most industry-specific guidance. The new standard requires that an entity recognize revenue to depict the transfer
of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The update also requires additional disclosure about the nature, amount,
timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This new guidance will be
effective for annual reporting periods (including interim reporting periods within those years) beginning on January 1, 2018. Early adoption in 2017 is permitted. Companies have the option of applying this new guidance retrospectively to each
prior reporting period presented or retrospectively with the cumulative effect of initially applying this update recognized at the date of initial application. The Company elected to early adopt the standard on January 1, 2017. The Company does
not have any revenue generating arrangements and the adoption of this standard had no impact on the Companys financial position, results of operations or cash flows. Recently Issued Accounting Pronouncements In May 2017,
the FASB issued ASU 2017-09, CompensationStock Compensation (Topic 718): Scope of Modification Accounting(ASU 2017-09). ASC 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment
award require an entity to apply modification accounting in Topic 718. The guidance is effective for annual periods beginning after December 15, 2017, with early adoption permitted, including adoption in any interim period for which financial
statements have not yet been issued. Upon adoption of this standard, the Company will apply modification accounting in accordance with the standard.  F-14




---

##### Table of Contents

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (ASU 2016-18),
which requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of
cash flows. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and should be applied using a retrospective transition method to each period presented. Early adoption is permitted. The Company has determined the impact
of adopting ASU 2016-18 will result in the inclusion of restricted cash in total cash and cash equivalents in the determination of changes in cash and cash equivalents in its statements of cash flows. The presentation of restricted cash on the
balance sheet will remain the same. Restricted cash amounted to $65, $165 and $0 at December 31, 2017, 2016, and 2015, respectively. In August
2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 reduces diversity in practice by providing guidance on the classification
of certain cash receipts and payments in the statement of cash flows. ASU 2016-15 clarifies that when cash receipts and cash payments have aspects of more than one class of cash flows and cannot be separated, classification will depend on the
predominant source or use. ASU 2016-15 is effective on a retrospective basis for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The adoption of this standard is
not expected to have a material impact on the Companys consolidated statements of cash flows upon adoption. In February 2016, the FASB issued ASU
No. 2016-02, Leases (Topic 842)(ASU 2016-02), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard
requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease
expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater
than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 supersedes the previous leases standard, ASC 840, Leases.
The standard is effective for public entities for annual periods beginning after December 15, 2018 and for interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption
of ASU 2016-02 will have on its consolidated financial statements. 3. Merger and Recapitalization On March 29, 2017, the Company completed a series of transactions, which included the issuance of Series 1 Senior Preferred Units pursuant to the Senior
Preferred Unit Purchase Agreement (the Senior Preferred Unit Purchase Agreement) and the merger of Solid GT into the Company pursuant to the merger agreement between the Company and Solid GT (the Merger Agreement),
collectively referred to as the Merger and Recapitalization. As part of the Merger and Recapitalization, the Company (a) issued 2,500,000 Series 1 Senior Preferred Units to new investors at $10.00 per unit resulting in gross
proceeds to the Company of $25,000, (b) merged operations of Solid GT into the Company, effected through the exchange of Solid GT units held by non-controlling interests of the Company into new classes of the Company units, and
(c) exchanged existing Redeemable Preferred Units and Series A Common Units of the Company into new units. The details of each component of the Merger and Recapitalization are as follows:  (a)
Issuance of Series 1 Senior Preferred Units Pursuant to the Senior Preferred Unit Purchase Agreement,
the Company issued 2,500,000 Series 1 Senior Preferred Units to new investors at $10.00 per unit resulting in gross proceeds to the Company of $25,000. See Note 10, Redeemable Preferred Units, Series 2 Senior Preferred Units, Series 1 Senior Preferred Units and Junior Preferred Units, for
additional information.  F-15




---

##### Table of Contents

(b)
Merger of Solid GT into the Company Prior to the Merger and Recapitalization, the Company issued
Class B Non-Voting and Class D Voting Units of Solid GT to holders which represent non-controlling interests of the Company. On March 29, 2017, in connection with the Merger and Recapitalization, the non-controlling interests were
eliminated as follows:  

50,000 Class B Non-Voting Units of Solid GT (Solid GT Class B Units) were exchanged for 1,635,916 Series C Common Units of the Company; and  

134,920 Class D Voting Units of Solid GT (Solid GT Class D Units) were exchanged for 4,414,356 Junior Preferred Units of the Company. In addition, the Class C Non-Voting Units of Solid GT (Solid GT Class C Restricted Units) were exchanged for Series D Common Units of
the Company. The Solid GT Class C Restricted Units were held by employees and consultants of Solid GT. See Note 12, Equity-Based Compensation, for additional information. Since there was no change in control in connection with the Solid GT merger, the exchange of Solid GT Class B Units, Class C Restricted Units and
Class D Units was accounted for as an equity transaction. In addition, because Solid GT Class D Units represented preferred units with preference over the other classes of Solid GT Units, the difference between the carrying value of the
Solid GT Class D Units and the fair value of Junior Preferred Units was recorded as a deemed dividend in members deficit, which impacts net loss attributable to common unitholders. See Note 15, Net Loss per Unit, for additional
information.  (c)
Exchange of the Companys existing Redeemable Preferred Units and Series A Common Units In
connection with the Merger and Recapitalization, the Company exchanged its existing Redeemable Preferred Units and Series A Common Units as follows:  

17,100,000 Redeemable Preferred Units of the Company were exchanged for 12,219,299 Series A Common Units of the Company. See Note 10, Redeemable Preferred Units, Series 2 Senior Preferred Units, Series 1
Senior Preferred Units and Junior Preferred Units, for additional information.  

4,560,000 Series A Common Units of the Company were exchanged for 3,258,480 Series B Common Units of the Company. See Note 11, Members Deficit, for additional information.  

563,917 Series A Common Units of the Company were exchanged for 402,963 Series D Common Units of the Company. See Note 11, Members Deficit, for additional information. The table below displays the pre-merger and post-merger capitalization structure of the Company:  Pre-Merger and
Recapitalization


Post-Merger and
RecapitalizationEntity

Class

Issued


Entity

Class

IssuedCompany

Redeemable Preferred


17,100,000


Company

Series A Common


12,219,299Company

Series A Common (Founders)


4,560,000


Company

Series B Common


3,258,480Company

Series A Common (Others)


563,917


Company

Series D Common


402,963Solid GT

Class A Voting


450,000


Ceased to existSolid GT

Class B Non-Voting


50,000


Company

Series C Common


1,635,916Solid GT

Class C Non-Voting


33,107


Company

Series D Common


1,083,205Solid GT

Class D Voting


134,920


Company

Junior Preferred


4,414,356Company (Total)

Common Units (Series A)


5,123,917


Company (Total)

Common Units
(Series A, B, C and D)


18,599,863  F-16




---

##### Table of Contents

4. Fair Value of Financial Assets and Liabilities The following tables present information about the Companys assets and liabilities that are measured at fair value on a recurring basis and indicate the
level of the fair value hierarchy utilized to determine such fair values:  Fair Value Measurements as of December 31, 2017Using:Level 1


Level 2


Level 3


TotalAssets:Available for sale securities

$



$
17,014


$



$
17,014  Fair Value Measurements as of December 31, 2016Using:Level 1


Level 2


Level 3


TotalAssets:Available for sale securities

$



$
29,980


$



$
29,980 As of December 31, 2017 and 2016, the fair values of the Companys available-for-sale securities, which consisted of
U.S. government agency securities and corporate bond securities were determined using Level 2 inputs. During the years ended December 31, 2017 and 2016, there were no transfers between Level 1, Level 2 and Level 3. The fair value of the Companys cash, restricted cash, accounts payable, and accrued expenses and other current liabilities approximate their carrying
value due to their short-term maturities. 5. Available-for-Sale Securities As of December 31, 2017 and 2016, the fair value of available-for-sale securities by type of security was as follows:  December 31, 2017AmortizedCost


GrossUnrealizedGain


GrossUnrealizedLoss


FairValueInvestments:U.S. government agency securities

$
9,473


$



$
(7
)

$
9,466Corporate bond securities


7,554







(6
)


7,548$
17,027


$



$
(13
)

$
17,014  December 31, 2016AmortizedCost


GrossUnrealizedGain


GrossUnrealizedLoss


FairValueInvestments:U.S. government agency securities

$
11,579


$
11


$



$
11,590Corporate bond securities


18,378



21



(9
)


18,390$
29,957


$
32


$
(9
)

$
29,980  F-17




---

##### Table of Contents

The estimated fair value and amortized cost of the Companys available-for-sale securities by
contractual maturity are summarized as follows:  December 31, 2016


December 31, 2017AmortizedCost


FairValue


AmortizedCost


FairValueDue in one year or less

$
28,732


$
28,757


$
17,027


$
17,014Due after one year through two years


1,225



1,223







Total available-for-sale securities

$
29,957


$
29,980


$
17,027


$
17,014 The average maturity of the Companys available-for-sale securities as of December 31, 2017 and 2016 and was
approximately 0.4 years and 0.5 years, respectively. 6. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:  December 31,2017


2016Prepaid research and development expenses

$
951


$
2,079Prepaid expenses and other assets


548



235$
1,499


$
2,314 7. Property and Equipment Property and equipment consists of the following:  December 31,2017


2016Furniture and fixtures

$
61


$
61Laboratory equipment


2,338



195Leasehold improvements


68



68Computer equipment


77



68Computer software


23



Construction in process


366



1162,933



508Less accumulated depreciation


504



56$
2,429


$
452 Depreciation expense was $448 and $56 for the years ended December 31, 2017 and 2016, respectively. There was no
depreciation expense for the year ended December 31, 2015. 8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following:  December 31,2017


December 31,2016Accrued research and development

$
1,855


$
1,953Accrued compensation


2,033



1,167Deferred funding from charitable organizations


233



345Accrued other


2,084



424$
6,205


$
3,889  F-18




---

##### Table of Contents

9. Preferred Unit Tranche Rights Included in the terms of the Redeemable Preferred Unit Purchase Agreement and the Series 1 Senior Preferred Unit Agreement were Tranche Rights which obligate
the investors to purchase additional preferred units under certain conditions. The Tranche Rights also provide the investors with the right to purchase these additional units. The Company concluded that the Tranche Rights met the definition of a
freestanding financial instrument as the Tranche Rights were legally detachable and separately exercisable from the Redeemable Preferred Units and the Series 1 Senior Preferred Units. Therefore, the Company allocated the net proceeds to each Tranche
Right and the Redeemable Preferred Units or the Series 1 Senior Preferred Units based on the fair value at the date of issuance with the remaining proceeds being allocated to the Redeemable Preferred Units or Series 1 Senior Preferred Units. For the year ended December 31, 2015 and through the final settlement date in October 2016, the Company estimated the fair value of the Redeemable
Preferred Unit Tranche Right based on the probability of closing the tranches and the estimated future value of the Redeemable Preferred Units. The Redeemable Preferred Unit Tranche Right was recorded as a liability as the purchase price of the
additional Redeemable Preferred Units is less than the estimated fair value of the Redeemable Preferred Units at the expected settlement date. Upon settlement, the Redeemable Preferred Unit Tranche Right is reclassified to Redeemable Preferred
Units. In October 2016, the Redeemable Preferred Unit Tranche Right was settled and no Redeemable Preferred Unit Tranche Right was outstanding subsequent to October 2016. The estimated fair value of the Series 1 Senior Preferred Unit Tranche Right was determined using a probability-weighted present value model that considered
the probability of closing the tranche through achievement of the preclinical milestones, estimated to be 50% on the date of issue and the estimated future value of Series 1 Senior Preferred Units at closing. The Company converted future values to
present value using a discount rate appropriate for probability adjusted cash flows. The estimates are based, in part, on subjective assumptions. Changes to these assumptions can have a significant impact on the fair value of the Series 1 Senior
Preferred Unit Tranche Right. The Series 1 Tranche Right was settled in connection with the closing of the Series 2 Senior Preferred Unit financing on October 26, 2017. A roll-forward of each tranche right is as follows:  RedeemablePreferred UnitTranche Right


Series 1SeniorPreferredUnit TrancheRightBalance at December 31, 2015

$
12,004


$
Change in fair value


(1,163
)


Reclassification to preferred units


(10,841
)


Balance at December 31, 2016






Issuance






459Change in fair value






(459
)Balance at December 31, 2017

$



$
 10. Redeemable Preferred Units, Series 2 and Series 1 Senior Preferred Units and Junior Preferred Units Redeemable Preferred Units The Company has issued
redeemable preferred units (Redeemable Preferred Units). The Redeemable Preferred Units are classified outside of members deficit because the units contain redemption features that are not solely within the control of the Company. In December 2013, the Company issued 3,420,000 Redeemable Preferred Units at an issuance price of $1.00 per unit for proceeds of $3,420.  F-19




---

##### Table of Contents

In December 2014, the Company issued 3,420,000 Redeemable Preferred Units at an issuance
price of $1.00 per unit for proceeds of $3,420. In October 2015, the Company issued 6,840,000 Redeemable Preferred Units at an issuance
price of $1.00 per unit for proceeds of $6,840. In November and December 2016, the Company issued an aggregate of 3,420,000 Redeemable
Preferred Units at $1.00 per unit for proceeds of $3,420. On March 29, 2017, the Redeemable Preferred Units were exchanged to Series A Common Units.
See Note 3, Merger and Recapitalization, for additional information. The Redeemable Preferred Units, which are carried at fair value due to their fair value redemption feature, were remeasured for a final time to their redemption value on
March 29, 2017 and then were reclassified to members deficit. Redeemable Preferred Units consisted of the following:  Authorized


IssuedandOutstanding


CarryingValue


LiquidationPreferenceAt December 31, 2016


60,000,000



17,100,000


$
71,649


$
55,746At December 31, 2017














 The holders of the Redeemable Preferred Units had the following rights and preferences: Tranche Right The Redeemable Preferred Unit Tranche
Right obligates the holders to purchase, and provides the holders with the right to purchase, additional Redeemable Preferred Units, under certain circumstances. The Redeemable Preferred unitholders purchased these additional units in 2016 and 2015.
In October 2016, the Redeemable Preferred Unit Tranche Right was settled with the closing of the Redeemable Preferred Unit financing. See Note 9, Preferred Unit Tranche Rights, for additional information. Redemption The Redeemable Preferred Units were
redeemable on or after December 27, 2022 at the option of the Redeemable Preferred unitholder. The Redeemable Preferred Units were redeemable at the fair market value on the redemption date. Conversion The Redeemable Preferred Units had no
conversion rights. Voting Rights The holders of
Redeemable Preferred Units are entitled to vote as a single class with the holders of the Series A Common Units on certain matters, including the election of managers, with each Redeemable Preferred Unit and Series A Common Unit carrying one vote
per unit. Distributions The Companys Board of
Managers has authority to determine the amount, if any, of proceeds available for distribution to the unitholders. Prior to the conversion of the Redeemable Preferred Units on March 29, 2017, such proceeds were to be distributed in accordance
with the following order of priority:  

First, to the holders of Redeemable Preferred Units, pro rata in proportion to the remaining amount to be distributed to each such holder, until each such holder has received distributions in an amount equal to the
cumulative capital contributions since inception in respect of the Redeemable Preferred Units.  F-20




---

##### Table of Contents



Thereafter, to all Redeemable Preferred Unitholders, Series A Common Units held by the Companys founders, Series A Common Units issued to non-founders between December 27, 2013 and December 26, 2014, and
vested Series A Restricted Common Unitholders issued subsequent to December 26, 2014 pro rata in proportion to their percentage interest at the time of distribution. No distributions were made in 2017, 2016 or 2015. Liquidation In the event of any liquidation,
dissolution, or winding-up of the Company, the assets of the Company will be distributed in accordance with the same order of priority as distributions. Series 2 Senior Preferred Units On October 26,
2017, the Company completed the sale of 4,886,000 Series 2 Senior Preferred Units at a price of $11.26 per unit resulting in net proceeds of $55,002. Series 2 Senior Preferred Units consist of the following:  Authorized


IssuedandOutstanding


CarryingValue


LiquidationPreference


CommonUnitsIssuableUponConversionAt December 31, 2017


4,886,000



4,886,000


$
55,002


$
55,002



4,886,000 Series 1 Senior Preferred Units On March 29, 2017, the Company issued 2,500,000 Series 1 Senior Preferred Units at an issuance price of $10.00 per unit for proceeds of $25,000. See Note
3, Merger and Recapitalization, for additional information. Series 1 Senior Preferred Units consist of the following:  Authorized


IssuedandOutstanding


CarryingValue


LiquidationPreference


CommonUnitsIssuableUponConversionAt December 31, 2017


2,500,000



2,500,000


$
25,000


$
25,000



2,500,000 Junior Preferred Units On March 29, 2017, 134,920 Solid GT Class D Units were exchanged for 4,414,356 Junior Preferred Units of the Company. See Note 3, Merger and
Recapitalization, for additional information. Junior Preferred Units consisted of the following:  Authorized


IssuedandOutstanding


CarryingValue


LiquidationPreferenceAt December 31, 2017


4,414,356



4,414,356


$
44,177


$
42,500  F-21




---

##### Table of Contents

The holders of the Series 1 and Series 2 Senior Preferred Units and Junior Preferred Units have the
following rights and preferences: Tranche Right The
holders of Series 1 Senior Preferred Units were obligated to purchase 1,973,430 Series 2 Senior Preferred Units at $12.67 per unit for gross proceeds of $25,000 in the event the Company achieves certain pre-clinical milestones. In addition, the
holders of a majority of the Series 1 Senior Preferred Units have the right to require the holders of the Series 1 Senior Preferred Units to purchase the Series 2 Senior Preferred Units at any time prior to September 1, 2017, which in August
2017, was extended to December 1, 2017. The Series 1 Tranche Right was subject to certain transfer rights. See Note 9, Preferred Unit Tranche Rights, for additional information. The Series 1 Tranche Right was settled in connection with
the closing of the Series 2 Senior Preferred Unit financing on October 26, 2017. Redemption The Series 1 and Series 2 Senior Preferred Units are redeemable on or after March 29, 2022 at the option of the holder at a redemption price equal to the
original purchase price of $10.00 and $11.26 per unit, respectively, plus any declared but unpaid distributions. The Company has presented Series 1 and Series 2 Senior Preferred Units outside of permanent equity since the redemption of Series 1 and
Series 2 Senior Preferred Units is outside the control of the Company. The consent of the Junior Preferred unitholders along with Series 1 and Series 2
Senior Preferred unitholders can effect a deemed liquidation event. Therefore, the Company has presented the Junior Preferred Units outside of permanent equity. Voting Rights The holders of the Series 1 and Series 2
Senior Preferred Units and Junior Preferred Units are entitled to vote together, and not as separate classes, with each Series 1 and Series 2 Senior Preferred Unit, Junior Preferred Unit, Series A Common Unit and Series B Common Unit
carrying one vote per unit. Subject to maintaining certain ownership levels, the Series 1 and Series 2 Senior Preferred unitholders as a class are
entitled to elect two of the nine board members while such units are outstanding. The Junior Preferred unitholders as a class are entitled to elect two of the nine board members while such units are outstanding. Dividends The holders of Series 1 and Series 2 Senior
Preferred Units are entitled to an 8% annual dividend based on the Series 1 and Series 2 Senior Preferred Unit issuance price of $10.00 and $11.26 per unit, respectively, when and if declared by the Board of Managers. No dividends were declared or
paid to Series 1 or Series 2 Senior Preferred unitholders. The holders of the Junior Preferred Units are entitled to an 8% annual dividend based on
the Junior Preferred Unit issuance price of $9.63 per unit, when and if declared by the Board of Managers. No dividends were declared or paid to Junior Preferred unitholders. Distributions The Companys Board of Managers has
authority to determine the amount, if any, of proceeds available for distribution. Such proceeds are to be distributed in accordance with the following order of priority:  

First, the Series 2 Senior Preferred unitholders are entitled to an amount distributed, on a pro rata basis, equal to the Series 2 Senior Preferred Unit price of $11.26 per unit and any declared but unpaid Series 2
Senior Preferred dividends.  F-22




---

##### Table of Contents



Second, the Series 1 Senior Preferred and the Junior Preferred unitholders are entitled to an amount distributed, on a pro rata basis, equal to the Series 1 Senior Preferred Unit price of $10.00 per unit and any
declared but unpaid Series 1 Senior Preferred dividends and the Junior Preferred Unit price of $9.63 per unit and any declared but unpaid Junior Preferred dividends, respectively.  

Third, the Series A, B, C and D Common unitholders are entitled to an amount distributed, on a pro rata basis, subject to certain limitations, until the cumulative amount distributed with respect to one Series A Common
Unit, Series B Common Unit, Series C Common Unit and vested Series D Common Unit equals the cumulative amount distributed to one Junior Preferred Unit.  

Fourth, the Junior Preferred unitholders and the Series A, B, C and vested D Common unitholders are entitled to an amount distributed on a pro rata basis, subject to certain limitations, until the cumulative amount
distributed with respect to one Junior Preferred Unit, Series A Common Unit, Series B Common Unit, Series C Common Unit and vested Series D Common Unit equals the cumulative amount distributed to one Series 1 Senior Preferred Unit.  

Fifth, the Series 1 and Series 2 Senior Preferred, the Junior Preferred and the Series A, B, C and vested D Common unitholders are entitled to participate on a pro rata basis in cumulative distributions,
subject to certain limitations, in the remaining proceeds available for distribution. As a result of the issuance of the Series 2 Senior
Preferred Units on October 26, 2017, the Series 2 Senior Preferred unitholders are entitled to cumulative amounts distributed equal to the amount paid per unit for the Series 2 Senior Preferred Units and any declared but unpaid Series 2 Senior
Preferred cumulative dividends, prior to and with priority over any distributions to any other unitholders. In addition, upon the issuance of the Senior Series 2 Preferred units, the holders of the Junior Preferred Units no longer share pro rata in
the order of distributions with the Senior Series 1 Preferred unitholders and are subordinate to distributions made to Series 1 Senior Preferred unitholders. No distributions were made during the year ended December 31, 2017. Liquidation In the event of any liquidation,
dissolution, or winding-up of the Company, the assets of the Company will be distributed in accordance with the same order of priority that applies to distributions. Corporate Conversion Immediately prior to the
effectiveness of the Companys registration statement on Form S-1, which occurred on January 25, 2018, the Company completed the Corporate Conversion whereby all the Series 1 and Series 2 Senior Preferred, Junior Preferred Units converted
into shares of common stock. 11. Members Deficit Series A, B, C and D Common Units Series A, B, C and D
Common Units consisted of the following:  December 31, 2017Authorized


IssuedandOutstanding


CarryingValueSeries A Common Units


12,219,299



12,219,299


$
55,964Series B Common Units


3,258,480



3,258,480



3,613Series C Common Units


1,635,916



1,635,916



2,053Series D Common Units


3,075,814



2,324,857



3,38420,189,509



19,438,552


$
65,014  F-23




---

##### Table of Contents

December 31, 2016Authorized


IssuedandOutstanding


CarryingValueSeries A Common Units


20,000,000



5,123,917


$
558 Series A Common Units Founders Series A Common Units On
December 27, 2013, the Company issued 4,560,000 restricted Series A Common Units to its founders with time-based vesting conditions. Unvested units of Series A Common Units may not be sold or transferred by the holder. These restrictions lapse
according to the time-based vesting conditions of each award. At December 31, 2016 and 2015, 3,420,000 and 2,280,000 and restricted Series A Common Units were vested. The aggregated intrinsic value of the restricted Series A Common Units that
vested during the year ended December 31, 2016 was $3,306. There were no restricted Series A Common Units that vested during the year ended December 31, 2017. On March 29, 2017, in connection with the Merger and Recapitalization, the 4,560,000 founders restricted Series A Common Units were exchanged for
3,258,480 restricted Series B Common Units. All restricted Series B Common Units will continue to vest pursuant to the original vesting terms under the restricted Series A Common Units agreements and the Company will continue to recognize
compensation expense over the related service period. In addition, in connection with the exchange of the founders restricted Series A Common Units
into restricted Series B Common Units, the Company recognized $2,710 of equity based compensation expense for vested units, which represents the incremental fair value of the units before and after the Merger and Recapitalization. The Company has
recorded the additional compensation expense in the amount of $904 over the remaining vesting period of the Series B Common units during the year ended December 31, 2017. Non-Founder Series A Common Units In March and
November 2014, the Company issued 169,667 restricted Series A Common Units at a per unit value of $2.59 to certain employees and consultants. In
September and November 2015, the Company issued 305,000 restricted Series A Common Units at per unit values between $2.39 and $2.65 to certain employees. In May and September 2016, the Company issued 60,000 restricted Series A Common Units at per unit values between $2.03 and $2.14 to certain employees. In December 2016, the Company issued 48,000 restricted Series A Common Units at a per unit value of $2.25 to certain employees. On March 29, 2017, in connection with the Merger and Recapitalization, 563,917 non-founder restricted Series A Common Units were exchanged for 402,963
restricted Series D Common Units. All restricted Series D Common Units will continue to vest pursuant to their original vesting period, which was generally four years, under the restricted Series A Common Units agreement, and the Company will
continue to recognize compensation expense over the related service period. In addition, in connection with the exchange of the non-founders
restricted Series A Common Units into restricted Series D Common Units, the Company recognized $140 of equity-based compensation expense for vested units, which represents the incremental fair value of the units before and after the Merger and
Recapitalization. The Company will record additional compensation expense in the amount of $115 over the remaining vesting period of the Series D Common units of which $48 has been recognized as of December 31, 2017.  F-24




---

##### Table of Contents

The holders of the Series A, B, C and D Common Units are entitled to the following rights and priorities: Voting Rights Holders of Series A and B Common
Units have the right to one vote per unit held by such member. The Series A Common unitholders as a class are entitled to elect two of the eight board members while such units are outstanding. The Series B Common unitholders as a class are entitled
to elect three of the eight board members while such units are outstanding Holders of Series C and D Common Units do not have the right to vote for the
election of board members. Redemption The Series A,
B, C and D Common Units are not redeemable. Distributions and Liquidation Preference The holders of the Series A, B, C and D Common Units are entitled to participate in distributions after preferential distributions are made to the Series 1 and
Series 2 Senior Preferred and Junior Preferred unitholders as follows:  

The Series A, B, C and D Common unitholders are entitled to participate in distributions on a pro rata basis, subject to certain limitations, until the cumulative amount distributed with respect to one Series A Common
Unit, Series B Common Unit, Series C Common Unit and vested Series D Common Unit equals the cumulative amount distributed to one Junior Preferred Unit.  

The Junior Preferred unitholders and the Series A, B, C and D Common unitholders are entitled to participate in distributions on a pro rata basis, subject to certain limitations, until the cumulative amount distributed
with respect to one Junior Preferred Unit, Series A Common Unit, Series B Common Unit, Series C Common Unit and vested Series D Common Unit equals the cumulative amount distributed to one Series 1 Senior Preferred Unit.  

The Series 1 Senior Preferred, Junior Preferred unitholders and the Series A, B, C and D Common unitholders are entitled to participate in distributions on a pro rata basis, subject to certain limitations, until the
cumulative amount distributed with respect to one Series 1 Senior Preferred Unit, Junior Preferred Unit, Series A Common Unit, Series B Common Unit, Series C Common Unit and vested Series D Common Unit equals the cumulative amount distributed to one
Series 2 Senior Preferred Unit.  

All unitholders are entitled to participate on a pro rata basis in cumulative distributions, subject to certain limitations, in the remaining proceeds available for distribution. No distributions were made to the Series A, B, C or D Common unitholders during the years ended December 31, 2017, 2016 and 2015. Corporate Conversion Immediately prior to the
effectiveness of the Companys registration statement on Form S-1, which occurred on January 25, 2018, the Company completed the Corporate Conversion whereby all the Series A, B, C, and D Common Units converted into shares of common stock. 12. Equity-Based Compensation The Company adopted
the Solid Ventures, LLC Equity Incentive Plan (the Plan) on January 1, 2015, which provided for the issuance of up to 1,140,000 Series A Common Units under the Plan. The Company has granted  F-25




---

##### Table of Contents

Series A Common Units with time-based vesting conditions. Unvested Series A Common Units may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting
conditions of each award. As of December 31, 2016, 576,083 units were available for future grants under the Plan. On March 29, 2017, the
Company amended the Plan and changed the name of the Plan to the Solid Biosciences, LLC Amended and Restated Equity Incentive Plan (the Amended Plan) and increased the number of Series D Common Units available for issuance under the
Amended Plan from 1,140,000 to 2,971,949 units. As of December 31, 2017, 750,956 Series D Common Units were available for future grants under the
Amended Plan. The following table summarizes the Companys restricted Series A Common Unit activity from December 31, 2016 through
March 31, 2017:  Units


Weighted-AverageGrant DateFair ValueUnvested restricted Series A Common Units at December 31, 2016


405,513


$
2.43Vested


(44,377
)


2.49Unvested restricted Series A Common Units at March 29, 2017


361,136



2.43Exchange of unvested restricted Series A Common Units to restricted Series D Common Units at
March 29, 2017 (unaudited)


258,060



3.39Issuance of unvested restricted Series D Common units


50,000



3.08Unvested restricted Series D Common Units at March 31, 2017


308,060


$
3.34 The following table summarizes the Companys restricted Series D Common Unit activity since March 31, 2017. The
opening balance includes the exchange of the Companys restricted Series A Common Units (308,060) and the exchange of Solid GTs Class C Restricted Common Units (511,485) to restricted Series D Common Units as a result of the
merger and recapitalization described in Note 3, Merger and Recapitalization.  Units


Weighted-AverageGrant DateFair ValueUnvested restricted Series D Common Units at March 31, 2017


819,545


$
3.34Issuance of unvested restricted Series D Common units


845,325



5.83Vested


(203,969
)


3.36Forfeited


(56,636
)


3.29Unvested restricted Series D Common Units at December 31, 2017


1,404,265


$
4.83 The aggregate intrinsic value of restricted Series D Common units that vested during the year ended December 31, 2017 was
$3,300. The aggregate intrinsic value of restricted Series A Common Units that vested during the year ended December 31, 2016 was $16. At
December 31, 2017, there was $6,458 of unrecognized equity-based compensation related to Series D Common Units, which is expected to be recognized over a weighted average period of 2.0 years. At December 31, 2016, there was $864 of
unrecognized equity-based compensation related to unvested Series A Common Units, which is expected to be recognized over a weighted average period of 2.8 years. The Companys Board of Managers approved the issuance of up to 185,781 Series D Common Units to employees upon the achievement of certain events. If
those events occur, the Series D Common Units will be  F-26




---

##### Table of Contents

issued and vest in accordance with their time-based vesting conditions, which is generally four years. The Company issued 67,891 of the 185,781 Series D Common Units in September 2017 when the
Company submitted its initial IND to the U.S. Food and Drug Administration. These 67,891 units are included within the 845,325 units included within the table above. The Solid GT LLC Agreement provides for the issuance of up to 55,555 Class C Restricted Common Units. The Company has granted Class C Restricted
Common Units with time-based vesting conditions. Unvested Class C Restricted Common Units may not be sold or transferred by the holder. These restrictions lapse according to the time-based vesting conditions of each award. As of
December 31, 2016, 22,073 units were available for future grants. On March 29, 2017, the Solid GT LLC Equity Incentive Plan was terminated and
all Class C Restricted Common Units were exchanged for Series D Common Units of the Company with no change in vesting conditions. No further Class C Restricted Common Unit activity has occurred subsequent to March 29, 2017. The following table summarizes the Solid GT Class C Restricted Common Unit activity from December 31, 2016 through March 31, 2017:  Units


Weighted-AverageGrant DateFair ValueUnvested Class C Restricted Units at December 31, 2016


19,397


$
107.24Vested


(3,764
)


100.20Unvested Class C Restricted Units at March 29, 2017 (unaudited)


15,633


$
108.94Exchange of Unvested Class C Restricted Units into Series D Common Units of the Company at
March 29, 2017 (unaudited)


511,485


$
3.34Unvested Restricted Series D Common Units at March 31, 2017


511,485


$
3.34 The aggregate intrinsic value of Solid GT Class C Common Units that vested during the years ended December 31, 2016
was $335. The aggregate intrinsic value of restricted Class C Restricted Common Units that vested during the year ended December 31, 2017 was $58. At December 31, 2016, there was $2,853 of unrecognized equity-based compensation, which is expected to be recognized over a weighted average period of
2.6 years. The Company recorded equity-based compensation expense related to the Companys restricted Series A Common Units, restricted Series D
Common Units and Solid GT Class C Common Units, in the following expense categories of its consolidated statements of operations:  Year Ended December 31,2017


2016


2015Research and development expenses

$
1,206


$
1,262


$
749General and administrative expenses


4,124



208



15$
5,330


$
1,470


$
764 13. Commitments and Contingencies Operating Lease The Company leases office and
laboratory space under an operating lease agreement. The lease expires in February 2018 with no extension periods. See Note 18, Subsequent Events. In addition, the Company leases additional office and laboratory space in Cambridge,
Massachusetts, for which the Company entered into a lease in May 2017, which was amended during the third and fourth quarter of 2017, and which extends through April 2018.  F-27




---

##### Table of Contents

During the years ended December 31, 2017, 2016 and 2015, the Company recognized $1,301, $270 and $108,
respectively, of rental expense related to office and laboratory space. Future minimum lease payments for these operating leases as of December 31,
2017 amounted to $783, all which will be recognized in the year ending December 31, 2018. Letter of Credit The Company has an outstanding letter of credit in the amount of $65 at December 31, 2017 and 2016, which was required as a condition of the
Companys office and laboratory lease. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties
with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification
agreements with members of its Board of Managers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as managers. The maximum potential amount of future
payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification arrangements. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results
of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2017 and 2016. Contingencies In the first quarter of 2017, the Company
terminated the development, manufacturing and testing agreement (the Agreement) it entered into in January 2016 with a third-party. The Company and the third-party are in dispute regarding the remaining amounts owned by the Company to
the third-party under the Agreement. The Company has recorded an accrual in the amount of $1,450 during the year ended December 31, 2017 for this matter. Legal Proceedings On March 27, 2018, a purported
stockholder of the Company (the Plaintiff), filed a putative class action complaint alleging violations of the federal securities laws, in the United States District Court for the District of Massachusetts (Case No. 18-10587),
against the Company and certain of the Companys current executive officers and underwriters in the Companys initial public offering. The Plaintiff claims to represent purchasers of the Companys common stock during the period from
January 25, 2018 to March 14, 2018 and seeks unspecified damages arising out of the alleged failure to disclose risks associated with toxicity and potential for adverse events related to the Companys lead product candidate. While the
Company is vigorously defending against all claims asserted, this litigation could result in substantial costs to the Company and a diversion of the Companys managements attention and resources, which could harm its business. In
addition, the uncertainty of the pending lawsuit or potential filing of additional lawsuits could lead to more volatility and a reduction in the Companys stock price. Given the early stage of the litigation, at this time the Company is unable
to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote. It is not currently possible to assess whether or not the outcome of these proceedings may have a material adverse effect on the
Company.  F-28




---

##### Table of Contents

14. License Agreements University of Washington License Agreement In 2015, the
Company entered into a license agreement with the University of Washington, acting through UW CoMotion, under which the Company obtained an exclusive, royalty-bearing, sublicensable, worldwide license under a patent application owned by the
University of Washington relating to novel micro-dystrophins and all patents claiming priority to such patent to develop, manufacture, and commercialize products for use in the treatment of DMD and related disease indications caused by a lack of
functional dystrophin. The Company has the right to grant sublicenses to third parties contingent upon written approval by the University of Washington prior to executing such sublicense, which approval may not be unreasonably withheld. In consideration for the rights granted by the agreement, the Company paid a one-time, non-refundable license fee, which was recorded as a research and
development expense in 2015. The Company is required to reimburse the University of Washington for costs incurred in applying for, prosecuting and maintaining patents and pay up to an aggregate of approximately $1 million upon the achievement
of certain milestones. In October 2017, the first milestone was achieved under this agreement. The milestone payment was recorded as a research and development expense in the fourth quarter of 2017. There were no milestones achieved as of
December 31, 2015 and 2016. The Company must also pay royalties of a low single digit percentage of future sales by the Company and its sublicensees of products developed under the licensed patent rights. In addition, the Company must pay an
annual maintenance fee until certain milestones are achieved, at which time a minimum annual royalty requirement will replace such maintenance fee and will apply to the Company and its sublicensees. The license agreement remains in effect until the expiration of the last-to-expire patent licensed under the agreement. The Company may terminate the
agreement at any time upon providing sixty days written notice to the University of Washington. The University of Washington may terminate the agreement upon the Companys uncured, material breach of the agreement or if the Company enters
into an insolvency-related event. The Company recorded research and development expense in the amount of $135, $0, and $25 for the years ended
December 31, 2017, 2016 and 2015, respectively, under the agreement. The University of Missouri License Agreement In 2015, the Company entered into a license agreement with the Curators of the University of Missouri, or the University of Missouri, a public corporation of
Missouri, under which the Company obtained an exclusive, royalty-bearing, sublicensable, worldwide license under certain patent and patent applications owned by the University of Missouri relating to a novel synthetic microdystrophin gene to make,
sell and distribute products for use in the treatment of DMD and related disease indications resulting from a lack of functional dystrophin. In
consideration for the rights granted by the agreement, the Company paid a one-time, non-refundable license fee, which was recorded as a research and development expense in 2015. The Company is required to reimburse the University of Missouri for
costs incurred in applying for, prosecuting and maintaining the licensed patents and pay up to an aggregate of approximately $1 million upon the achievement of certain milestones for each product developed based on the licensed patents. In
October 2017, the first milestone was achieved under this agreement. The milestone payment was recorded as a research and development expense in the fourth quarter of 2017. There were no milestones achieved as of December 31, 2015 and 2016. The
Company must pay a royalty of a low single digit percentage of future sales or by its sublicensees of products developed using the licensed patents. In addition, the Company must pay an annual maintenance fee until certain milestones are achieved,
after which time a minimum annual royalty will replace such maintenance fee. Under the agreement, the Company granted the University of Missouri a
non-exclusive, royalty-free, irrevocable, paid-up license, with the right to grant sublicenses to non-profit, academic, educational or governmental institutions, to practice and use improvements made by the Company using the licensed patent rights,
solely for non-commercial research purposes.  F-29




---

##### Table of Contents

The license agreement remains in effect until the expiration of the last-to-expire patent or the abandonment
of the last to be abandoned patent application licensed under the agreement. The University of Missouri may terminate the agreement, or render the license granted thereunder non-exclusive, in individual countries if the Companys sublicensees
fail to achieve certain milestones. The Company may terminate the license agreement at any time upon providing six months written notice to the University of Missouri and paying a termination fee. Each of the University of Missouri and the
Company may also terminate the agreement for an uncured default or breach of the agreement by the other party. The Companys ability to cure such breach only applies to the first two notices of such breach provided by the University of
Missouri, and thereafter, the University of Missouri may terminate the agreement for the Companys default or breach of the agreement upon thirty days written notice without an opportunity to cure such default or breach. The Company recorded research and development expense in the amount of $11, $0, and $40 for the year ended December 31, 2017, 2016 and 2015,
respectively, under the agreement. The University of Michigan License Agreement In 2016, the Company entered into a license agreement with the Regents of the University of Michigan, or the University of Michigan, a constitutional
corporation of Michigan, under which the Company obtained an exclusive, royalty-bearing, sublicensable, worldwide license to make, sell and distribute products under certain patents owned by the University of Michigan related to microdystrophin and
utrophin spectrin-like nucleic acid sequences for any use that, but for this agreement, would comprise an infringement of a valid claim included in the licensed patent rights. In consideration for the rights granted by the agreement, the Company paid a one-time license fee and a separate fee to cover past patent prosecution costs,
which the Company recorded as a research and development expense in 2016. The Company is required to reimburse the University of Michigan for costs incurred in applying for, prosecuting and maintaining patents, and pay up to an aggregate of
approximately $1 million upon the achievement of certain milestones. There were no milestones achieved as of December 31, 2016 and 2017. The Company must also pay a royalty of a low single digit percentage on future sales by the Company or
its sublicensees of products developed using the licensed rights, with a minimum annual royalty after certain milestones are achieved. In addition, the Company must pay an annual maintenance fee in any year in which the minimum annual royalty is not
reached. Under the agreement, the University of Michigan reserves for itself and its affiliates the right to use the licensed rights for non-commercial
research, public service, internal and educational purposes and the right to grant the same limited non-commercial rights to other non-profit research institutions. The license agreement remains in effect until the expiration of the last-to-expire patent licensed under the agreement. The University of Michigan may
terminate the agreement upon the Companys uncured material breach of the agreement, including failure to make required payments under the agreement or to achieve certain milestones, or if the Company becomes insolvent or bankrupt. The Company
may terminate the license agreement at any time upon providing sixty days written notice to the University of Michigan. The Company recorded and
research and development expense in the amount of $4 and $145 for the years ended December 31, 2017 and 2016, respectively, under the agreement. Harvard College License Agreements In 2016, the Company
entered into a license agreement with the President and Fellows of Harvard College, or Harvard College, under which the Company obtained a non-exclusive, royalty-bearing, sublicensable, worldwide license to use certain intellectual property owned by
Harvard College to develop, manufacture, and commercialize products for use in the treatment of DMD.  F-30




---

##### Table of Contents

In consideration for the rights granted by the agreement, the Company paid a one-time, non-refundable
license fee, which was recorded as a research and development expense in 2016. The Company is required to pay an annual license maintenance fee until certain milestones are achieved, after which time the annual maintenance fee will increase
annually. Such annual maintenance fee will further increase if the Company grants certain rights to a sublicensee or strategic partner with whom the Company collaborates on the development and commercialization of licensed products. The annual
maintenance fee is creditable against royalty payments. The Company also must pay a milestone payment within thirty days after achieving certain milestones. There were no milestones achieved as of December 31, 2016 and 2017. The Company must
pay a royalty of a low single digit percentage on future sales by the Company or its sublicensees of products developed using the licensed technology. The license agreement remains in effect for an initial term of fifteen years, with automatic three-year renewal periods thereafter unless one of the parties
provides notice of non-renewal. The Company may terminate the license agreement at any time upon providing sixty days written notice to Harvard College. Harvard College may terminate the agreement in the event the Company becomes bankrupt or
insolvent. Both Harvard College and the Company may also terminate the agreement for an uncured material breach of the agreement by the other party. The
Company recorded research and development expense in the amount of $45 and $45 for the years ended December 31, 2016 and 2017, respectively, under the agreement. In August 2017, the Company entered into another license agreement with Harvard College, under which the Company obtained a non-exclusive, royalty-bearing,
sublicensable, worldwide license to use certain intellectual property owned by Harvard College to develop, manufacture, and commercialize products for use in the treatment of DMD. In consideration for the rights granted by the agreement, the Company paid a one-time, non-refundable license fee, which was recorded as a research and
development expense in 2017. The Company is required to pay an annual license maintenance fee until certain milestones are achieved, after which time the annual maintenance fee will increase annually. Such annual maintenance fee will further
increase if the Company grants certain rights to a sublicensee or strategic partner with whom the Company collaborates on the development and commercialization of licensed products. The annual maintenance fee is creditable against royalty payments.
The Company also must pay a milestone payment within thirty days after achieving certain milestones. There were no milestones achieved as of December 31, 2017. The Company must pay a royalty of a low single digit percentage on future sales by
the Company or its sublicensees of products developed using the licensed technology. The license agreement remains in effect for an initial term of
fifteen years, with automatic three-year renewal periods thereafter unless one of the parties provides notice of non-renewal. The Company may terminate the license agreement at any time upon providing sixty days written notice to Harvard
College. Harvard College may terminate the agreement in the event the Company becomes bankrupt or insolvent. Both Harvard College and the Company may also terminate the agreement for an uncured material breach of the agreement by the other party. The Company recorded research and development expense in the amount of $23 for the year ended December 31, 2017 under the agreement. Other License Agreements In 2016, the Company entered
into a license agreement with Life Technologies Corporation, or Life Technologies. In consideration for obtaining a non-exclusive, royalty-free, worldwide license to use certain technologies and associated know-how to develop product candidates, the
Company paid a one-time, non-refundable license fee. This fee was recorded as a research and development expense in 2016. The license  F-31




---

##### Table of Contents

agreement will remain effective in perpetuity unless earlier terminated. Life Technologies has the right to terminate the agreement upon the Companys material, uncured breach of the
agreement or in the event that it determines that continued performance of the agreement may violate any laws. The Company is obligated to diligently pursue regulatory approval necessary for the development, manufacture and sale of the licensed
products. The Company has the right to terminate the agreement at any time upon providing thirty days written notice to Life Technologies. 15.
Net Loss per Unit Basic and diluted net loss per common unit were calculated as follows: The numerator for basic and diluted net loss per unit is as follows:  Year Ended December 31,2017


2016


2015Net loss

$
(53,178
)

$
(23,773
)

$
(6,664
)Net loss attributable to non-controlling interest


(1,060
)


(2,234
)


(287
)Net loss attributable to Solid Biosciences, LLC

$
(52,118
)

$
(21,539
)

$
(6,377
)Decretion (accretion) of preferred units to redemption value


(959
)


4,309



(68
)Redemption of preferred units


15,685







Redemption of redeemable interest from non-controlling interest in Solid GT


(1,925
)






Net loss attributable to common unitholders

$
(39,317
)

$
(17,230
)

$
(6,445
) The denominator is as follows:  Year Ended December 312017


2016


2015Weighted average common units outstanding, basic and diluted


13,649,485



1,698,904



846,569 Net loss per unit attributable to common unitholders, basic and diluted is as follows:  Year Ended December 31,2017


2016


2015Net loss per unit attributable to common unitholders, basic and diluted

$
(2.88
)

$
(10.14
)

$
(7.61
) The following potential common units, presented based on amounts outstanding at each period end, were excluded from the
calculation of diluted net loss per share attributable to common unitholders for the periods indicated because including them would have had an anti-dilutive effect:  Year Ended December 31,2017


2016


2015Series A common units






1,104,391



1,924,718Series B common units










Series D common units


1,404,265







1,404,265



1,104,391



1,924,718  F-32




---

##### Table of Contents

16. Retirement Plan The Company has a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees who
meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Company contributions to the plan may be made at the discretion of the Companys board of managers. The Company
made no contributions to the plan during the years ended December 31, 2015, 2016 and 2017. 17. Selected Quarterly Financial Information
(Unaudited) Selected quarterly results from operations for the years ended December 31, 2016 and 2017 are as follows:  2016 Quarter EndedMarch 31


June 30


September 30


December 31(in thousands, except for per unit data)Revenues

$



$







$



$
Operating expenses


4,069



5,212







7,574



8,721Loss from operations


(4,069
)


(5,212
)






(7,574
)


(8,721
)Net loss


(2,991
)


(4,834
)






(7,429
)


(8,519
)Net loss attributable to Solid Biosciences, LLC


(2,680
)


(4,372
)






(6,731
)


(7,756
)Net loss attributable to common unitholders


(1,653
)


(4,133
)






(6,799
)


(4,645
)Net loss per unit attributable to common unitholders

$
(0.99
)

$
(2.46
)





$
(4.03
)

$
(2.64
)  2017 Quarter EndedMarch 31


June 30


September 30


December 31(in thousands, except for per unit data)Revenues

$



$



$



$
Operating expenses


14,113



11,887



13,696



15,161Loss from operations


(14,113
)


(11,887
)


(13,696
)


(15,161
)Net loss


(13,875
)


(11,311
)


(13,505
)


(14,487
)Net loss attributable to Solid Biosciences, LLC


(12,815
)


(11,311
)


(13,505
)


(14,487
)Net loss attributable to common unitholders


(14
)


(11,311
)


(13,505
)


(14,487
)Net loss per unit attributable to common unitholders

$
(0.01
)

$
(0.66
)

$
(0.79
)

$
(0.84
) 18. Subsequent Events In
January 2018, the Company executed a lease agreement for lab space in Cambridge, Massachusetts. The lease consists of approximately 9,500 square feet with an initial term of five years with the option to extend the term for one additional two year
term. The future minimum rent commitment for the initial five year term is approximately $3,800. In addition to rent, the lease requires the Company to pay additional amounts for taxes, insurance, maintenance and other operating expenses. In January 2018, the Company executed a lease agreement for office space in Cambridge, Massachusetts. The lease will serve as the Companys corporate
headquarters and consists of approximately 16,000 square feet. The term of the lease runs through February 2022. The future minimum rent commitment for the lease term is approximately $4,600. In addition to rent, the lease requires the Company to
pay additional amounts for taxes, insurance, maintenance and other operating expenses. Immediately prior to the effectiveness of the Companys
registration statement on Form S-1 on January 25, 2018, the Company converted into a Delaware corporation pursuant to a statutory conversion and changed the Companys name to Solid Biosciences Inc. As a result of the corporate conversion,
the holders of the Series 1 and 2 Senior Preferred and Junior Preferred Units and Series A, B, C and D Common Units of Solid Biosciences, LLC became holders of common stock of Solid Biosciences Inc.  F-33




---

##### Table of Contents

On January 30, 2018, the Company completed its initial public offering with the sale of 8,984,375
shares of common stock, including shares of common stock issued upon the exercise in full of the underwriters over-allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $129,300, after deducting
underwriting discounts and commissions and offering expenses. In connection with the closing of the Companys initial public offering, the board of
directors and stockholders approved a new equity compensation plan, the 2018 Omnibus Incentive Plan, which provides for the reservation of 5,001,000 shares of common stock for equity awards.  F-34